```
Welcome to STN International! Enter x:x
LOGINID: ssspta1653adk
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jul 12 BELLSTEIN enhanced with new display and select
                       resulting in a closer connection to BABS IFIPAT/IFIUDB/IFICDB reloaded with new search and
NEWS 4
display
       4 AUG 02
```

NEWS 5 AUG 02 CAplus and CA patent records enhanced with European and Japan NEWS 6 AUG 02 Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7. 01 for Windows) now available
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal

NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder

wizard within STN Express with Discover! New display format, HITSTR, available in NEWS 11 SEP 01 NEWS 11 SEP 01 New 013Pta, 100 mac, 120 mg, 12

JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0rc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004 STN Operating Hours Plus Help Desk availability General Internet Information Welcome Banner and News Items Direct Dial and Telecommunication Network Access to NEWS HOURS NEWS INTER NEWS LOGIN NEWS PHONE

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

Please note that search-term pricing does apply when conducting ${\sf SmartSELECT}$ searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> S 300832-84-2/RN L1 1 300832-84-2/RN

=> DEL SEL Y

=> SEL RN E1 THROUGH E1 ASSIGNED

=> INDEX BEILSTEIN, GMELIN COST IN U.S. DOLLARS TOTAL

SINCE FILE

ENTRY

SESSION FULL ESTIMATED COST 2.48

INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004

2 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^{\star} with SET DETAIL OFF.

=> S E1 AND OPTICAL?/FA FILE 'BEILSTEIN'

7:LE BELLSTEIN'
0 300832-84-2/BI
(300832-84-2/RN)
753186 OPTICAL?/FA
0 300832-84-2/BI AND OPTICAL?/FA
FILE 'GMELIN' ELIN' 0 300832-84-2/BI (300832-84-2/RN) 12899 OPTICAL?/FA 0 300832-84-2/BI AND OPTICAL?/FA

QUE 300832-84-2/BI AND OPTICAL?/FA

NO F-NUMBERS HAD GREATER THAN ZERO HITS

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

SINCE FILE

ENTRY

```
All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.
```

FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004

=> index biosci FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED COST IN U.S. DOLLARS SINCE FILE ENTRY SESSION FULL ESTIMATED COST 0.42 0.42

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUACI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOȘIS, BIOTECHABS, BIOTECHOS, BIOTECHOS, CADAR CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONSECT. CONFSCI, CROPB CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:25:23 ON 26 OCT 2004

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^{\star} with SET DETAIL OFF.

=> fil reg COST IN U.S. DOLLARS SINCE FILE TOTAL FNTRY SESSION FULL ESTIMATED COST 1.56 1.14

FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6 DICTIONARY FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

SESSION FULL ESTIMATED COST 3.05

0.57

FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

;MF 15 L1 52155 BMF/RL 0 L1/BMF (L1 (L) BMF/RL) => S L1/BMF L3

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL SINCE FILE ENTRY SESSION FULL ESTIMATED COST 5.31 2.26

FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storion storing of this information, without the prior written consent of CAS, is

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 5 L1/BPN 15 L1 102210 BPN/RL 0 L1/BPN (L1 (L) BPN/RL)

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

SINCE FILE

SESSION FULL ESTIMATED COST 7.57 ENTRY 2.26

FILE 'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

IMF 15 L1 390491 IMF/RL 0 L1/IMF (L1 (L) IMF/RL) => S L1/IMF

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

GI

SINCE FILE

ENTRY

KZ, MD; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, (English). CODEN: PIXXD2. APPLICATION: WO 2003-US30402 20030925. PRIORITY: US 2002-PV414940 20020930; US 2002-PV421904 20021029; 2002-PV433834 20021216; US 2003-PV443662 20030130.

COSH

Disclosed are oral pharmaceutical compns., kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein Compound (I), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range. Also disclosed are the use of I or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV.
300832-84-2
RL: PAC (Pharmacological activity): PEP (Physical engineering

1

RL: PAC (Pharmacological activity); PEP (Physical, engineering

chemical process); PYP (Physical process); THU (Therapeutic use);

BIOL (Biological study); PROC (Process); USES (Uses)
(potent inhibitor of HCV serine protease)

SESSION FULL ESTIMATED COST 9.83

2.26

FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA textoon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

_/PEP
15 L1
1687596 PEP/RL
1 L1/PEP
(L1 (L) PEP/RL)
4TTRN => S L1/PEP

=> DIS L6 1 CBIB ABS HITRN

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN 2004:310970 Document No. 140:327091 Potent inhibitor of HCV serine

protease. Chen, Shirlynn; Nehmiz, Gerhard; Croenlein, Jens Oliver; Steinmann

Gerhard; Gunn, Jocelyn Abella; Costa, Phuong Do (Boehringer Ingelheim International G.m.b.H., Germany). PCT Int. Appl. WO 2004030670

Αŀ 20040415, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU,

BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,

EG, EG, EG, EG, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG,

=> FIL CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL **ENTRY** FULL ESTIMATED COST 14.95 SESSION 5.12 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL SINCE FILE ENTRY SESSION CA SUBSCRIBER PRICE 0.70 -0.70

FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

PUR 15 L1 201134 PUR/RL 0 L1/PUR (L1 (L) PUR/RL) => 5 L1/PUR

SESSION

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL SINCE FILE **ENTRY** SESSION 2.26 FULL ESTIMATED COST 17.21 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL SINCE FILE ENTRY CA SUBSCRIBER PRICE 0.70

FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S (L1/SPN OR L1/CPN)
15 L1
1660968 SPN/RL
6 L1/SPN (L1 (L) SPN/RL)15 L1 1155 CPN/RL 0 L1/CPN (L1 (L) CPN/RL) 6 (L1/SPN OR L1/CPN) L8

=> FOCUS L8
PROCESSING COMPLETED FOR L8
L9 6 FOCUS L8 1-

⇒> DIS L9 1- CBIB ABS HITRN
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):Y

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2004:580783 Document No. 141:261053 Synthesis of BILN 2061, an HCV Protease Inhibitor with Proven Antiviral Effect in Humans. er, Anne-Marie; Bailey, Murray D.; Beaulieu, Pierre L.; Brochu,

Duceppe, Jean-Simon; Ferland, Jean-Marie; Ghiro, Elise; Gorys, vida; Halmos, Ted; Kawai, Stephen H.; Poirier, Martin; Simoneau,

Bruno; Tsantrizos, Youla S.; Llinas-Brunet, Montse (Chemistry

MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN. YU. ZĂ, ZM, ZW, AM, AZ, BY, KG, KZ, MD; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, CM, CT, DE, DA, CD, TS, CM, CM, CT, DE, DA, CD, TS, CM, CM, CT, DE, DA, CD, TS, CM, CDEN: PIXXD2.

APPLICATION: WO 2003-CA1604 20031020. PRIORITY: US 2002-PV421414 20021025; US 2002-PV433820 20021216; US 2003-PV442768 20030127.

1

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2004:168624 Document No. 140:350045 Structure-activity study on a series of macrocyclic inhibitors of the hepatitis C virus NS3 leading to the discovery of BILN 2061. Llinas-Brunet, Montse;

Department, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.). Organic 6(17), 2901-2904 (English) 2004. CODEN: ORLEF7. ISSN: O. Publisher: American Chemical Society. 1523-7060.

AB The synthesis of BILN 2061 (1), a hepatitis C virus (HCV) NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclin. pharmacol. evaluation.

IT 300832-84-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of peptidyl macrocycle BILN 2061, activity)

(preparation of peptidyl macrocycle BILN-2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans)

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2004:370958 Document No. 140:357673 Preparation of macrocyclic peptides active against the hepatitis C virus. Llinas-Brunet, Montse; Bailey,
Murray D. (Boehringer Ingelheim International G.m.b.h.,
Germany). PCT DESIGNATE (1.20040506 40 np. DESIGNATE Germany). PCT Int. Appl. wo 2004037855 A1 20040506, 40 pp. DESIGNATED STATES: W: AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, LC, DE, DK, DM, DZ, LC, LC, LK, LR, LS, LT, LU, LV, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,

Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-

e; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole;

Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre Daniel (Departments of Chemistry and Biological Sciences,

Boehringer
Ingelheim (Canada) Ltd., Laval, QC, H7S 265, Can.). Journal of Medicinal Chemistry, 47(7), 1605-1608 (English) 2004. CODEN: JMCMAR.

ISSN: 0022-2623. Publisher: American Chemical Society.
From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man. 300832-84-2P

PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic

thetic preparation); BIOL (Biological study); PREP (Preparation) (BILN 2061; structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to

discovery of BILN 2061)

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2003:648255 Document No. 139:197768 Preparation of macrocyclic peptides active against the hepatitis C virus. Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-Marie; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Halmos, Teddy;
Llinas-Brunet, Montse (Boehringer Ingelheim (Canada) Ltd., Can.). U.S. US 6608027 Bl 20030819, 90 pp., Cont.-in-part of U.S. Ser. No. 542,675, abandoned. (English). CODEN: USXXAM. APPLICATION: US 2001-20010116. PRIORITY: US 1999-PV128011 19990406; US 2000-542675 20000403

Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONNR32, CONNR32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: 0, 5, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moietyl were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis c virus. Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = COZH; R3CH-D = (5)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed 1C50 > 0.1 µM in the full-length NS3-NS4A = (5)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed IC50 > 0.1 µM in the full-length NS3-NS4A heterodimer protein fluorogenic assay.

IT 300832-84-2P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic peptides active against the hepatitis C virus)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2003:511084 Document No. 139:69527 Preparation of macrocyclic compounds as inhibitors of hepatitis C virus. Campbell, Jeffrey Allen; Good, Charles (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2003053349 A2 20030703, 225 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW:

AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN 1999-PV128U11 19990406. PIXXD2. APPLICATION: WO 2000-CA353 20000403. PRIORITY: US PV128011

Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxy, alkoxyalkyl, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONHR32, COZR32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: 0, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moietyl were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = COZH; R3CH-D = (S)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed ICSO > 0.1 µM in the full-length NS3-NS4A = (s)-(Me3COZCNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed IC50 > 0.1 μM in the full-length NS3-NS4A heterodimer protein fluorogenic assay. IT 300832-84-2P RL: BAC (Biological activity or effector, except adverse); BSU (Biological

ogical study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US39926 PRIORITY: US 2001-PV344080 20011220; US 2002-PV382103 20020520.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE

The invention relates to macrocyclic compds. I [R1 = (cyclo)alkyl; R2 = H, halo, alkyl, alkoxy, cycloalkoxy, (un)substituted aryl or heterocyclyl; R3 = H, halo, CF3, alkoxy, cycloalkoxy; R4 = NH2 or NH86, where R6 is alkanoyl, alkylaminocarbonyl, or carbalkoxy; Q is a 3-9 atom (un)saturated alkylene chain optionally containing 1-3 heteroatoms O, S, SO, or SO2], including methods for their synthesis and use in pharmaceutical compns. for therapeutic or prophylactic prevention or treatment of hepatitis C virus (HCV) infection. Thus, 3,13-diazatricyclo[11.3.0.04,6]hexadec-7-ene derivative II was prepared by a multistep procedure and assayed for inhibition of HCV NS3/4A protease (TCSO < 5 MM). of HCV NS3/4A protease (IC50 < 5 μ M). 300832-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of macrocyclic compds. as inhibitors of hepatitis C virus)

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2000:725652 Document No. 133:296659 Preparation of macrocyclic peptides active against the hepatitis C virus. Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-marie; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-brunet, Montse (Boehringer Ingelheim (Canada) Ltd., Can.). PCT Int. Appl. WO 2000059929 Al 20001012, 154 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CA AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,

(preparation of macrocyclic peptides active against the hepatitis C virus)

=> FIL REGISTRY
COST IN U.S. DOLLARS
TOTAL SINCE FILE ENTRY SESSION FULL ESTIMATED COST 42.78 25.57 SINCE FILE DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) ENTRY CA SUBSCRIBER PRICE 4.90 SESSION

FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6 DICTIONARY FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting ${\sf SmartSELECT}$ searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> d his

(FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:25:23 ON 26 OCT 2004

```
FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004
1 S 300832-84-2/RN
SET SMA OFF
DEL SEL Y
L1
                        SEL RN
SET SMA LOGIN
        INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004
SEA E1 AND OPTICAL?/FA
                        QUE 300832-84-2/BI AND OPTICAL?/FA
L2
        FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004
0 S L1/BMF
L3
        FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004
0 S L1/BPN
        FILE 'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004 0 S L1/IMF
L5
        FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004
1 S L1/PEP
       FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004
0 S L1/PUR
L7
        FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004
6 S (L1/SPN OR L1/CPN)
6 FOCUS L8 1-
L8
L9
       FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004
=> file hcaplus
COST IN U.S. DOLLARS
TOTAL
                                                                           SINCE FILE
                                                                                  ENTRY
SESSION
FULL ESTIMATED COST
                                                                                   0.84
43.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                           SINCE FILE
TOTAL
                                                                                  ENTRY
CA SUBSCRIBER PRICE 4.90
                                                                                   0.00
FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available
```

English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE 20030425 US 2004058982 US 6248776 19990217 <---US 6476066 20010227 <---PRIORITY APPLN. INFO.: 19990217 20040325 us 2003-422848 20010619 us 1999-251467 в1 20021105 us 2001-793416 us 1999-251467 Α3 us 2001-793416 ΑZ 20010227 US 1997-56382P 19970826 us 1997-997259 19971223 OTHER SOURCE(S): MARPAT 140:281350 L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2003:886572 HCAPLUS Full-text DOCUMENT NUMBER: TITLE: effects in 140:122161 An NS3 protease inhibitor with antiviral humans infected with hepatitis C virus Lamarre, Daniel; Anderson, Paul C.; Bailey, AUTHOR(S): Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.: 5t. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse Departments of Biological Sciences, CORPORATE SOURCE: Boehringer Ingelheim (Canada) Ltd, Laval, QC, H7S 2G5, Nature (London, United Kingdom) (2003), 426(6963), 186-189 CODEN: NATUAS; ISSN: 0028-0836 Nature Publishing Group SOURCE:

LANGUAGE:

PUBLISHER:

```
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in
 databases on STN. Any dissemination, distribution, copying, or
of this information, without the prior written consent of CAS, is strictly prohibited.
FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)
  This file contains CAS Registry Numbers for easy and accurate substance identification.
=> s 11
L10
                      15 L1
=> 110 and crystal
1117482 CRYSTAL
600101 CRYSTALS
1385437 CRYSTAL
(CRYSTAL OR CRYSTALS)
L11 0 L10 AND CRYSTAL
=> 110 and crystal?
1605797 CRYSTAL?
L12 0 L10 AND CRYSTAL?
=> 110 and alcohol
217243 ALCOHOL
149677 ALCOHOLS
339514 ALCOHOL
                        (ALCOHOL OR ALCOHOLS)

0 L10 AND ALCOHOL
 L13
=> 110 and pd<20030327
23271868 PD<20030327
(PD<20030327)
L14 3 L10 AND PD<20030327
 => d 114 1-3 ibib
L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2004:252197 HCAPLUS Full-text 140:281350
L14 ANSWER 1 OF
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
pass effect
INVENTOR(S):
                                               Spiro compounds for inhibiting the first-
                                              Harris, James W.
Bioavailability System, LLC, USA
U.S. Pat. Appl. Publ., 133 pp., Cont.-in-
 PATENT ASSIGNEE(S):
SOURCE:
part of U.S.
                                              Ser. No. 793,416.
CODEN: USXXCO
Patent
DOCUMENT TYPE:
 DOCUMENT TYPE:
                                              Journal
                                              English
30 THERE ARE 30 CITED REFERENCES
 I ANGUAGE:
 REFERENCE COUNT:
AVAILABLE FOR THIS
                                                         RECORD. ALL CITATIONS AVAILABLE IN THE
                                               Preparation of macrocyclic peptides active
```

```
RE FORMAT
L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2000:725652 HCAPLUS Full-text 133:296659
TITLE:
against the
                                 hepatitis C virus
Tsantrizos, Youla S.; Cameron, Dale R.;
INVENTOR(S):
                                 Anne-marie; Ghiro, Elise; Goudreau,
Nathalie; Halmos,
                                 Teddy; Llinas-brunet, Montse
Bochringer Ingelheim (Canada) Ltd., Can.
PCT Int. Appl., 154 pp..
CODEN: PIXXD2
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                 Patent
English
      PATENT NO.
                                                          APPLICATION NO.
DATE
      wn 2000059929
                                  Δ1
                                          20001012
                                                         WO 2000-CA353
20000403
                AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,
CN, CR,
                 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR. HU.
                 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU,
                 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE,
                 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA,
            ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
                 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1169339 A1 20020109 EP 2000-913999
20000403 <--
                339 B1 20040929
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
      EP 1169339
      IE, SI, LT, LV, FI, RO
BR 2000009599 A 20020115
                                                          BR 2000-9599
20000403
      1403 <--
TR 200102878
                                  т2
                                          20020121
                                                          TR 2001-200102878
```

```
20000403 <--
EE 200100516
20000403 <--
                                           20021216
                                                           EE 2001-516
NZ 515286
20000403
                                           20040227
                                                           NZ 2000-515286
EP 1437362
20000403
                                   A1
                                           20040714
                                                           EP 2004-9264
            R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
IE, SI, LT, LV,

BG 105970 A

20011002 <--
HR 2001000720 A1

20011004 <--
                                           , RO, CY
20020531
                                                            BG 2001-105970
                                           20021231
                                                           HR 2001-720
NO 2001004857
20011005 <--
PRIORITY APPLN. INFO.:
19990406
                                           20011031
                                                            NO 2001-4857
                                                            US 1999-128011P
                                                           EP 2000-913999
                                                                                      Α3
 20000403
                                                            WO 2000-CA353
20000403
OTHER SOURCE(S):
REFERENCE COUNT:
                                  MARPAT 133:296659
1 THERE ARE 1 CITED REFERENCES AVAILABLE
 FOR THIS
                                          RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT
 => d 114 1 hitstr
```

```
L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

IT 300832-84-2, BILN 2061
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spiro compds. for inhibiting the first-pass effect)
RN 300832-84-2 HCAPLUS
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylic
acid, 6-[[(cyclopentyloxy)carbonyl]amino]-
1,2,3,6,7,8,9,10,11,13a,14,15,16
,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-
 thiazolvil
                  4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI)
                  INDEX NAME)
```

Absolute stereochemistry.
Double bond geometry as shown.

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL

SESSION CA SUBSCRIBER PRICE 4.90

=> s BILN 2061 FILE '1MOBILITY'

0 "BILN" 0 "2061"

0 BILN 2061 ("BILN"(W)"2061") FILE '2MOBILITY'

TTY'
0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061")


```
FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
     index
=> index
ENTER FILE OR CLUSTER NAMES (NONE):
ENTER FILE OR CLUSTER NAMES (NONE):all
FILE 'ENCOMPLIT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPLIT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
TOTAL
                                                                                   SINCE FILE
                                                                                           ENTRY
SESSION
FULL ESTIMATED COST 93.08
                                                                                           15.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL
                                                                                   SINCE FILE
                                                                                           ENTRY
SESSION
CA SUBSCRIBER PRICE
4.90
                                                                                             0.00
INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
           ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
            BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS,
BIOTECHADS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...'
ENTERED AT 15:24:55 ON 26 OCT 2004
143 FILES IN THE FILE LIST IN STNINDEX
```

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^\star with SET DETAIL OFF.

SINCE FILE

ENTRY

0.00



PAGE 1-B

PAGE 2-B

=> FIL HOME COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 77.33 33.71

```
FILE 'ABI-INFORM'
                    1 BILN
65 2061
0 BILN 2061
                           (BILN(W)2061)
FILE 'ADISCTI'
                   3 BILN
21 2061
2 BILN 2061
(BILN(W)2061)
FILE 'AEROSPACE'
                   0 BILN
20 2061
0 BILN 2061
(BILN(W)2061)
(BILN(W)2061)
FILE 'AGRICOLA'

0 BILN
18 2061
0 BILN 2061
(BILN(W)2061)
FILE 'ALUMINIUM'
0 BILN
0 BILN
0 BILN
                        BILN
2061
                     0 BILN
0 2061
0 BILN 2061
FILE 'ANABSTR'
0 BILN
6 2061
                            (BILN(W)2061)
                     6 2061
0 BILN 2061
(BILN(W)2061)
FILE 'ANTE'
                     0 BILN
0 2061
0 BILN 2061
                            (BILN(W)2061)
FILE 'APOLLIT'
                     0 BILN
6 2061
0 BILN 2061
(BILN(W)2061)
FILE 'AQUALINE'
                      Õ BILN
2 2061
                        BILN 2061
(BILN(W)2061)
                     ō
FILE 'AQUASCI'
                        "BILN"
"2061"
                     0 BILN 2061
                           ("BILN"(W)"2061")
FILE 'AQUIRE'
                    0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'BABS'
```

24 2061
1 BILIN 2061
(BILN(W)2061)
FILE 'BIBLIODATA'
0 BILN 2061
0 BILN 2061
(BILN(W)2061)
FILE 'BIOBUSINESS'
0 "BILN"
4 "2061"
0 BILN 2061
("BILN"(W)"2061")
FILE 'BIOCOMMERCE'
0 BILN 2061
0 BILN 2061
(BILN(W)2061)
FILE 'BIOENG'
FILE 'BIOENG'
7 2061
2 BILN 2061
(BILN(W)2061)
FILE 'BIOSIS'
27 BILN 129 2061
18 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHABS'
0 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHOS'
0 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHOS'
0 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHOS'
0 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHOO'
12 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHOO'
12 BILN 2061
(BILN(W)2061)
FILE 'BIOTECHOO'
12 BILN 2061
(BILN(W)2061)
FILE 'BLOB'
(BILN(W)2061)
FILE 'CABA'
0 BILN 2061
(BILN(W)2061)
FILE 'CABA'
0 BILN 2061
(BILN(W)2061)
FILE 'CANCERLIT'
11 BILN
13 2061
0 BILN 2061

FILE 'CAOLD' 0 BTIN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CAPLUS 20 BILN 382 2061 10 BILN 2061 (BILN(W)2061) FILE 'CASREACT' 1 BILN 6 2061 0 BILN 2061 (BILN(W)2061) FILE 'CBNB' BILN 2061 2 BILN 2061 (BILN(W)2061) FILE 'CEABA-VŢB' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CEN' 0 "BILN" 8 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'CERAB' FILE 'CERAB'

0 BILN

0 2061

0 BILN 2061

(BILN(W)2061)

FILE 'CHEMINFORMRX' 0 BILN 7 2061 / 2001 0 BILN 2061 ___ (BILN(W)2061) FILE 'CHEMSAFE' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CIN' 1 "BILN" 12 "2061" 1 BILN 2061 ("BILN"(W)"2061") ("BILN")
FILE 'CIVILENG'
0 BILN
1 2061
0 BILN 2061 (BILN(W)2061) FILE 'COMPENDEX'

(BILN(W)2061)

4 BILN 22 2061 2 BILN 2061 (BILN(W)2061) FILE 'COMPUAB COMPUAB'

0 "BILN"

0 "2061"

0 BILN 2061

("BILN"(W)"2061")

'COMPUSCIENCE' 0 BILN 0 2061 0 BILN 2061 FILE 'CONFSCI'

2 "BILN"

9 "2061"

0 BILN 2061

FILE 'COPPERLIT'

0 BILN 2061

0 BILN 2061

0 BILN 2061 (BILN(W)2061) (BILN(W)2061)
FILE 'CORROSION' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CROPE' 0 BILN 2061 BILN 2061 (BILN(W)2061) FILE 'CROPU' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CSNB' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DDFB' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DDFU' 13 BILN 21 2061 10 BILN 2061 (BILN(W)2061) FILE 'DETHERM' 0 BILN 0 2061

0 BILN 2061 . (BILN(W)2061) FILE 'DGENE' E' 0 BILN 303 2061 0 BILN 2061 (BILN(W)2061) FILE 'DISSABS' 1 BILN 24 2061 0 BILN 2061 (BILN(W)2061) FILE 'DKF' 0 BILN 1 2061 0 BILN 2061 (BILN(W)2061) FILE 'DPCI' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DRUGB' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DRUGU' 13 BILN 36 2061 10 BILN 2061 (BILN(W)2061) FILE 'ELCOM' 1 "BILN" 0 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'EMA' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'EMBAL' 1 BILN 4 2061 1 BILN 2061 (BILN(W)2061) FILE 'EMBASE' 5E'
48 "BILN"
124 "2061"
42 BILN 2061
("BILN"(W)"2061") FILE 'ENERGY' y'
0 BILN
31 2061
0 BILN 2061
(BILN(W)2061)

18 2061 0 BILN 2061 FILE 'HEALSAFE'

0 "BILN"

0 "2061"

0 BILN 2061

("BILN"(W)"2061") FILE 'ENTEC' 0 BILN 2 2061 0 BILN 2061 - SIEN 2061 FILE 'ENVIROENG' 0 BILN 0 2061 0 BILN 2061 U BILN 2061 (BILN(W)2061) FILE 'ESBIOBASE' 3 BILN 49 2061 3 BILN 2061 (BILN(W)2061) FILE 'EUROPATFULL' 2 RTIN 0 BILN 1 2061 0 BILN 2061 (BILN(W)2061) FILE 'IFICLS' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) 2 BILN 425 2061 0 BILN 2061 (BILN(W)2061) FILE 'IFIPAT' 1 RTIN 1 BILN
39 2061
1 BILN 2061
(BILN(W)2061)

FILE 'IMSDRUGNEWS'
3 "BILN"
5 "2061"
3 BILN 2061
("BILN"(W)"2061")

FILE 'INFODATA' FILE 'FOMAD' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'INFODATA'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061) FILE 'FORIS' 0 BILN 0 2061 0 BILN 2061 - SILN 2061 (BILN(W)2061) FILE 'FRANCEPAT' 0 BILN 0 2061 0 BILN 2061 1 BILN 22 2061 0 BILN 2061 (BILN(W)2061) (BILN(W)2061) FILE 'FRFULL' 3 BILN 54 2061 0 BILN 2061 (BILN(W)2061) FILE 'INPADOC' 0 BILN 3 2061 0 BILN 2061 (BILN(W)2061) FILE 'FROSTI' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'INSPEC' 0 BILN 73 2061 0 BILN 2061 (BILN(W)2061) FILE 'FSTA' 0 BILN 11 2061 FILE 'INSPHYS' 0 BILN 2061 (BILN(W)2061) FILE 'INSPHYS'

1 BIIN
2 2061
0 BIIN 2061
(BILN(W)2061)

FILE 'INVESTEXT'
20 "BILN"
1 "BILNS"
21 "BILN" FILE 'GENBANK' 0 "BILN" 3412 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'GEOREF' 0 BILN ("BILN" OR "BILNS")
"2061" 13 BILN 2061 (BILN(W)2061) 1864 15 BILN 2061 ("BILN"(W)"2061") FILE 'METADEX' TILE 0 BL.

FILE 'NAPRALERT'
0 "BILN"
2 "2061"
0 BILN 2061
("BILN"(w)"2061") 0 BILN 14 2061 0 BILN 2061 (BILN(W)2061) FILE 'IPA' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'ITRD' 0 BILN 5 2061 0 BILN 2061 (BILN(W)2061) FILE 'JAPIO' O BTIN (BILN(W)2061) L8 2061 O BILN 2061 FILE 'NLDB' 4 "BILN" 274 "2061" 3 BILN 2061 ("BILN"(w)"2061") (BILN(W)2061) -EPLUS' 0 BILN 58 2061 0 BILN 2061 (BILN(W)2061) FILE 'NTIS' FILE 'NTIS'

0 BILN
27 2061
0 BILN 2061
FILE 'NUTRACEUT'
0 BILN
0 2061
0 BILN 2061
0 BILN 2061
FILE 'OCEAN'

FILE 'OCEAN' FILE 'KOSMET' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'LIFESCI' "BILN" "2061" 0 "BILN" 0 "2061" 0 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'PAPERCHEM2' 4 BILN 2061 ("BILN"(W)"2061")

0 BILN 2 2061

0 BILN 0 2061

FILE 'PASCAL'

FILE 'PATDD'

FILE 'PATDPA'

2 2061 0 BILN 2061 (BILN(W)2061)

13 BILN 69 2061 4 BILN 2061 (BILN(W)2061)

0 BILN 2061 (BILN(W)2061)

0 BILN 5 2061 0 BILN 2061 (BILN(W)2061)

FILE 'MATBUS'

FILE 'MATH'

FILE 'MATHDI'

0 BILN 5 2061 0 BILN 2061 (BILN(W)2061)

0 BILN 8 2061 0 BILN 2061 (BILN(W)2061)

6 2061 0 BILN 2061 (BILN(W)2061)

0 BILN

FILE 'MECHENG'
0 BILN
2 2061
0 BILN 2061
(BILN(W)2061)

19 BILN 122 2061

```
538 "2061"
1 BILN 2061
("BILN"(W)"2061")
FILE 'PATDPAFULL'
                     1 BILN
210 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                       FILE 'RAPRA'
                                                                                                                                                                                                0 BILN
8 2061
0 BILN 2061
(BILN(W)2061)
FILE 'PATOSDE'
                        E'

0 BILN

0 2061

0 BILN 2061

(BILN(W)2061)
                                                                                                                                                                       FILE 'RSWB'
                                                                                                                                                                                                0 BILN
5 2061
0 BILN 2061
(BILN(W)2061)
FILE 'PATOSEP'
                        0 BILN
4 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                       FILE 'RUSSCI
                                                                                                                                                                       0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'SCISEARCH'
27 BILN
168 2061
FILE 'PATOSWO'
                        0'
0 BILN
1 2061
0 BILN 2061
(BILN(W)2061)
FILE 'PCTFULL'
40 BILN
2832 2061
11 BILN 2061
                                                                                                                                                                                               22 BILN 2061
(BILN(W)2061)
                                                                                                                                                                       FILE 'SIGLE'
                                                                                                                                                                       FILE 'SIGLE'

0 BILN
0 2061
0 BILN 2061
0 BILN(W)2061)
FILE 'SOLIDSTATE'
0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061")
                                (BILN(W)2061)
FILE PCTGEN'
0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'PHARMAML'
FILE 'PCTGEN'
                         0 BILN
0 2061
0 BILN 2061
                                                                                                                                                                       FILE 'SOLIS'
                                                                                                                                                                                                0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                      0 b. (Bil.)

FILE 'SYNTHLINE'
1 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061")
                                 (BILN(W)2061)
FILE 'PHIC'
                          0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061")
FILE 'PHIN'
                              "BILN"
"2061"
                          2 BILN 2061
("BILN"(W)"2061")
                                                                                                                                                                       FILE 'TEMA'

1 BILN
12 2061
0 BILN 2061
(BILN(W)2061)

FILE 'TEXTILETECH'
0 BILN
6 2061
0 BILN 2061
(BILN(W)2061)

FILE 'TOXCENTER'
6 BILN
63 2061
4 BILN 2061
FILE 'PIRA'
                         0 "BILN"
1 "2061"
0 BILN 2061
("BILN"(W)"2061")
FILE 'POLLUAB'
                         B'

0 "BILN"

1 "2061"

0 BILN 2061

("BILN"(W)"2061")
FILE 'PROMT'
                         7 "BILN"
```

```
(BILN(W)2061)
                                                                                                                                                                                            4 BILN
70 2061
2 BILN 2061
(BILN(W)2061)
FILE 'TRIBO'
                         0 BILN
0 2061
                         0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                     FILE 'WPIFV
                                                                                                                                                                                              0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'TULSA'
                         0 BILN
0 2061
0 BILN 2061
                                                                                                                                                                     FILE 'WPINDEX'
                                                                                                                                                                                            4 BILN
70 2061
                                 (BILN(W)2061)
FILE 'TULSA2'
                                                                                                                                                                                              2 BILN 2061
(BILN(W)2061)
                         0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                     FILE 'WSCA'
                                                                                                                                                                     1 2061
0 BILN 2061
(BILN(W)2061)
FILE 'WTEXTILES'
FILE 'UFORDAT'
                         0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                                              0 BILN
8 2061
0 BILN 2061
FILE 'ULIDAT'
0 BILN
1 2061
0 BILN 2061
(BILN(W)2061)
FILE 'USPATFULL'
                                                                                                                                                                                                     (BILN(W)2061)
                                                                                                                                                                     L15 QUE BILN 2061
                   ATFULL'
17 BILN
4661 2061
6 BILN 2061
(BILN(W)2061)
                                                                                                                                                                     F1
F2
F3
F4
F5
F6
F7
F8
F10
F11
F12
F13
                                                                                                                                                                           d rank
                                                                                                                                                                                                      EMBASE
SCISEARCH
BIOSIS
                                                                                                                                                                                            422185311000864444333222222111111
                                                                                                                                                                                                       INVESTEXT
FILE 'USPAT2'
                                                                                                                                                                                                     INVESTEXT
MEDLINE
PCTFULL
CAPLUS
DDFU
DRUGU
BIOTECHNO
USPATFULL
LIFESCI
PASCAL
TOXCENTER
ESBIOBASE
INSDRUGNEWS
NI DR
                     0 BILN
210 2061
                         0 BILN 2061
(BILN(W)2061)
 FILE 'VETB'
                         0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'VETU'
                         0 BILN
3 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                      F16
                                                                                                                                                                                                      IMSDRUGNES
NLDB
ADISCTI
BIOENG
CBNB
COMPENDEX
FILE 'WATER'
                         0 BILN
2 2061
2 2061

0 BILN 2061

(BILN(W)2061)

FILE 'WELDASEARCH'

0 BILN

0 2061

0 BILN 2061
                                                                                                                                                                                                       PHIN
                                                                                                                                                                                                       WPIDS
WPINDEX
                                                                                                                                                                                                       BABS
CIN
EMBAL
                                                                                                                                                                      F26
F27
F28
F29
                                  (BILN(W)2061)
                                                                                                                                                                                                       IFIPAT
PROMT
 FILE 'WPIDS'
```

```
=> index f1-f29
COST IN U.S. DOLLARS
TOTAL
                                                                 SINCE FILE
                                                                        ENTRY
SESSION
                                                                         1.14
FULL ESTIMATED COST 94.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                  SINCE FILE
                                                                         ENTRY
CA SUBSCRIBER PRICE 4.90
                                                                          0.00
INDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL, CAPLUS, DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER,
. WPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON 26 OCT 2004
29 FILES IN THE FILE LIST IN STNINDEX
Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^{\star} with SET DETAIL OFF.
       (FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004)
3 L10 AND PD<20030327
       FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
        INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
AGRICOLA,
ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
BABS, BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS,
BIOTECHABS,
BIOTECHABS,
BIOTECHABS,
BIOTECHOS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
15:24:55 ON
26 OCT 2004
                      SEA BILN 2061
                         FILE BABS
FILE BIOSIS
FILE BIOSIS
FILE BIOTECHNO
FILE CAPLUS
FILE CBNB
FILE CIN
                   18
                   8
10
2
1
```

```
20 "BILN"
1 "BILNS"
21 "BILN"
1 "BILN"
1864 "2061"
15 BILN 2061
("BILN"(W)"2061")
34452 CRYSTAL?
0 L15 AND CRYSTAL?
FILE 'MEDLINE'
19 BILN
122 2061
13 BILN 2061
(BILN(W)2061)
122732 CRYSTAL?
0 L15 AND CRYSTAL?
FILE 'PCTFULL'
81LN
2832 2061
11 BILN 2061
(BILN(W)2061)
127299 CRYSTAL?
9 L15 AND CRYSTAL?
FILE 'CAPLUS'
20 BILN
382 2061
10 BILN 2061
(BILN(W)2061)
1605797 CRYSTAL?
FILE 'DDFU'
13 BILN
21 2061
10 BILN 2061
(BILN(W)2061)
7961 CRYSTAL?
FILE 'DDFU'
13 BILN
21 2061
10 BILN 2061
(BILN(W)2061)
7961 CRYSTAL?
FILE 'DRUGU'
13 BILN
21 2061
10 BILN 2061
(BILN(W)2061)
7961 CRYSTAL?
FILE 'DRUGU'
13 BILN
2061
(BILN 2061)
12117 CRYSTAL?
FILE 'BIOTECHNO'
12 BILN
43 2061
(BILN 2061)
(BILN 2061)
27086 CRYSTAL?
3 L15 AND CRYSTAL?
FILE 'USPATFULL'
17 BILN
4661 2061
(BILN 2061)
(BILN 2061)
(BILN 2061)
17 BILN
4661 2061
(BILN 2061)
```

```
2 FILE COMPENDEX
10 FILE DDFU
10 FILE DDFU
10 FILE DRUGU
1 FILE EMBAL
42 FILE EMBASE
3 FILE ESIDBASE
1 FILE IFIPAT
3 FILE INDRUGNEWS
15 FILE INVESTEXT
4 FILE LIFESCI
13 FILE MUDINE
3 FILE MUDINE
4 FILE PASCAL
11 FILE PCTFULL
2 FILE PHIN
1 FILE PCTFULL
2 FILE PROMT
22 FILE SCISEARCH
4 FILE USPATFULL
2 FILE WPINDEX
12 FILE WPINDEX
15 QUE BILN 2061

LINDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL, CAPLUS, DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER, ESBIOBASE, IMPINDEX, MPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON 26 OCT 2004

>> 115 and crystal?
FILE 'EMBASE'
48 "BILN"
124 "2061"
42 BILN 2061

"PETLIF WON "2061"
42 BILN 2061
"PETLIF WON" 2061"
42 BILN 2061
"PETLIF WON" 2061"
42 BILN 2061
"PETLIF WON" 2061"
42 BILN 2061
```

⇒ 115 and crystal?

FILE 'EMBASE'

48 "BILN"

124 "2061"

42 BILN 2061

("BILN"(W)"2061")

97097 CRYSTAL?

4 L15 AND CRYSTAL?

FILE 'SCISEARCH'

27 BILN

168 2061

22 BILN 2061

(BILN(W)2061)

689047 CRYSTAL?

FILE 'BIOSIS'

27 BILN

129 2061

18 BILN 2061

(BILN(W)2061)

111782 CRYSTAL?

111782 CRYSTAL?

FILE 'INVESTEXT'

```
FILE 'LIFESCI'

28 "2061"

4 BILN 2061
("BILN"(W)"2061")

27296 CRYSTAL?

FILE 'PASCAL'

3 BILN
69 2061
4 BILN 2061
(BILN(W)2061)
517682 CRYSTAL?

0 L15 AND CRYSTAL?

FILE 'TOXCENTER'
6 BILN
63 2061
4 BILN 2061
(BILN(W)2061)
66181 CRYSTAL?

FILE 'ESBIOBASE'
3 BILN
49 2061
3 BILN 2061
(BILN(W)2061)
619 CRYSTAL?

FILE 'IMSDRUGNEW'
5 "2061"
3 BILN 2061
("BILN"(W)2061)
618 CRYSTAL?

FILE 'NLOB' 4 BILN"
5 "2061"
3 BILN 2061
("BILN"(W)"2061)
118 CRYSTAL?

FILE 'NLOB' 4 BILN"
274 "2061
3 BILN 2061
("BILN"(W)"2061")
118 CRYSTAL?

FILE 'NLOB' 4 BILN"
3 BILN 2061
("BILN"(W)"2061")
118 CRYSTAL?

FILE 'NLOB' 4 BILN"
3 BILN 2061
("BILN"(W)"2061")
125 AND CRYSTAL?

FILE 'ADISCTI'
3 BILN 2061
("BILN"(W)"2061")
125 AND CRYSTAL?

FILE 'ADISCTI'
1 BILN 2061
("BILN"(W)"2061)
1 BILN 2061
(BILN(W)2061)
463 CRYSTAL?
FILE 'BIOENG'

FILE 'BIOENG'

8 BILN 2061
(BILN(W)2061)
7912 CRYSTAL?
0 L15 AND CRYSTAL?
```

```
FILE 'CBNB'
 2 BILN
15 2061
2 BILN 2061
(BILN(W)2061)
5823 CRYSTAL?
0 L15 AND CRYSTAL?
FILE 'COMPENDEX'
                       OMPENDEX'
4 BILN
22 2061
2 BILN 2061
(BILN(W)2061)
443469 CRYSTAL?
O L15 AND CRYSTAL?
3 "BILN"
35 "2061"
2 BILN 2061
("BILN"(W)"2061")
1251 CRYSTAL?
FILE 'WPIDS'
 FILE 'WPIOS'

4 BILN

70 2061

2 BILN 2061

(BILN(W)2061)

362675 CRYSTAL?

0 L15 AND CRYSTAL?

FILE 'WPINDEX'

BILN

FILE 'WPINDEX'

BILN

FILE 'WPINDEX'
## CRYSTAL?

### 4 BILN

### 70 2061

### 2061

### 2061

### 2061

### 2061

### 2061

### 362675 CRYSTAL?

### 5 BABS

### 1 2000

### CRYSTAL?
                           1 BILN
24 2061
1 BILN 2061
(BILN(W)2061)
91052 CRYSTAL?
0 L15 AND CRYSTAL?
   FILE 'CIN'
                             1 "BILN"

12 "2061"

1 BILN 2061

("BILN"(W)"2061")

6321 CRYSTAL?
                                      0 L15 AND CRYSTAL?
   FILE 'EMBAL'
                             AL'
1 BILN
4 2061
1 BILN 2061
(BILN(W) 2061)
1192 CRYSTAL?
                                      0 L15 AND CRYSTAL?
   FILE 'IFIPAT'
   => 116
L18
                                    25 L16
   => dup rem
ENTER L# LIST OR (END):118
PROCESSING COMPLETED FOR L18
L19 21 DUP REM L18 (4 DUPLICATES REMOVED)
    => 119 and pd<20030327
1 FILES SEARCHED...
3 FILES SEARCHED...
L20 2 L19 AND PD<20030327
    => d 120 1-2 ibib hitstr abs kwic
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'EMBASE'
    The following are valid formats:
    The default display format is BIB.
  ABS ------ AB
ALL ----- AN, DN, TI, AU, CS, SO, PUI, CY, DT, FS, LA, SL, AB,
CT, RN, CN, NP, CO, GEN
BIB ------ AN, DN, TI, AU, CS, SO, PUI, CY, DT, FS, LA, SL
CBIB ------ ADD TI, AU, CS, SO, PUI, CY, DT, FS, LA, SL
CBIB ------ ALL, delimited for post-processing
IABS ------ ALL, indented with text labels
IABL ------ ALL, indented with text labels
IBIB ------ BIB, indented with text labels
IND ------ CT, RN, CN, NP, CO, GEN
TRIAL ----- II, CT, RN, CN, NP, CO, GEN
(SAM, TRI)
HIT ------ All fields containing hit terms
HITIND ----- IND
    HIT ------ IND

KWIC ----- All hit terms plus 20 words on either side
OCC ----- List of display fields containing hit terms
and number of occurrences in each field
    Hit terms will be highlighted in all displayable fields.
   To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'BIB'; 'AB'; 'SO,ST'. You may specify the format fields in any order, and the information will be displayed in the same order as the format specification.
    The same formats (except for HIT, HITIND, KWIC, and OCC) may be used with the DISPLAY ACC command to display the record for a specified Accession Number.
     ENTER DISPLAY FORMAT (BIB): iall
     L20 ANSWER 1 OF 2 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. On STN
```

```
1 BILN
39 2061
1 BILN 2061
(BILN(W)2061)
146324 CRYSTAL?
                     0 L15 AND CRYSTAL?
FILE 'PROMT'
              DMT'
7 "BILN"
538 "2061"
1 BILN 2061
("BILN"(W)"2061")
95992 CRYSTAL?
0 L15 AND CRYSTAL?
L16 QUE L15 AND CRYSTAL?
                            EMBASE
                             SCISEARCH
                            BTOTECHNO
=> file f3-5,f1,f2
COST IN U.S. DOLLARS
TOTAL
                                                                                   SINCE FILE
                                                                                           ENTRY
SESSION
FULL ESTIMATED COST
95.93
                                                                                            1.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                                   SINCE FILE
                                                                                           ENTRY
SESSION
CA SUBSCRIBER PRICE
4.90
                                                                                            0.00
FILE 'EMBASE' ENTERED AT 15:27:48 ON 26 OCT 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.
FILE 'SCISEARCH' ENTERED AT 15:27:48 ON 26 OCT 2004 Copyright (c) 2004 The Thomson Corporation.
FILE 'BIOTECHNO' ENTERED AT 15:27:48 ON 26 OCT 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'PCTFULL' ENTERED AT 15:27:48 ON 26 OCT 2004 COPYRIGHT (C) 2004 Univentio
FILE 'USPATFULL' ENTERED AT 15:27:48 ON 26 OCT 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
=> 116, dup rem
L17 0 L16, DUP REM
```

F1 F2 F3 F4 F5

ACCESSION NUMBER:

```
TITLE:
antiviral
                                     treatment and prevention of hepatitis C.
Hugle T.; Cerny A.
Dr. A. Cerny, Clinica Medica, Ospedale Civico,
AUTHOR:
CORPORATE SOURCE:
CH-6903
                                   Lugano, Switzerland. andreas.cerny@bluewin.ch
Reviews in Medical Virology, (2003) 13/6
(361-371).
Refs: 79
ISSN: 1052-9276 CODEN: RMVIEW
United Kingdom
Journal; General Review
004 Microbiology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
Pharmacy
English
SOURCE:
COUNTRY:
DOCUMENT TYPE:
FILE SEGMENT:
LANGUAGE:
SIMMARY LANGUAGE: English
ABSTRACT:
Current therapeutic options for hepatitis C are limited, especially
for
genotype 1. For genotypes 2 and 3, pegylated interferon in combination with ribavirin, can lead to a sustained virological response in up to 80% of
patients. Unfortunately, adverse effects of IFN and ribavirin are a
patients. Unfortunately, doverse effects of Irw and Thavillim are a major problem and the list of contraindications for HCV therapy is long, including decompensated cirrhosis of the liver and psychiatric disorders. Therefore, alternative therapeutic approaches are needed. New delivery options for IFN and properties are recorded.
 ribavirin are aimed at optimising efficiency and reducing adverse effects.
 Recent progress in the molecular virology of HCV has identified new
targets for
antiviral intervention. Inhibition of HCV gene expression and
replication as
well as immunotherapeutic concepts aimed at enhancing the cellular
 Immune
response against HCV are being explored. Solution of the crystal
structures of HCV key enzymes led to the design of specific
inhibitor.
 including compounds active against the well characterised NS3 serine
protease
and RNA-dependent RNA polymerase which are currently in the early
phase
clinical investigation. New strategies for inhibiting HCV gene
 expression include the use of antisense oligodeoxynucleotides and ribozymes. 
Immunomodulation by agents such as inosine monophosphate
 dehydrogenase
inhibitors, thymosin-alpha 1, histamine or amantadine are being
```

2003468113 EMBASE $\frac{Full-text}{new\ molecular}$ approaches to

```
ribavirin: CT, clinical trial
ribavirin: CM, drug combination
ribavirin: CM, drug comparison
ribavirin: DT, drug therapy
ribavirin: PX, pharmacokinetics
ribavirin: PD, pharmacology
ribavirin: PO, oral drug administration
albumin conjugate: PR, pharmaceutics
liposome: PR, pharmaceutics
polyaminoacid: PR, pharmaceutics
polyaminoacid: PO, oral drug administration
ribavirin derivative: CR, drug combination
ribavirin derivative: CR, drug comparison
ribavirin derivative: CR, drug comparison
ribavirin derivative: DT, drug therapy
ribavirin derivative: PD, pharmacology
viramidine: AE, adverse drug reaction
viramidine: CT, clinical trial
viramidine: CM, drug comparison
viramidine: CM, drug comparison
viramidine: CM, drug comparison
viramidine: DT, drug therapy
viramidine: CM, drug comparison
viramidine: DT, drug therapy
viramidine: CT, clinical trial
levovirin: CM, drug comparison
levovirin: CM, drug comparison
levovirin: CM, drug comparison
levovirin: DT, drug therapy
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PO, oral drug

biln 2061: AE, adverse drug reaction
biln 2061: AE, adverse drug reaction
biln 2061: CT, clinical trial
  combination with IFN and/or ribavirin. Immunotherapeutic vaccination with
with recombinant HCV E1 protein improved host immunity against HCV and thus seems to be a promising new option. Copyright .COPYRGT. 2003 John Wiley & Sons, Ltd.
                                                                                      Medical Descriptors:
*hepatitis C: DT, drug therapy
*hepatitis C: ET, etiology
*hepatitis C: PC, prevention
*infection prevention
virus gene
genotype
drug response
drug contraindication
drug delivery system
side effect: SI, side effect
gene expression
drug targeting
immunotherapy
enzyme structure
crystal structure
drug design
 CONTROLLED TERM:
                                                                                       enzyme structure
crystal structure
drug design
drug activity
antiviral activity
protein targeting
immunomodulation
vaccination
Hepatitis C virus
immune response
cellular immunity
hemolytic anemia: SI, side effect
flu like syndrome: SI, side effect
flu like syndrome: SI, side effect
leukopenia: SI, side effect
thrombocytopenia: SI, side effect
teratogenicity
virus replication
drug hypersensitivity: SI, side effect
human
nonhuman
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  biln 2061: AE, adverse drug reaction biln 2061: CT, clinical trial biln 2061: DD, drug dose biln 2061: DD, drug therapy biln 2061: PK, pharmacokinetics biln 2061: PD, pharmacology biln 2061: PD, pharmacology biln 2061: PD, oral drug administration vx 950: DT, drug therapy vx 950: PD, pharmacology virus protein NSSB RNA directed DNA polymerase inhibitor: CT,
                                                                                                                                                                                                                                                                                                                                                                                          administration
                                                                                      nonhuman clinical trial review
Drug Descriptors:
alpha interferon: AE, adverse drug reaction alpha interferon: CT, clinical trial alpha interferon: CB, drug combination alpha interferon: DT, drug therapy alpha interferon: TO, drug toxicity alpha interferon: PR, pharmaceutics alpha interferon: PR, pharmacelogy alpha interferon: SC, subcutaneous drug
                                                                                           human
                                                                                                                                                                                                                                                                                                                                                                                          clinical trial
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     RNA directed DNA polymerase inhibitor: DT, drug
                                                                                                                                                                                                                                                                                                                                                                                          therapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    RNA directed DNA polymerase inhibitor: PD.
                                                                                                                                                                                                                                                                                                                                                                                          pharmacology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    jtk 003: CT, clinical trial
jtk 003: DT, drug therapy
jtk 003: PD, pharmacology
ribozyme: AE, adverse drug reaction
administration
                                                                                           ribavirin: AE, adverse drug reaction
                                                                                        ribozyme: CT, clinical trial ribozyme: DT, drug therapy ribozyme: DT, drug therapy ribozyme: TO, drug toxicity ribozyme: PD, pharmacology hepatozyme: AE, adverse drug reaction hepatozyme: CT, clinical trial hepatozyme: DT, drug therapy hepatozyme: TO, drug toxicity hepatozyme: PD, pharmacology antisense oligodeoxynucleotide: CT, clinical
                                                                                                                                                                                                                                                                                                                                                                                         L20 ANSWER 2 OF 2 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
                                                                                                                                                                                                                                                                                                                                                                                         on STN
ACCESSION NUMBER:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2003195244 EMBASE <u>Full-text</u>
Hepatitis C virus therapies: Current treatments,
                                                                                                                                                                                                                                                                                                                                                                                          TITLE:
targets
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  and future perspectives.
Walker M.P.; Appleby T.C.; Zhong W.; Lau J.Y.N.;
                                                                                                                                                                                                                                                                                                                                                                                          AUTHOR:
                                                                                      antisense oligodeoxynucleotide: CT, clinical
antisense oligodeoxynucleotide: DT, drug therapy
antisense oligodeoxynucleotide: PD, pharmacology
isis 14803: CT, clinical trial
isis 14803: DT, drug therapy
sis 14803: DT, drug therapy
sis 14803: DT, pharmacology
RNA derivative: DV, drug development
RNA derivative: DT, drug therapy
RNA derivative: PD, pharmacology
small interfering rna: DV, drug development
small interfering rna: DT, drug therapy
small interfering rna: DT, drug therapy
monoclonal antibody: DT, drug therapy
monoclonal antibody: DT, drug therapy
xtl 002: DT, drug therapy
xtl 002: DT, drug therapy
cicavir: DT, drug therapy
cicavir: PD, pharmacology
inmunomodulating agent: CB, drug combination
immunomodulating agent: CB, drug therapy
thymosin alphal: CT, clinical trial
thymosin alphal: CB, drug dose
thymosin alphal: DD, drug dose
thymosin alphal: DT, drug therapy
                                                                                                                                                                                                                                                                                                                                                                                          Hong Z.
CORPORATE SOURCE:
Mesa, CA,
trial
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Z. Hong, Ribapharm Inc., Hyland Avenue, Costa
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                United States. zhihong@ribapharm.com
Antiviral Chemistry and Chemotherapy, (2003) 14/1
(1-21).
Refs: 208
ISSN: 0956-3202 CODEN: ACCHEH
United Kingdom
Journal: General Review
004 Microbiology
030 Pharmacology
037 Drug Literature Index
048 Gastroenterology
English
                                                                                                                                                                                                                                                                                                                                                                                          SOURCE:
                                                                                                                                                                                                                                                                                                                                                                                         COUNTRY:
DOCUMENT TYPE:
FILE SEGMENT:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                English
English
                                                                                                                                                                                                                                                                                                                                                                                          LANGUAGE:
SUMMARY LANGUAGE:
                                                                                                                                                                                                                                                                                                                                                                                          ABSTRACT:
                                                                                                                                                                                                                                                                                                                                                                                          Chronic hepatitis C virus (HCV) infection is the cause of an emerging global epidemic of chronic liver disease. Current combination therapies are
                                                                                                                                                                                                                                                                                                                                                                                          at best
80% efficacious and are often poorly tolerated. Strategies to improve
                                                                                                                                                                                                                                                                                                                                                                                          therapeutic response include the development of novel interferons,
                                                                                                                                                                                                                                                                                                                                                                                         nucleoside
analogues with reduced haemolysis compared with ribavirin and inosine
5'-monophosphate dehydrogenase inhibitors. Compounds in preclinical
combination
                                                                                         inosinate dehydrogenase inhibitor: DT, drug
                                                                                                                                                                                                                                                                                                                                                                                          or early
clinical trials include small molecules that inhibit virus-specific
```

clinical trials include small molecules that indirections specific enzymes (such as the serine proteases, RNA polymerase and helicase) or interfere with translation (including antisense molecules, iRNA and ribozymes). Advances in understanding HCV replication, obtaining a sub-genomic replicon and contribution.

understanding McV replication, obtaining a sub-galactic contriving potential small animal models, in addition to solving crystallographic structures for the replication enzymes, have improved prospects for developing novel therapies. This review summarizes current and evolving transpare for

chronic hepatitis C infection. In addition, progress in HCV targets and drug discovery tools valuable in the search for novel anti-HCV agents is detailed.

therapy

pharmacology

198821-22-6,

CHEMICAL NAME:

COMPANY NAME:

CAS REGISTRY NO.: 37205-61-1:

inosinate dehydrogenase inhibitor: PD,

merimepodib: CT, clinical trial merimepodib: CB, drug combination merimepodib: DT, drug therapy merimepodib: PD, pharmacology unindexed drug unclassified drug (ribavirin) 36791-04-5; (proteinase inhibitor)

(thymosin alpha1) 69521-94-4; (merimepodib)

Sciclone; RegeneRx; Maxim

198821-38-4 (1) vx 950; (2) Jtk 003; Biln 2061; Isis 14803; Xtl 002 (1) Vertex; (2) Akros; Ribozyme Pharmaceuticals;

```
Medical Descriptors:
*hepatitis C: DT, drug therapy
*hepatitis C: EP, epidemiology
*hepatitis C: ET, etiology
*chronic liver disease: ET, etiology
drug efficacy
drug tolerance
hemolytic anemia: SI, side effect
side effect: SI, side effect
alanine aminotransferase blood level
virus replication
replicon
crystal structure
RNA translation
untranslated region
internal ribosome entry site
monotherapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             nucleoside derivative: DV, drug development
nucleoside derivative: PR, pharmaceutics
nucleoside derivative: PD, pharmacology
ribavirin: AE, adverse drug reaction
ribavirin: CT, clinical trial
ribavirin: CB, drug combination
ribavirin: CM, drug comparison
ribavirin: DO, drug dose
ribavirin: DT, drug therapy
ribavirin: PD, pharmacology
inosinate dehydrogenase inhibitor: CM, drug
CONTROLLED TERM:
                                                                                                                                                                                                                                                                                                                                                                                                                                                      comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               inosinate dehydrogenase inhibitor: DT, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                       therapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              inosinate dehydrogenase inhibitor: PD,
                                                                                                    internal ribosome ent
monotherapy
virus load
treatment outcome
treatment indication
immunomodulation
drug safety
treatment failure
chimpanzee
transgenic mouse
Hepatitis GB virus B
IC 50
structure activity per
                                                                                                                                                                                                                                                                                                                                                                                                                                                      pharmacology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              serine proteinase: EC, endogenous compound
RNA polymerase: EC, endogenous compound
helicase: EC, endogenous compound
ribozyme: EC, endogenous compound
recombinant alpha2a interferon: CM, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                     comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             recombinant alpha2a interferon: DO, drug dose
recombinant alpha2a interferon: DT, drug therapy
recombinant alpha2a interferon: PD, pharmacology
recombinant alpha2a interferon: SC, subcutaneous
                                                                                                                                                                                                                                                                                                                                                                                                                                                      drug
                                                                                                         structure activity relation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              administration recombinant alpha2b interferon: CM, drug
                                                                                                      structure actively drug structure virus assembly human nonhuman clinical trial
                                                                                                                                                                                                                                                                                                                                                                                                                                                       comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              recombinant alpha2b interferon: DO, drug dose
recombinant alpha2b interferon: DT, drug therapy
recombinant alpha2b interferon: PD, pharmacology
recombinant alpha2b interferon: SC, subcutaneous
                                                                                                   clinical trial
review
priority journal
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: CT, clinical trial
*antivirus agent: AN, drug analysis
*antivirus agent: CB, drug combination
*antivirus agent: CM, drug comparison
*antivirus agent: DV, drug development
*antivirus agent: DV, drug dose
*antivirus agent: DT, drug therapy
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
*antivirus agent: IV, intravenous drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                       drua
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             administration
consensus interferon: CM, drug comparison
consensus interferon: DO, drug dose
consensus interferon: DT, drug therapy
consensus interferon: PD, pharmacology
consensus interferon: SC, subcutaneous drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            peginterferon alpha2b: CT, clinical trial peginterferon alpha2b: CB, drug combination peginterferon alpha2b: CB, drug combination peginterferon alpha2b: DO, drug dose peginterferon alpha2b: DT, drug therapy peginterferon alpha2b: DT, drug therapy peginterferon alpha2b: PD, pharmacology peginterferon alpha2a: CT, clinical trial peginterferon alpha2a: CB, drug combination peginterferon alpha2a: CB, drug comparison peginterferon alpha2a: DO, drug dose peginterferon alpha2a: DO, drug dose peginterferon alpha2a: DT, drug therapy peginterferon alpha2a: PD, pharmacology levovirin: CT, clinical trial levovirin: CN, drug analysis levovirin: CM, drug comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                       administration
 administration
                                                                                                        *antivirus agent: SC, subcutaneous drug
 administration
                                                                                                      alpha interferon: AE, adverse drug reaction alpha interferon: CB, drug combination alpha interferon: CM, drug comparison alpha interferon: DO, drug dose alpha interferon: DT, drug therapy alpha interferon: PD, pharmacology nucleoside derivative: AN, drug analysis nucleoside derivative: CM, drug comparison
                                                                                                   levovirin: DV, drug development
levovirin: DO, drug dose
levovirin: DT, drug therapy
levovirin: PD, pharmacology
viramidine: CT, clinical trial
viramidine: AN, drug analysis
viramidine: DN, drug dose
viramidine: DT, drug therapy
viramidine: PD, pharmacology
merimepodib: CT, clinical trial
merimepodib: CM, drug analysis
merimepodib: CM, drug comparison
merimepodib: DN, drug development
merimepodib: DV, drug development
merimepodib: DV, drug development
merimepodib: DN, drug development
thymosin alphal: CT, clinical trial
thymosin alphal: CB, drug combination
thymosin alphal: DN, drug dose
thymosin alphal: SC, subcutaneous drug
amantadine: CT, clinical trial
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          biln 2061: CT, clinical trial
biln 2061: DO, drug dose
biln 2061: PD, pharmacology
biln 2061: PD, oral drug administration
peptide derivative: AN, drug analysis
peptide derivative: DV, drug development
peptide derivative: PD, pharmacology
peptide alpha keto acid: DV, drug development
pyrrolidine derivative: AN, drug analysis
pyrrolidine derivative: PD, pharmacology
pyrrolidine 5,5 lactam: AN, drug analysis
pyrrolidine 5,5 lactam: AN, drug analysis
pyrrolidine 5,5 lactam: PD, drug development
pyrrolidine 5,5 lactam: PD, drug development
IDdb3: PD, pharmacology
unindexed drug
unclassified drug
isis 14803
gw 3112
gw 2549
gw 0569
n [4 [[[6,7 dihydro 2 (4 methylphenyl) 5h
                                                                                                                                                                                                                                                                                                                                                                                                                                                       administration
                                                                                                   thymosin alphal: PD, pharmacology thymosin alphal: SC, subcutaneous drug amantadine: CH, drug camplisis amantadine: CM, drug analysis amantadine: CM, drug comparison amantadine: CM, drug development amantadine: PD, pharmacology recombinant interleukin 12: CT, clinical trial recombinant interleukin 12: CM, drug analysis recombinant interleukin 12: CM, drug comparison recombinant interleukin 12: CM, drug dose recombinant interleukin 12: DV, drug development recombinant interleukin 12: DV, drug development recombinant interleukin 12: DV, drug development recombinant interleukin 12: DV, drug dose recombinant interleukin 12: DV, drug dose recombinant interleukin 12: DV, drug dose recombinant interleukin 12: PD, pharmacology histamine: CT, clinical trial histamine: AN, drug analysis histamine: CB, drug combination histamine: DV, drug development histamine: DV, drug development histamine: DV, drug therapy histamine: DV, drug therapy histamine: DV, drug development gamma interferon: CM, drug combination gamma interferon: DV, drug development gamma interferon: DV, drug development gamma interferon: DV, drug therapy gamma interferon: PD, pharmacology proteinase inhibitor: DO, drug dose proteinase inhibitor: DO, drug dose proteinase inhibitor: PO, pharmacology proteinase inhibitor: PO, pharmacology proteinase inhibitor: PO, pharmacology proteinase inhibitor: PO, pharmacology proteinase inhibitor: PO, pharmacology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 n [4 [[[6.7 dihydro 2 (4 methylphenyl) 5h
 administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                       benzocyclohepten
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               8 yl]carbonyl]amino]benzyl] n,n dimethyl 2h
                                                                                                                                                                                                                                                                                                                                                                                                                                                        tetrahydropyran
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              4 aminium chloride
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane)
(ribavirin) 36791-04-5; (serine proteinase)
                                                                                                                                                                                                                                                                                                                                                                                                                                                        CAS REGISTRY NO.: 37259-58-8:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (RNA polymerase) 9014-24-8; (helicase) 42613-29-
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 (recombinant alpha2b interferon) 98530-12-2;
                                                                                                                                                                                                                                                                                                                                                                                                                                                        (peginterferon
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               alpha2b) 215647-85-1; (peginterferon alpha2a)
                                                                                                                                                                                                                                                                                                                                                                                                                                                        198153-51-4;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (merimepodib) 198821-22-6, 198821-38-4; (thymosin
                                                                                                                                                                                                                                                                                                                                                                                                                                                        alpha1)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 69521-94-4; (amantadine) 665-66-7, 768-94-5;
                                                                                                                                                                                                                                                                                                                                                                                                                                                        (histamine)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 51-45-6, 56-92-8, 93443-21-1; (gamma interferon)
82115-62-6; (proteinase inhibitor) 37205-61-1; (n
                                                                                                                                                                                                                                                                                                                                                                                                                                                        [4 [[[6,7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              dihydro 2 (4 methylphenyl) 5h benzocyclohepten 8
yl]carbonyl]amino]benzyl] n,n dimethyl 2h
```

tetrahydropyran 4

3100: IDdb3

CHEMICAL NAME: 779; Amd

aminium chloride) 229005-80-5; (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5 (1) vx 497; (2) Ceplene; (3) Biln 2061; (4) Isis 14803; Zadaxin; Gw 3112; Gw 2549; Gw 0569; Tak

```
Viropharma: Japanese tobacco: IRBM
=> d his
       (FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004)
       INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE,
AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS,
BIOTECHOS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN,
CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:25:23 ON
26 OCT 2004
       FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004
1 S 300832-84-2/RN
SET SMA OFF
DEL SEL Y
SEL RN
SET SMA LOGIN
L1
       INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004
SEA E1 AND OPTICAL?/FA
                       QUE 300832-84-2/BI AND OPTICAL?/FA
L2
       FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004
0 S L1/BMF
L3
       FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004 0 S \text{L1/BPN}
L4
       FILE 'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004
0 S L1/IMF
ι.5
       FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004 1 S 11/PEP
L6
       FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004
0 S L1/PUR
L7
       FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004
6 S (L1/SPN OR L1/CPN)
6 FOCUS L8 1-
L9
       FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004
        IMSDRUGNEWS, NLDB, ADISCTI, BIOENG, CBNB, COMPENDEX, PHIN,
WPIDS, WPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON
26 OCT
        2004
                        SEA L15 AND CRYSTAL?
                           FILE EMBASE
FILE SCISEARCH
FILE PCTFULL
FILE BIOTECHNO
                            FILE USPATEUL
                        QUE L15 AND CRYSTAL?
L16
        FILE 'EMBASE, SCISEARCH, BIOTECHNO, PCTFULL, USPATFULL' ENTERED
AT
       15:27:48 ON 26 OCT 2004

0 L16, DUP REM

25 L16

21 DUP REM L18 (4 DUPLICATES REMOVED)

2 L19 AND PD<20030327
 ı 17
L18
L19
L20
    stnindex
-> STANIOGEX
ENTER FILE OR CLUSTER NAMES (NONE):all
FILE 'ENCOMPLIT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPLIT2' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
                                                                       STNCE FILE
 TOTAL
                                                                              ENTRY
FULL ESTIMATED COST 112.45
                                                                              16.52
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                       STNCE FILE
                                                                              ENTRY
CA SUBSCRIBER PRICE 4.90
                                                                                0.00
 INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
          ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
```

BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,

BIOTECHOS, BIOTECHOO, BLLDB, CABA, CANCERLIT, ... ENTERED AT 15:32:46 ON 26 OCT 2004

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^{\star} with SET DETAIL OFF.

143 FILES IN THE FILE LIST IN STNINDEX

BIOTECHABS

(1) Vertex (United States); (2) Maxim; (3)

(United States); Glaxo SmithKline (United

Myers Squibb (United States); Celera (United

Ingelheim; (4) Isis (United States); Ribapharm;

COMPANY NAME:

Kingdom); Bristol

Boehringer

States);

```
FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004
                               15 S L1

0 L10 AND CRYSTAL

0 L10 AND CRYSTAL?

0 L10 AND ALCOHOL
L11
L12
L13
L14
                                 0 L10 AND ALCOHOL
3 L10 AND PD<20030327
            FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
            INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
           LULA,
ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
BABS.
            BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS
BIOTECHASS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT 15:24:55 ON 26 OCT 2004
                                       SEA BILN 2061
                                             FILE ADISCTI
FILE BABS
FILE BIOENG
FILE BIOTECHNO
                                  10
                                              FILE CAPLUS
                                             FILE CAPLUS
FILE CBNB
FILE CINB
FILE COMPENDEX
FILE DOFU
FILE DENGU
FILE EMBAL
FILE ESBIOBASE
FILE ESBIOBASE
FILE INFORTUS
FILE INFORTUS
FILE INFORTUS
FILE INFORTUS
FILE PASCAL
FILE FILE FILE
FILE FILE FILE
FILE FILE FILE
FILE FILE
FILE WPINDEX
FILE WPINDEX
FILE WPINDEX
FILE WINDEX
                                               FILE CBNB
                                  10
10
                                  42
                                  3
15
4
13
3
4
L15
                                       QUE BILN 2061
INDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL, CAPLUS,
DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER,
 ESBIOBASE,
```

```
=> ciluprevir/cn
FILE 'IMOBILITY'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE '2MOBILITY'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'ABI-INFORM'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AGISCIT'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AGRICOLA'
O CILUPREVIR/CN
FILE 'AGRICOLA'
O CILUPREVIR/CN
FILE 'ANABSTR'
O CILUPREVIR/CN
FILE 'ANABSTR'
O CILUPREVIR/CN
FILE 'ANTE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'APOLLIT'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUALINE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUALINE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUALINE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUALINE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BABS'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIBLIODATA'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIBLIODATA'
CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIOSUSINESS'
C'N' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIOSUSINESS'
C'N' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIOCOMMERCE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIOCOMMERCE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
CON' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
CON' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
CON' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
CON' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
CON' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
CON' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIORUSINESS'
SEARCH ENDED BY USER
FILE 'BIOTECHABS'
SEARCH ENDED BY USER
```

	0 CILUPREVIR
=> ciluprevir/ FILE 'lmOBILITY'	FILE 'BIOENG' O CILUPREVIR
'CILUPREVIR/' IS NOT A VALID FIELD CODE For a list of field codes for the current file, enter "HELP SFIELDS" at an arrow prompt (=>).	0 CILUPREVIR FILE 'BIOSIS' 0 CILUPREVIR
=> ciluprevir	O CILUPREVIR FILE 'BIOTECHABS'
FILE 'IMOBILITY' 0 CILUPREVIR	0 CILUPREVIR 0 CILUPREVIR
O CILUPREVIR FILE '2MOBILITY' 0 CILUPREVIR	FILE 'BIOTECHDS' O CILUPREVIR O CILUPREVIR
U CILUPREVIR 0 CILUPREVIR FILE 'ABI-INFORM'	FILE 'BIOTECHNO' O CILUPREVIR
O CILUPREVIR O CILUPREVIR	0 CILUPREVIR FILE 'BLLDB'
FILE 'ADISCTI' CILUPREVIR 0 CILUPREVIR	0 CILUPREVIR 0 CILUPREVIR FILE 'CABA'
FILE 'AEROSPACE' 0 CILUPREVIR	0 CILUPREVIR 0 CILUPREVIR
0 CILUPREVIR FILE 'AGRICOLA'	FILE 'CANCERLIT' 0 CILUPREVIR
O CILUPREVIR O CILUPREVIR FILE 'ALUMINIUM'	0 CILUPREVIR FILE 'CAOLD' 0 CILUPREVIR
0 CILUPREVIR 0 CILUPREVIR	0 CILUPREVIR FILE 'CAPLUS'
FILE 'ANABSTR' 0 CILUPREVIR	O CILUPREVIR O CILUPREVIR FILE 'CASREACT'
0 CILUPREVIR FILE 'ANTE' 0 CILUPREVIR	0 CILUPREVIR 0 CILUPREVIR
0 CILUPREVIR FILE 'APOLLIT'	FILE 'CBNB' 0 CILUPREVIR
0 CILUPREVIR 0 CILUPREVIR	O CILUPREVIR FILE 'CEABA-VTB' O CILUPREVIR
FILE 'AQUALINE' 0 CILUPREVIR 0 CILUPREVIR	0 CILUPREVIR FILE 'CEN'
FILE 'AQUASCI' 0 CILUPREVIR	0 CILUPREVIR 0 CILUPREVIR
O CILUPREVIR FILE 'AQUIRE' O CILUPREVIR	FILE 'CERAB' 0 CILUPREVIR 0 CILUPREVIR
0 CILUPREVIR FILE 'BABS'	FILE 'CHEMINFÖRMRX' 0 CILUPREVIR
O CILUPREVIR O CILUPREVIR FILE 'BIBLIODATA'	0 CILUPREVIR FILE 'CHEMSAFE' 0 CILUPREVIR
FILE 'BIBLIODATA' O CILUPREVIR FILE 'BIOBUSINESS'	0 CILUPREVIR FILE 'CIN'
0 CILUPREVIR 0 CILUPREVIR	0 CILUPREVIR 0 CILUPREVIR FILE 'CIVILENG'
FILE 'BIOCOMMERCE' 0 CILUPREVIR	0 CILUPREVIR

	0 CILUPREVIR	0 CILUPREVIR
FILE	'COMPENDEX'	0 CILUPREVIR
	0 CILUPREVIR	FILE 'EMBAL'
	0 CILUPREVIR	0 CILUPREVIR
FILE	'COMPUAB'	0 CILUPREVIR
	0 CILUPREVIR	FILE 'EMBASE' 3 CILUPREVIR
CT. C	0 CILUPREVIR	FILE 'ENERGY'
FILE	'COMPUSCIENCE' 0 CILUPREVIR	0. CILUPREVIR
	0 CILUPREVIR	O CILUPREVIR
ETLE	'CONFSCI'	FILE 'ENTEC'
, ,,,,	0 CILUPREVIR	0 CILUPREVIR
	0 CILUPREVIR	0 CILUPREVIR
FILE	'COPPERLIT'	FILE 'ENVIROENG'
	0 CILUPREVIR	0 CILUPREVIR
	0 CILUPREVIR	0 CILUPREVIR
FILE	'CORROSION'	FILE 'ESBIOBASE'
	0 CILUPREVIR	2 CILUPREVIR
	0 CILUPREVIR	FILE 'EUROPATFULL'
FILE	'CROPB'	0 CILUPREVIR
	0 CILUPREVIR	0 CILUPREVIR FILE 'FOMAD'
CTIC	0 CILUPREVIR	0 CILUPREVIR
LILE	0 CILUPREVIR	0 CILUPREVIR
	0 CILUPREVIR	FILE 'FORIS'
FTLE	'CSNB'	0 CILUPREVIR
	0 CILUPREVIR	FILE 'FRANCEPAT'
	0 CILUPREVIR	0 CILUPREVIR
FILE	'DDFB'	0 CILUPREVIR
	0 CILUPREVIR	FILE 'FRFULL'
	0 CILUPREVIR	0 CILUPREVIR
FILE	'DDFU'	O CILUPREVIR FILE 'FROSTI'
	1 CILUPREVIR	0 CILUPREVIR
FILE	'DETHERM' 0 CILUPREVIR	0 CILUPREVIR
	0 CILUPREVIR	FILE 'FSTA'
FTLF	'DGENE'	0 CILUPREVIR
	0 CILUPREVIR	0 CILUPREVIR
	0 CILUPREVIR	FILE 'GENBANK'
FILE	'DISSABS'	0 CILUPREVIR
	0 CILUPREVIR	FILE 'GEOREF'
	0 CILUPREVIR	O CILUPREVIR
FILE	'DKF'	0 CILUPREVIR FILE 'HEALSAFE'
	0 CILUPREVIR	O CILUPREVIR
CTIC	0 CILUPREVIR	O CILUPREVIR
1 1 1 1 1	0 CILUPREVIR	FILE 'ICONDA'
	0 CILUPREVIR	0 CILUPREVIR
FILE	'DRUGB'	0 CILUPREVIR
	0 CILUPREVIR	FILE 'IFICLS'
	0 CILUPREVIR	0 CILUPREVIR
FILE	'DRUGU'	0 CILUPREVIR
	1 CILUPREVIR	FILE 'IFIPAT'
FILE	'ELCOM'	O CILUPREVIR
	0 CILUPREVIR	0 CILUPREVIR FILE 'IMSDRUGNEWS'
ETLE	0 CILUPREVIR	0 CILUPREVIR
1116	LIN	U CILUPREVIR

	1=	0 CILUPREVIR
FILE	'INFODA	O CILUPREVIR
	ì	0 CILUPREVIR
FILE	'INIS'	O CILOFALVIA
	11123	O CILUPREVIR
		O CILUPREVIR
FILE	'INPADO	
		0 CILUPREVIR 0 CILUPREVIR
FILE	'INSPEC	0 CILUPREVIR
LIFE	INSEC	O CILUPREVIR
		0 CILUPREVIR
FILE	'INSPHY	
		0 CILUPREVIR
		0 CILUPREVIR
FILE	'INVEST	O CILUPREVIR
		0 CILUPREVIR
FILE	'IPA'	O CILONKEVIK
,	-,,,	O CILUPREVIR
		<pre>0 CILUPREVIR</pre>
FILE	'ITRD'	
		O CILUPREVIR O CILUPREVIR
FILE	'JAPIO'	O CILOPKEVIK
FILE	JAPIO	0 CILUPREVIR
		O CILUPREVIR
FILE	'JICST-	EPLUS'
		O CILUPREVIR
	LVOCUET	,0 CILUPREVIR
FILE	'KOSMET	0 CILUPREVIR
		0 CILUPREVIR
FILE	'LIFESC	
		O CILUPREVIR
_		0 CILUPREVIR
FILE	'MATBUS	0 CILUPREVIR
		0 CILUPREVIR
FILE	'MATH'	O CILOTREVIA
		<pre>0 CILUPREVIR</pre>
		0 CILUPREVIR
FILE	'MATHDI	
		0 CILUPREVIR 0 CILUPREVIR
FILE	'MECHEN	
FILE	MECHEN	0 CILUPREVIR
		O CILUPREVIR
FILE	MEDLIN	
		2 CILUPREVIR
FILE	'METADE	O CILUPREVIR
		0 CILUPREVIR
FILE	'NAPRAL	ERT'
		<pre>0 CILUPREVIR</pre>
		0 CILUPREVIR

```
FILE 'NIOSHTIC'

0 CILUPREVIR

0 CILUPREVIR
FILE 'NLDB
                  O CILUPREVIR
                     CILUPREVIR
0 CILUPREVIR
0 CILUPREVIR
FILE 'NUTRACEUT'
FILE 'NTIS'
                  0 CILUPREVIR
0 CILUPREVIR
FILE 'OCEAN'
0 CILUPREVIR
0 CILUPREVIR
FILE 'PAPERCHEM2'
                  0 CILUPREVIR
0 CILUPREVIR
       'PASCAL'
FILE
                  0 CILUPREVIR
0 CILUPREVIR
FILE 'PATDD'
                  0 CILUPREVIR
       'PATDPA
                   O CILUPREVIR
      0 CILUPREVIR
FILE
0 CILUPREVIR
                  0 CILUPREVIR
0 CILUPREVIR
FILE 'PATOSWO
                   0 CILUPREVIR
0 CILUPREVIR
FILE 'PCTFULL
                   0 CILUPREVIR
0 CILUPREVIR
FILE 'PCTGEN'
                   0 CILUPREVIR
0 CILUPREVIR
FILE 'PHARMAML'

0 CILUPREVIR

0 CILUPREVIR
                   0 CILUPREVIR
0 CILUPREVIR
 FILE 'PHIN'
                     CILUPREVIR
CILUPREVIR
FILE 'PIRA'
                   0 CILUPREVIR
0 CILUPREVIR
        'POLLUAB
                   0 CILUPREVIR
0 CILUPREVIR
FILE PROMT
```

```
FILE 'RAPRA'
                     0 CILUPREVIR
                     0 CILUPREVIR
                     0 CILUPREVIR
         'RUSSCI
        O CILUPREVIR
O CILUPREVIR
'SCISEARCH'
2 CILUPREVIR
         'SIGLE'
FILE
        'SIGLE'

0 CILUPREVIR
0 CILUPREVIR
'SOLIDSTATE'
0 CILUPREVIR
0 CILUPREVIR
FILE
        0 CILUPREVIR
0 CILUPREVIR
'SYNTHLINE'
FILE
                    0 CILUPREVIR
0 CILUPREVIR
FILE
        0 CILUPREVIR
0 CILUPREVIR
'TEXTILETECH'
FILE
         0 CILUPREVIR
0 CILUPREVIR
'TOXCENTER'
                     0 CILUPREVIR
0 CILUPREVIR
FILE
        'TRIRO'
                     O CILUPREVIR
O CILUPREVIR
         'TULSA'
                     0 CILUPREVIR
0 CILUPREVIR
         TULSA2
                     0 CILUPREVIR
0 CILUPREVIR
                     0 CILUPREVIR
        'ULIDAT
                     0 CILUPREVIR
         'USPATFUL
                     0 CILUPREVIR
0 CILUPREVIR
          'USPATZ'
                     0 CILUPREVIR
0 CILUPREVIR
FILE 'VETB'
                     O CILUPREVIR O CILUPREVIR
FILE 'VETU'
                      O CILUPREVIR
```

0 CILUPREVIR 0 CILUPREVIR

```
FILE 'WATER'
                      0 CILUPREVIR
0 CILUPREVIR
O CILUPREVIR
O CILUPREVIR
FILE 'WELDASEARCH'
O CILUPREVIR
                      0 CILUPREVIA
0 CILUPREVIA
FILE 'WPIDS'
                     0 CILUPREVIR
0 CILUPREVIR
        'WPIFV'
FILE
                      0 CILUPREVIR
0 CILUPREVIR
FILE 'WPINDEX
                      0 CILUPREVIR
0 CILUPREVIR
FILE 'WSCA'
0 CILUPREVIR 0 CILUPREVIR FILE 'WTEXTILES'
                      0 CILUPREVIR
0 CILUPREVIR
L21 QUE CILUPREVIR
     d rank
                             EMBASE
ESBIOBASE
MEDLINE
SCISEARCH
DDFU
                             DRUGU
```

O CILUPREVIR

=> fil f1-6 COST IN U.S. DOLLARS TOTAL	SINCE FILE
	ENTRY
SESSION FULL ESTIMATED COST 118.15	5.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE
TOTAL	
1	ENTRY
SESSION CA SUBSCRIBER PRICE 4.90	0.00
FILE 'EMBASE' ENTERED AT 15:39:01 ON 26 OCT 2 COPYRIGHT (C) 2004 Elsevier Inc. All rights i	2004 reserved.
FILE 'ESBIOBASE' ENTERED AT 15:39:01 ON 26 OC	CT 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 15:39:01 ON 26 OCT 2004

```
FILE 'SCISEARCH' ENTERED AT 15:39:01 ON 26 OCT 2004
Copyright (c) 2004 The Thomson Corporation.
FILE 'DDFU' ACCESS NOT AUTHORIZED
FILE 'DRUGU' ENTERED AT 15:39:01 ON 26 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION
                        10 L21
=> 122 and pd<20030327

1 FILES SEARCHED...

2 FILES SEARCHED...

'20030327' NOT A VALID FIELD CODE

'20030327' NOT A VALID FIELD CODE

L23 1 L22 AND PD<20030327
=> d 123
L23 ANSWER 1 OF 1 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.

ON STN
AN 2004039472 EMBASE Full-text
TI Gateways to Clinical Trials.
AU Bayes M.; Rabasseda X.; Prous J.R.
CS M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona,
Spain.
          ...
mbayes@prous.com
Methods and Findings in Experimental and Clinical Pharmacology,
           2003) 25/10 (831-855).
Refs: 145
ISSN: 0379-0355 CODEN: MFEPDX
           Journal; General Review
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
           English
English
 => FIL STNGUIDE
COST IN U.S. DOLLARS
TOTAL
                                                                                                   SINCE FILE
                                                                                                              ENTRY
 SESSION
                                                                                                                8.37
 FULL ESTIMATED COST
126.52
                                                                                                    SINCE FILE
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                                                              ENTRY
 SESSION
                                                                                                               0.00
 CA SUBSCRIBER PRICE
```

```
exenatide, exisulind, ezetimib; Febuxostat; Gallium maltolate, ganirelix acetate, garenoxacin mesilate, gefitinib; H11, HUMAX; IL-15, IDD-1, IGIV-C, imatinib mesylate, ISIS-14803, ITF-1697, ivabradine hydrochloride; KRN-5500; L-365260, levetiracetam, levosimendan, licofelone, linezolid, LJP-1082, lopinavir lumiracoxib; MCC-478, melatonin, morphine hydrochloride, morphine-6-glucuronide, moxidectin; N-Acetylcarnosine, natalizumab, Omeprazole/sodium bicarbonate, OPC-28326, ospemifene; PEG-filgrastim peginterferon alfa-Za, pegsunercept, pirfenidone, pralmorelin, pregabalin; Recombinant glucagon-like peptide-1 (7-36) amide, repifermin, RSD-1235; S-8184, selodenoson, sodium dichloroacetate, suberanilohydroxamic acid; IAS-102, terfenadine, teriparatide, tipranavir troxacitabine; Ximelagatran; YM-337. COPYRGT. 2003 Prous Science. All rights reserved.

CT Medical-Descriptors: "drug monitoring drug indication drug efficacy drug safety side effect: SI, side effect disease exacerbation systemic lupus erythematosus: SI, side effect disease exacerbation systemic lupus erythematosus: SI, side effect neutropenia: SI, side effect human clinical trial abetimus: IV, intravenous drug administration adalimumab: AE, adverse drug reaction adalimumab: AE, adverse drug reaction adalimumab: CT, clinical trial linezolid: CT, clinical trial alemtuzumab: CT, clinical trial ivabradine: IV, intravenous drug administration recombinant interleukin 1 receptor blocking agent: CT, clinical trial ivabradine: IV, intravenous drug administration glucagon like peptide 1: CT, clinical trial ivabradine: CT, clinical trial bosentan: CT, clinical trial ciclesonide: CT, clinical trial cicle
```

```
FILE 'SINGUIDE' ENTERED AT 15:40:30 ON 26 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 22, 2004 (20041022/UP).

>> 123 all
MISSING OPERATOR L23 ALL
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

>> d 123 all
YOU HAVE REQUESTED DATA FROM FILE 'EMBASE' - CONTINUE? (Y)/N:y

L23 ANSWER 1 OF 1 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED.

ON STN
AN 2004039472 EMBASE Full-text
II Gateways to Clinical Trials.
AU Bayes M.; Rabasseda X.; Prous J.R.
CS M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona,
Spain.

Mayes@prous.com
Methods and findings in Experimental and Clinical Pharmacology,
(
2003) 25/10 (831-855).
Refs: 145
ISSN: 0379-0355 CODEN: MFEPDX

CY Spain
DI Journal; General Review
FO 30 Pharmacology
037 Drug Literature Index
038 ish
Bayes to Clinical Trials is a guide to the most recent
clinical trials in current literature and congresses. The data
in the following tables has been retrieved from the Clinical
Studies Knowledge Area of Prous Science Integrity*, the drug
discovery and development portal, http://integrity.prous.com.
This issue focuses on the following selection of drugs: Abetimus
sodium, adalimumab, alefacept, alemtuzumab, almotriptan, AMCN-
0007, anakinra, anti-CTLA-4 Mab, L-arginine hydrochloride,
aroxifene hydrochloride, astemizole, atazanavir sulfate,
atlizumab; Belimumab, 8G-9928, binodenoson, bosentan, botulinum
toxin type B, bovine lactoferrin, BufferGel; Caspofungin
acetate, ciclesonide, cilomilast, ciluprevir, clofarabine, CVT-
3146; Darbepoetin alfa, desloratadine, diflomotecan, doripenem,
dronedarone hydrochloride, drotrecogin alfa (activated), DT388-
GM-CSF, duloxetine hydrochloride, E-5564, efalizumab,
enfuvirtide, esomeprazole magnesium, estradiol acetate, ETC-642,
```

```
efalizumab: CT, clinical trial
imatinib: CT, clinical trial
terfenadine: CT, clinical trial
tipranavir: CT, clinical trial
tipranavir: CP, oral drug administration
ximelagatran: CP, clinical trial
ximelagatran: PO, oral drug administration
ym 337: CT, clinical trial
moxidectin: CT, clinical trial
moxidectin: CT, clinical trial
novel erythropoiesis stimulating protein: CT, clinical trial
novel erythropoiesis stimulating protein: IV, intravenous drug
administration
novel erythropoiesis stimulating protein: SC, subcutaneous drug
administration
desloratadine: CT, clinical trial
desloratadine: CT, clinical trial
desloratadine: CT, clinical trial
deflomotecan: CT, clinical trial
diflomotecan: IV, intravenous drug administration
diflomotecan: PO, oral drug administration
diflomotecan: PO, oral drug administration
morphine: CT, clinical trial
divectine: CT, clinical trial
duloxetine: CT, clinical trial
duloxetine: CT, clinical trial
unindexed drug
(abetimus) 167362-48-3, 169147-32-4; (adalimumab) 331731-18-1;
(linezolid)
165800-03-3; (alemtuzumab) 216503-57-0; (ivabradine) 148849-67-6
6,
148870-80-8, 155974-00-8; (glucagon like peptide 1) 89750-14-1;
(astemizole) 68844-77-9; (atazanavir) 198904-31-3; (bosentan)
147536-97-8,
157212-55-0; (caspofungin) 189768-38-5; (ciclesonide) 126544-47-
6;
(ciomilast) 153259-65-5; (efalizumab) 214745-43-4; (imatinib)
152459-95-5, 220127-57-1; (terfenadine) 50679-08-8; (tipranavir)
174484-14-4; (ximelagatran) 192939-46-1, 260790-58-7;
(moxidectin)
11507-06-5; (estradiol) 50-28-2; (desloratadine) 100643-71-8;
(diflomotecan) 220997-97-7; (morphine) 52-26-6, 57-27-2;
(etiracetam)
10767-28-2, 33996-58-6; (doripenem) 148016-81-3; (duloxetine)
11639-59-4, 136434-34-9

N Ym 337

>> DIS HIST

(FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE,
AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN,
```

CONFSCI, CROPB, CROPU, DGENE, DISSABS, ...' ENTERED AT 14:25:23 ON

```
26 OCT 2004
       FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004
1 S 300832-84-2/RN
SET SMA OFF
DEL SEL Y
SEL RN
SET SMA LOGIN
L1
       INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004
SEA E1 AND OPTICAL?/FA
L2
                         QUE 300832-84-2/BI AND OPTICAL?/FA
       FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004
0 S L1/BMF
L3
               'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004
0 S L1/BPN
L4
               'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004
0 S L1/IMF
               'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004
1 S L1/PEP
L6
        FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004
0 S L1/PUR
L7
       FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004 6 S (L1/SPN OR L1/CPN) 6 FOCUS L8 1-
       FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004
       FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004
15 S L1
0 L10 AND CRYSTAL
0 L10 AND CRYSTAL?
0 L10 AND ALCOHOL
3 L10 AND PD<20030327
L10
L11
L12
L13
L14
        FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
        INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
        .OLA,
ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
        BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
 BIOTECHABS
BIDIECHABS,
BIOTECHDS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
15:24:55 ON
26 OCT 2004
SEA BILN 2061
                             FILE ADISCTI
         INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
AGRICOLA,
ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
BABS,
BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIBLIODATA, BIOGESTALES, -----
BIOTECHAS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
15:32:46 ON
26 OCT 2004
SFA CTLUPREVIR/CN
                       SEA CILUPREVIR/CN

* FILE 1MOBILITY

* FILE 2MOBILITY

* FILE ADISCTI

* FILE ALIMINIUM

* FILE ALUMINIUM

* FILE APOLLIT

* FILE AQUALINE

* FILE AQUASCI

* FILE BABS

* FILE BIBLIODATA

* FILE BIOCOMMERCE

* FILE BIOCOMMERCE

* FILE BIOCOMMERCE
                          SEA CILUPREVIR/
                         O* FILE 1MOBILITY
SEA CILUPREVIR
                          1 FILE DDFU
1 FILE DRUGU
3 FILE EMBASE
2 FILE ESBIOBASE
2 FILE MEDLINE
2 FILE SCISEARCH
QUE CILUPREVIR
 121
 FILE 'EMBASE, ESBIOBASE, MEDLINE, SCISEARCH, DRUGU' ENTERED AT 15\colon 39\colon 01 ON 26 OCT 2004 L22 10 S L21 L22 AND PD<20030327
         FILE 'STNGUIDE' ENTERED AT 15:40:30 ON 26 OCT 2004
         FILE 'EMBASE' ENTERED AT 15:41:46 ON 26 OCT 2004
         FILE 'STNGUIDE' ENTERED AT 15:41:46 ON 26 OCT 2004
```

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

```
COST IN U.S. DOLLARS
TOTAL

SESSION
FULL ESTIMATED COST
130. 58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
TOTAL

SESSION
CA SUBSCRIBER PRICE
4.90

SINCE FILE
ENTRY
ENTRY
CA SUBSCRIBER PRICE
4.90
```

STN INTERNATIONAL LOGOFF AT 15:42:43 ON 26 OCT 2004

Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID:ssspta1653adk

```
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
```

* * * * * * * * * * Welcome to STN International * * * * * * * * * * * Web Page URLs for STN Seminar Schedule - N. America "Ask CAS" for self-help around the clock Jul 12 BEILSTEIN enhanced with new display and select NEWS 1 NEWS 2 NEWS 3 resulting in a closer connection to BABS

4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display AUG 02 CAplus and CA patent records enhanced with European NEWS S and Japan not Japan

NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!

(Version 7.01 for Windows) now available
BIOCOMMERCE: Changes and enhancements to content coverage NEWS 8 for legal AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added status data from INPADOC
SEP 01 INPADOC: New family current-awareness alert (SDI) NEWS 9 SEP 01 INPADOC: New family current available NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within

STN Express with Discover!

NEWS 11 SEP 01 New display format, HITSTR, available in

WPIDS/WPINDEX/WPIX

NEWS 12 SEP 27 STANDARDS will no longer be available on STN

NEWS 13 SEP 27 SWETSCAN will no longer be available on STN NEWS EXPRESS
JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
Welcome Banner and News Items NEWS INTER NEWS LOGIN NEWS PHONE

Enter NEWS followed by the item number or name to see news on that

Direct Dial and Telecommunication Network Access to

CAS World Wide Web Site (general information)

Please note that search-term pricing does apply when conducting ${\sf SmartSELECT}$ searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> S 300832-84-2/RN L1 1 300832-84-2/RN

=> DEL SEL Y

NEWS WWW

=> SEL RN E1 THROUGH E1 ASSIGNED

⇒> INDEX BEILSTEIN, GMELIN COST IN U.S. DOLLARS TOTAL

SINCE FILE ENTRY

FULL ESTIMATED COST 2.48 SESSION

0.92

INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004

2 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^{\star} with SET DETAIL OFF.

>> S E1 AND OPTICAL?/FA
FILE 'BEILSTEIN'
0 300832-84-2/BI
(300832-84-2/RN)
753186 OPTICAL?/FA
0 300832-84-2/BI AND OPTICAL?/FA
FILE 'GMELIN'
0 300932-84-2/BI AND OPTICAL?/FA

ELIN' 0 300832-84-2/BI (300832-84-2/RN) 12899 OPTICAL?/FA 0 300832-84-2/BI AND OPTICAL?/FA

L2 QUE 300832-84-2/BI AND OPTICAL?/FA

NO F-NUMBERS HAD GREATER THAN ZERO HITS

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

SINCE FILE

ENTRY

```
specific topic.
```

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementa

THENTIFIC TESTS THE PROPERTY OF THE PROPERT

FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004

=> index biosci FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED COST IN U.S. DOLLARS

SINCE FILE

FULL ESTIMATED COST 0.42 SESSION

ENTRY 0.42

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE,

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICULA, ANABSIR, ANIE,
AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN,
CONFSCI, CROPB,

CONTINUE, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:25:23 ON 26 OCT 2004

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^\star with SET DETAIL OFF.

=> fil reg COST IN U.S. DOLLARS TOTAL

SINCE FILE

SESSION

FULL ESTIMATED COST 1.56

1.14

FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem. $\,$

STRUCTURE FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6
DICTIONARY FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

SESSION FULL ESTIMATED COST 3.05

FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L1/BMF 15 L1 52155 BMF/RL 0 L1/BMF (L1

(L1 (L) BMF/RL)

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

SINCE FILE

SESSION FULL ESTIMATED COST 5.31

FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing storing of this information, without the prior written consent of CAS, is

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

8PN 15 L1 102210 BPN/RL 0 L1/BPN (L1 (L) BPN/RL) => S L1/BPN

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

STNCE FTLE

ENTRY

SESSION FULL ESTIMATED COST 7.57

2.26

FILE 'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L1/IMF 15 L1 390491 IMF/RL 0 L1/IMF L5 (L1 (L) IMF/RL)

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL

SINCE FILE

ENTRY

KZ, MD; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI. F GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, (English). CODEN: PIXXD2. APPLICATION: WO 2003-US30402 20030925. PRIORITY: US 2002-PV414940 20020930; US 2002-PV421904 20021029; US 2002-PV433834 20021216; US 2003-PV443662 20030130. GI

CO2H cor

Disclosed are oral pharmaceutical compns., kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein Compound (I), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range. Also disclosed are the use of I or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV.
300832-84-2
RL: PAC (Pharmacological activity): PEP (Physical apprecause

Ι

RL: PAC (Pharmacological activity); PEP (Physical, engineering

chemical process); PYP (Physical process); THU (Therapeutic

use); BIOL (Biological study); PROC (Process); USES (Uses) (potent inhibitor of HCV serine protease) FULL ESTIMATED COST 9.83

2.26

FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in Searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

./PEP

15 L1

1687596 PEP/RL

1 L1/PEP

(L1 (L) PEP/RL)

41TRN => 5 L1/PEP

=> DIS L6 1 CBIB ABS HITRN

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN 2004:310970 Document No. 140:327091 Potent inhibitor of HCV serine protease.
 Chen, Shirlynn; Nehmiz, Gerhard; Croenlein, Jens Oliver;

Steinmann Gerhard; Gunn, Jocelyn Abella; Costa, Phuong Do (Boehringer

International G.m.b.H., Germany). PCT Int. Appl. WO 2004030670

20040415, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA

BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP,

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,

=> FIL CAPLUS COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY FULL ESTIMATED COST 14.95 5.12 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) STNCE FILE ENTRY SESSION CA SUBSCRIBER PRICE 0.70 -0.70

FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

PUR 15 L1 201134 PUR/RL 0 L1/PUR (L1 (L) PUR/RL) => S L1/PUR

=> FIL CAPLUS COST IN U.S. DOLLARS TOTAL SINCE FILE ENTRY SESSION FULL ESTIMATED COST 17.21 2.26 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL SINCE FILE

ENTRY

SESSION

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S (L1/SPN OR L1/CPN) 15 L1 1660968 SPN/RL 6 L1/SPN (L1 (L) SPN/RL) 15 LI 15 L1 1155 CPN/RL 0 L1/CPN (L1 (L) CPN/RL) 6 (L1/SPN OR L1/CPN)

=> FOCUS L8
PROCESSING COMPLETED FOR L8
L9 6 FOCUS L8 1-

=> DIS L9 1- CBIB ABS HITRN YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):Y

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2004:580783 Document No. 141:261053 Synthesis of BILN 2061, an HCV Protease Inhibitor with Proven Antiviral Effect in Humans.

Fauchei Anne-Marie; Bailey, Murray D.; Beaulieu, Pierre L.; Brochu, Christian;

Duceppe, Jean-Simon; Ferland, Jean-Marie; Ghiro, Elise; Gorys,

Vida; Halmos, Ted; Kawai, Stephen H.; Poirier, Martin; Simoneau, Bruno; Tsantrizos, Youla S.; Llinas-Brunet, Montse (Chemistry

MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZM, AM, AZ, BY, KG, KZ, MD; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, CM, CY, DE, DR, CJ, LY, ...

NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2003-CA1604 20031020. PRIORITY: US 2002-PV421414 20021025; US 2002-PV433820 20021216; US 2003-PV442768 20030127.

Macrocyclic peptides I [R1 is (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, aryl or heteroaryl] or their pharmaceutically-acceptable salts were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease. Thus, I (R = Me) was prepared by a multistep sequence involving peptide coupling, olefin metathesis to form the macrocycle and methanesulfonamidation.

300832-84-2P

1

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of macrocyclic peptides active against the hepatitis C virus)

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2004;168624 Document No. 140:350045 Structure-activity study on a series of macrocyclic inhibitors of the hepatitis C virus NS3 leading to the discovery of BILN 2061. Llinas-Brunet, Montse;

Department, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2GS, Can.). Organic nic Letters, 6(17), 2901-2904 (English) 2004. CODEN: ORLEF7. ISSN: 1523-7060. Publisher: American Chemical Society. GI

AB The synthesis of BILN 2061 (I), a hepatitis C virus (HCV) NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclin. pharmacol. evaluation.

1 300832-84-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Uses)
(Uses)
(preparation); USES
(Uses)
(preparation of peptidyl macrocycle BILN-2061, an HCV NS3 protease inhibitor
with proven antiviral effect in humans)

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2004;370958 Document No. 140:357673 Preparation of macrocyclic peptides against the hepatitis C virus. Llinas-Brunet, Montse; Bailey,
Murray D. (Boehringer Ingelheim International G.m.b.h.,
Germany). PCT Germany). PCT Int. Appl. wo 2004037855 Al 20040506, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CJ, DE, DM, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA. MD.

Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie: : Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; , Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre,
Daniel (Departments of Chemistry and Biological Sciences,

Boehringer
Ingelheim (Canada) Ltd., Laval, QC, H7S 265, Can.). Journal of Medicinal Chemistry, 47(7), 1605-1608 (English) 2004. CODEN: JMCMAR.

ISSN: O022-2623. Publisher: American Chemical Society.
From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man. 300832-84-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN thetic

preparation); BIOL (Biological study); PREP (Preparation)
(BILN 2061; structure-activity study on a novel series of macrocyclic

inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061)

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS On STN 2003:648255 Document No. 139:197768 Preparation of macrocyclic peptides active against the hepatitis C virus. Tsantrizos, Youla S.; Cameron, Dale
R.; Faucher, Anne-Marie; Ghiro, Elise; Goudreau, Nathalie;
Halmos, Teddy;
Llinas-Brunet, Montse (Boehringer Ingelheim (Canada) Ltd.,
Can.). U.S. US
6608027 B1 20030819, 90 pp., Cont.-in-part of U.S. Ser. No. 73, abandoned. (English). CODEN: USXXAM. APPLICATION: US 2001-20010116. PRIORITY: US 1999-PV128011 19990406; US 2000-542675

Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxy, alkoxy, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONNR32, CONR32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: 0, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moietyl were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = COZH; R3CH-D = (S)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed IC50 > 0.1 µM in the full-length NS3-NS4A

= (S)-(Me3CO/ZCNH)CH(CHZ)3CH:CH(CHZ)2-E (syn to acid)] was prepared and showed Ic50 > 0.1 µM in the full-length NS3-NS4A heterodimer protein fluorogenic assay.

IT 300832-84-2P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of macrocyclic peptides active against the hepatitis C virus)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2003:511084 Document No. 139:69527 Preparation of macrocyclic compounds as inhibitors of hepatitis C virus. Campbell, Jeffrey Allen; Good, Charles (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2003053349 A2 20030703, 225 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,

AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PTXXD2. APPLICATION: WO 2000-CA353 20000403. PRIORITY: US 1999-PV128011

TM: RW

Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONNR32, COR32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: 0, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moietyl were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = COZH; R3CH-D = (S)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed 1C50 > 0.1 µm in the full-length NS3-NS4A prepared and showed IC50 > 0.1 µM in the full-length NS3-NS4A heterodimer protein fluorogenic assay.

IT 300832-84-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological activity or effector).

ogical study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);

KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR. GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US39926 20021213. PRIORITY: US 2001-PV344080 20011220; US 2002-PV382103 20020520.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE

AB The invention relates to macrocyclic compds. I [R1 = (cyclo)alkyl; R2 = H, halo, alkyl, alkoxy, cycloalkoxy, (un)substituted aryl or heterocyclyl; R3 = H, halo, CE3, alkoxy, cycloalkoxy; R4 = NH2 or NHR6, where R6 is alkanoyl, alkylaminocarbonyl, or carbalkoxy; Q is a 3-9 atom (un)saturated alkylene chain optionally containing 1-3 heteroatoms O, S, SO, or So2], including methods for their synthesis and use in pharmaceutical compns. for therapeutic or prophylactic prevention or treatment of hepatitis C virus (HCV) infection. Thus, 3,13-diazatricyclo[11.3,0.04,6]hexadec-7-ene derivative II was prepared by a multistep procedure and assayed for inhibition of HCV NS3/4A protease (ICSO < 5 μM).

IT 300832-84-2P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of macrocyclic compds. as inhibitors of hepatitis C virus)

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN 2000:725652 Document No. 133:296659 Preparation of macrocyclic peptides active against the hepatitis C virus. Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-marie; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-brunet, Montse (Boehringer Ingelheim (Canada) Ltd., Can.). PCT Can.). PCT Int. Appl. wo 2000059929 A1 20001012, 154 pp. DESIGNATED STATES: W: AE, AT All. AZ. BA. BB, BG, BR, BY, CA, CH, CN, CF ES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, 1P, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,

(preparation of macrocyclic peptides active against the hepatitis C virus)

=> FIL REGISTRY
COST IN.U.S. DOLLARS
TOTAL SINCE FILE **ENTRY** SESSION FULL ESTIMATED COST 42.78 25.57 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE **FNTRY** CA SUBSCRIBER PRICE 4.90 SESSION -4.20

FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6 DICTIONARY FILE UPDATES: 25 OCT 2004 HIGHEST RN 769101-30-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting ${\sf SmartSELECT}$ searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBS\$/registryss.html

=> d his

(FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 14:25:23 ON 26 OCT 2004

```
FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004
1 S 300832-84-2/RN
SET SMA OFF
DEL SEL FY
SEL RN
L1
                       SET SMA LOGIN
       INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004
SEA E1 AND OPTICAL?/FA
                       QUE 300832-84-2/BI AND OPTICAL?/FA
       FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004 0 S L1/BMF
L3
       FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004 0 S L1/BPN
L4
       FILE 'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004
0 S L1/IMF
L5
       FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004 1\ \mbox{S} L1/PEP
L6
       FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004
0 S L1/PUR
L7
       FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004
6 S (L1/SPN OR L1/CPN)
6 FOCUS L8 1-
L8
L9
        FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004
=> file hcaplus
COST IN U.S. DOLLARS
TOTAL
                                                                       SINCE FILE
                                                                               ENTRY
SESSION
FULL ESTIMATED COST 43.62
                                                                                0.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                       SINCE FILE
TOTAL
                                                                               ENTRY
CA SUBSCRIBER PRICE 4.90
                                                                                0.00
FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available
```

English 5

```
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
      PATENT NO.
                                 KIND
                                         DATE
                                                         APPLICATION NO.
DATE
US 2004058982
20030425
US 6248776
19990217 <--
                                         20040325
                                                         us 2003-422848
                                  A1
                                          20010619
US 6476066
20010227 <--
                                          20021105
                                                         us 2001-793416
                                  в1
PRIORITY APPLN. INFO.: 19990217
                                                         us 1999-251467
                                                                                    Α3
                                                                                    ΑŻ
                                                         us 2001-793416
20010227
                                                         US 1997-56382P
19970826
                                                         us 1997-997259
                                                                                    Α2
19971223
                                 MARPAT 140:281350
OTHER SOURCE(S):
L14 ANSWER 2 OF 3 HCAPLUS
ACCESSION NUMBER: 200
                                 US COPYRIGHT 2004 ACS on STN 2003:886572 HCAPLUS Full-text
DOCUMENT NUMBER:
TITLE:
effects in
                                 140:122161
                                 An NS3 protease inhibitor with antiviral
                                humans infected with hepatitis C virus
Lamarre, Daniel; Anderson, Paul C.; Bailey,
AUTHOR(S):
Murray;
                                 Beaulieu, Pierre; Bolger, Gordon; Bonneau,
Pierre;
                                 Boes, Michael; Cameron, Dale R.; Cartier,
Mireille:
                                 Cordingley, Michael G.; Faucher, Anne-Marie;
Goudreau,
                                 Nathalie; Kawai, Stephen H.; Kukolj, George;
Lagace,
                                 Lisette; LaPlante, Steven R.; Narjes, Hans;
Poupart,
                                 Marc-Andre; Rancourt, Jean; Sentjens, Roel
E.; St.
                                 George, Roger; Simoneau, Bruno; Steinmann,
                                 Thibeault, Diane; Tsantrizos, Youla S.;
Weldon, Steven
                                 M.; Yong, Chan-Loi; Llinas-Brunet, Montse
Departments of Biological Sciences,
CORPORATE SOURCE:
Boehringer
                                 Ingelheim (Canada) Ltd, Laval, QC, H7S 2G5,
Can.
SOURCE:
                                 Nature (London, United Kingdom) (2003),
426(6963), 186-189
CODEN: NATUAS; ISSN: 0028-0836
Nature Publishing Group
```

PUBLISHER:

```
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in
searching
databases on STN. Any dissemination, distribution, copying, or
storing of this information, without the prior written consent of CAS, is strictly prohibited.
FILE COVERS 1907 - 26 Oct 2004 VOL 141 ISS 18 FILE LAST UPDATED: 25 Oct 2004 (20041025/ED)
  This file contains CAS Registry Numbers for easy and accurate substance identification.
=> s 11
L10
                       15 L1
=> 110 and crystal
1117482 CRYSTAL
600101 CRYSTALS
1385437 CRYSTAL
                         (CRYSTAL OR CRYSTALS)

0 L10 AND CRYSTAL
L11
=> 110 and crystal?
1605797 CRYSTAL?
L12 0 L10 AND CRYSTAL?
 => 110 and alcohol
217243 ALCOHOL
149677 ALCOHOLS
339514 ALCOHOL
                         (ALCOHOL OR ALCOHOLS)
0 L10 AND ALCOHOL
113
 ⇒> 110 and pd<20030327
23271868 PD<20030327
(PD<20030327)
L14 3 L10 AND PD<20030327
 L14
 => d 114 1-3 ibib
 L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2004;252197 HCAPLUS Full-text DOCUMENT NUMBER: 140:281350
 TITLE:
pass effect
INVENTOR(S):
PATENT ASSIGNEE(S):
                                                   Spiro compounds for inhibiting the first-
                                                  Harris, James W.
Bioavailability System, LLC, USA
U.S. Pat. Appl. Publ., 133 pp., Cont.-in-
 SOURCE:
part of U.S.
                                                  Ser. No. 793,416.
CODEN: USXXCO
Patent
 DOCUMENT TYPE:
```

DOCUMENT TYPE:

LANGUAGE: REFERENCE COUNT:

```
Journal
English
30 TH
AVAILABLE FOR THIS
                                        RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT
L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS ON STN ACCESSION NUMBER: 2000:725652 HCAPLUS Full-text 133:296659
                                 Preparation of macrocyclic peptides active
against the
                                 hepatitis C virus
Tsantrizos, Youla S.; Cameron, Dale R.;
INVENTOR(S):
                               Teddy; Llinas-brunet, Montse
Boehringer Ingelheim (Canada) Ltd., Can.
PCT Int. Appl., 154 pp.
CODEN: PIXXD2
Patent
English
2
Nathalie; Halmos,
PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
      PATENT NO.
                                 KIND
                                                         APPLICATION NO.
DATE
         2000059929
                                         20001012
                                                          WO 2000-CA353
20000403
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,
CN, CR,
                 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR. HU.
                 ID. IL. IN. IS. JP. KE. KG. KP. KR. KZ. LC. LK. LR. LS
LT. LU.
                 LV. MA. MD. MG. MK. MN. MW. MX. NO. NZ. PL. PT. RO. RU.
SD, SE,
                 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA,
            ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY. DE.
                 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TC
EP 1169339 A1 20020109 EP 2000-913999
20000403 <---
      14U3 <--
EP 1169339
                                          20040929
                                  в1
IE, SI, LT, LV, FI, RO
BR 2000009599 A 20020115
TR 200102878 T?
                AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
                                                          BR 2000-9599
                                                          TR 2001-200102878
```

THERE ARE 30 CITED REFERENCES

```
20000403 <--
EE 200100516
                                                                                                                                                                               20021216
                                                                                                                                                                                                                                                EE 2001-516
  EE 2001009
20000403 <---
NZ 515286
20000403
                                                                                                                                                                               20040227
                                                                                                                                                                                                                                                NZ 2000-515286
                                              1437362
                                                                                                                                                                              20040714
                                                                                                                                                                                                                                                EP 2004-9264
   20000403
BG 105970 A 20011002 <-- A 20011004 <-- A 20011004 <-- A 20011004 <-- A 2001204 <-- A 
                                                 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
                                                                                                                                                                                 RO, CY
20020531
                                                                                                                                                                                                                                                 BG 2001-105970
                                                                                                                                                                                 20021231
                                                                                                                                                                                                                                                HR 2001-720
  NO 2001004857
20011005 <--
PRIORITY APPLN. INFO.:
19990406
                                                                                                                                                                                 20011031
                                                                                                                                                                                                                                                NO 2001-4857
                                                                                                                                                                                                                                                US 1999-128011P
                                                                                                                                                                                                                                                                                                                                                              р
                                                                                                                                                                                                                                                  EP 2000-913999
                                                                                                                                                                                                                                                                                                                                                              Α3
    20000403
                                                                                                                                                                                                                                                wo 2000-CA353
    20000403
OTHER SOURCE(S):
REFERENCE COUNT:
                                                                                                                                             MARPAT 133:296659

THERE ARE 1 CITED REFERENCES AVAILABLE
     FOR THIS
                                                                                                                                                                            RECORD. ALL CITATIONS AVAILABLE IN THE
     RE FORMAT
     => d 114 1 hitstr
```

L14 ANSWER 1 DF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

17 300832-84-2, BILN 2061
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spiro compds. for inhibiting the first-pass effect)
RN 300832-84-2 HCAPLUS
CN Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)carboxylic
acid, 6-[[(cyclopentyloxy)carbonyl]amino]1,2,3,6,7,8,9,10,11,13a,14,15,16
16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4thiazolyl]4-quinolinyl]oxyl-5,16-dioxo-. (2R.6S.12Z.13as.14aR.16as)- (9CT) 4-quinolinyl]oxy]-5,16-dioxo-, (2R,6S,12Z,13aS,14aR,16aS)- (9CI) INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE **ENTRY** SESSION CA SUBSCRIBER PRICE 4.90 0.00 FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004 => index
ENTER FILE OR CLUSTER NAMES (NONE):
ENTER FILE OR CLUSTER NAMES (NONE):
FILE 'ENCOMPLIT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
TOTAL SINCE FILE **ENTRY** SESSION FULL ESTIMATED COST 93.08 15.75 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL SINCE FILE **ENTRY** SESSION CA SUBSCRIBER PRICE 4.90 0.00 INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE, ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE, BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHAPS,
BIOTECHOS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...'
ENTERED AT 15:24:55 ON 26 OCT 2004 143 FILES IN THE FILE LIST IN STNINDEX Enter SET DETAIL ON to see search term postings or to view search error messages that display as O* with SET DETAIL OFF. => 5 BILN 2061
FILE '1MOBILITY'
0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061")
FILE '2MOBILITY'
0 "BILN"

0 "BILN" 0 "2061" 0 BILN 2061 ("BILN"(W)"2061")

PAGE 1-B

PAGE 2-B

> FIL HOME COST IN U.S. DOLLARS

SINCE FILE

SESSION

ENTRY 33.71

FULL ESTIMATED COST 77.33

```
FILE 'ABI-INFORM'
1 BILN
65 2061
                    0 BILN 2061
                          (BILN(W)2061)
 FILE 'ADISCTI'
                  3 BILN
21 2061
2 BILN 2061
L DILM 2061
(BILN(W)2061)
FILE 'AEROSPACE'
FILE 'AGRICOLA'

0 BILN
18 2061
0 BILN 2061
(BILN(W)2061)
                  0 BILN
20 2061
0 BILN
                    0 BILN 2061
(BILN(W)2061)
 FILE 'ANABSTR'
                    0 BILN
6 2061
                     0 BILN 2061
                           (BILN(W)2061)
 FILE 'ANTE'
                     0 BILN
0 2061
0 BILN 2061
                           (BILN(W)2061)
 FILE 'APOLLIT'
                    f'
0 BILN
6 2061
0 BILN 2061
(BILN(W)2061)
 FILE 'AQUALINE'
                     0 BILN
2 2061
0 BILN 2061
(BILN(W)2061)
 FILE 'AOUASCI'
                     1 "BILN"
8 "2061"
0 BILN 2061
("BILN"(w)"2061")
 FILE 'AQUIRE'
                     0 BILN
0 2061
                     0 BILN 2061
(BILN(W)2061)
 FILE 'BABS'
                     1 BILN
```

24 2061
1 BILN 2061
(BILN(W)2061)

FILE 'BIBLIODATA'
0 BILN 2061
0 BILN 2061
(BILN(W)2061)

FILE 'BIOBUSINESS'
4 "2061"
0 BILN 2061
("BILN"(W)"2061")

FILE 'BIOCOMMERCE'
0 BILN 2061
0 BILN 2061
0 BILN 2061
(BILN(W)2061)

FILE 'BIOENG'
7 2061
2 BILN 2061
2 BILN 2061
1 BILN 2061
(BILN(W)2061)

FILE 'BIOSIS'
7 BILN 129 2061
18 BILN 2061
(BILN(W)2061)

FILE 'BIOTECHABS'
0 BILN 2061
(BILN(W)2061)

FILE 'BIOTECHOS'
0 BILN 2061
0 BILN 2061
(BILN(W)2061)

FILE 'BIOTECHNO'
12 BILN 30 2061
0 BILN 2061
(BILN(W)2061)

FILE 'BIOTECHNO'
12 BILN 30 2061
0 BILN 2061
(BILN(W)2061)

FILE 'BLUBB'
0 BILN 2061
(BILN(W)2061)

FILE 'CABA'
0 BILN 2061
(BILN(W)2061)

FILE 'CABA'
0 BILN 2061
(BILN(W)2061)

FILE 'CANCERLIT'
11 BILN
13 2061
0 BILN 2061

4 BILN 22 2061 2 BILN 2061 (BILN(W)2061) O "BILN"
O "2061"
O BILN 2061
("BILN"(W)"2061")
FILE 'COMPUSCIENCE' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CONFSCI' "BILN" "2061" 9 "2061" 0 BIN 2061 ("BILN"(w)"2061") 'COPPERLIT' 0 BILN 0 2061 0 BILN 2061 U BILN 2061

FILE 'CORROSION'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'CROPB' FILE 'CROPB' 0 BILN 1 2061 0 BILN 2061 (BILN(W)2061) FILE 'CROPU' O BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CSNB' 0 BILN 0 2061 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DDFB' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DDFU' 13 BILN 21 2061 10 BILN 2061 (BILN(W)2061) FILE 'DETHERM' 0 BILN 0 2061

(BILN(W)2061) FILE 'CAOLD' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CAPLUS 20 BILN 382 2061 10 BILN 2061 (BILN(W)2061) FILE 'CASREACT' TT 1 BILN 6 2061 0 BILN 2061 (BILN(W)2061) 2 BILN 15 2061 2 BILN 2061 (BILN(W)2061) FILE 'CEABA-VTB' VTB'
0 BILN
0 2061
0 BILN 2061
(BILN(W)2061) FILE 'CEN' 0 "BILN" 8 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'CERAB' FILE 'CERAB'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'CHEMINFORMRX' 0 BILN 7 2061 0 BILN 2061 (BILN(W)2061) FILE 'CHEMSAFE' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'CIN' "BILN" "2061" 1 BILN 2061 ("BILN"(W)"2061") FILE 'CIVILENG'
0 BILN
1 2061
0 BILN 2061 (BILN(W)2061) FILE 'COMPENDEX'

0 BILN 2061 (BILN(W)2061) FILE 'DGENE' 0 BILN 303 2061 0 BILN 2061 (BILN(W)2061) FILE 'DISSABS' 1 BILN 24 2061 0 BILN 2061 (BILN(W)2061) FILE 'DKF' 0 BILN 1 2061 0 BILN 2061 (BILN(W)2061) FILE 'DPCI' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DRUGB' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'DRUGU' 13 BILN 36 2061 10 BILN 2061 (BILN(W)2061) FILE 'ELCOM' "BILN" "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'EMA' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'EMBAL' 1 BILN 4 2061 1 BILN 2061 (BILN(W)2061) FILE 'EMBASE' SE'
48 "BILN"
124 "2061"
42 BILN 2061
("BILN"(W)"2061") FILE 'ENERGY' 0 BILN 31 2061 0 BILN 2061 (BILN(W)2061)

FILE 'ENTEC' 0 BILN 2061 (BILN(W)2061) FILE 'ENVIROENG'

0 BILN
0 2061
0 BILN 2061 (BILN(W)2061) 3 BILN 49 2061 3 BILN 2061 (BILN(W)2061)
FILE 'EUROPATFULL' 2 BILN 425 2061 0 BILN 2061 (BILN(W)2061) FILE 'FOMAD' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'FORIS' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'FRANCEPAT' PAT' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'FRFULL' 3 BILN 54 2061 0 BILN 2061 (BILN(W)2061) FILE 'FROSTI' 0 BILN 2061 (BILN(W)2061) FILE 'FSTA' 0 BILN 11 2061 0 BILN 2061 (BILN(W)2061) FILE 'GENBANK' BANK' 0 "BILN" 3412 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'GEOREF' 0 BILN

("BILN" OR "BILNS") 1864 "2061" 15 BILN 2061 ("BILN"(W)"2061") FTIF 'TPA 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'ITRD 0 BILN 5 2061 0 BILN 2061 (BILN(W)2061) 'JAPIO 0 BILN 18 2061 18 2061
0 BILN 2061
(BILN(W)2061)
FILE 'JICST-EPLUS'
0 BILN
58 2061
0 BILN 2061
(BILN 2061) (BILN(W)2061) FILE 'KOSMET' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'LIFESCI' (BLU"

5 "BILN"

28 "2061"

4 BILN 2061

("BILN"(W)"2061") 0 BILN 5 2061 0 BILN 2061 (BILN(W)2061) FILE 'MATH 0 BILN 8 2061 0 BILN 2061 (BILN(W)2061) 0 BILN 6 2061 0 BILN 2061 (BILN(W)2061) FILE 'MECHENG' G' 0 BILN 2 2061 0 BILN 2061 (BILN(W)2061) FILE 'MEDLINE' 19 BILN 122 2061

18 2061 0 BILN 2061 (BILN(W)2061) FE'
0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061") FILE 'ICONDA' 1 2061 0 BILN 2061 (BILN(W)2061) FILE 'IFICLS' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'IFIPAT GNEWS'
3 "BILN"
5 "2061"
3 BILN 2061
("BILN"(W)"2061") FILE 'INFODATA'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061) 22 2001 O BILN 2061 (BILN(W)2061) FILE 'INPADOC' 0 BILN 3 2061 0 BILN 2061 (BILN(W)2061) FILE 'INSPEC' 0 BILN 73 2061 0 BILN 2061 (BILN(W)2061) FILE 'INSPHYS' FILE 'INSPHYS'

1 BILN
2 2061
0 BILN 2061
(BILN(W)2061)

FILE 'INVESTEXT'
20 "BILN"
1 "BTLNS"
21 "BTLN"

13 BILN 2061 (BILN(W)2061) FILE 'METADEX' 0 BILN 14 2061 14 2061 0 BILN 2061 (BILN(W)2061) FILE 'NAPRALERT' 0 "BILN" 2 "2061" 0 BILN 2061 ("BILN"(W)"2061") FILE 'NIOSHTIC' FILE 'NIOSHTIC' O BILN 1 2061 0 BILN 2061 (BILN(W)2061) FILE 'NLDB' 4 "BILN"
274 "2061"
3 BILN 2061
("BILN"(W)"2061") FILE 'NTIS' FILE 'NTIS'

0 BILN
27 2061
0 BILN 2061
(BILN(W)2061)
FILE 'NUTRACEUT' EUT' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'OCEAN' FILE 'OCEAN'

0 "BILN"
0 "2061"
0 BILN 2061
FILE 'PAPERCHEM2'
0 BILN
2 2061
0 BILN 2061
(BILN 2061)
FILE 'PASCAL' FILE PASCAL 13 BILN 69 2061 4 BILN 2061 (BILN(W)2061) FILE 'PATOD' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061) FILE 'PATDPA' 0 BILN 5 2061 0 BILN 2061 (BILN(W)2061)

```
538 "2061"
1 BILN 2061
("BILN"(W)"2061")
FILE 'PATDPAFULL'
                                                                                                                                                                          FILE 'RAPRA'
                          0 BILN 2061
                                                                                                                                                                                                    0 BILN
8 2061
0 BILN 2061
(BILN(W)2061)
                                   (BILN(W)2061)
 FILE PATOSDE
                          0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                          FILE 'RSWB'
                                                                                                                                                                                                    0 BILN
5 2061
0 BILN 2061
(BILN(W)2061)
 FILE 'PATOSEP'
                          0 BILN
4 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                          FILE 'RUSSCI'
                                                                                                                                                                          FILE 'RUSSCI'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'SCISEARCH'
27 BILN
168 2061
 FILE 'PATOSWO'
                          0 BILN
1 2061
0 BILN 2061
(BILN(W)2061)
FILE 'PCTFULL'
40 BILN
2832 2061
11 BILN 2061
(BILN(W)2061)
                                                                                                                                                                                                  22 BILN 2061
(BILN(W)2061)
                                                                                                                                                                           FILE 'SIGLE'
                                                                                                                                                                          FILE 'SIGLE'

0 BILN
0 2061
0 BILN 2061
FILE 'SOLIOSTATE'
0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061)')
FILE 'SOLIS'
                          0 BILN
0 2061
0 BILN 2061
FILE 'PHARMAML' (b...

FILE 'PHARMAML' 0 BILN 0 2061 0 BILN 2061 (BILN(W)2061)
                                                                                                                                                                           FILE 'SOLIS'
                                                                                                                                                                          FILE 'SOLIS'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
FILE 'SYNTHLINE'
1 "BILN"
0 "2061"
                            0 "BILN"
0 "2061"
0 BILN 2061
("BILN"(W)"2061")
  FILE 'PHIN'
                          3 "BILN"
35 "2061"
2 BILN 2061
("BILN"(W)"2061")
                                                                                                                                                                                                     0 BILN 2061
("BILN"(W)"2061")
                                                                                                                                                                           FILE 'TEMA'
                                                                                                                                                                                                     1 BILN
2 2061
                                                                                                                                                                          12 2061

0 BILN 2061

(BILN(W)2061)

FILE 'TEXTILETECH'

0 BILN 2061

(BILN(W)2061)

FILE 'TOXCENTER'

6 BILN 63 2061

4 BILN 2061
  FILE 'PIRA'
                           0 "BILN"
1 "2061"
0 BILN 2061
("BILN"(W)"2061")
  FILE 'POLLUAB'
                            0 "BILN"
1 "2061"
0 BILN 2061
                                    ("BILN"(W)"2061")
   FILE 'PROMT'
                           7 "BILN"
                                                                                                                                                                                                    4 BILN
70 2061
2 BILN 2061
(BILN(W)2061)
                                     (BILN(W)2061)
   FILE 'TRIBO
                            0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                            FILE 'WPIFV
                                                                                                                                                                                                     0 BILN
0 2061
   FILE 'TULSA'
                                                                                                                                                                                                     0 BILN 2061
(BILN(W)2061)
                            0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                            FILE 'WPINDEX'

4 BILN

70 2061

2 BILN 2061
   FILE 'TULSA2'
                             0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                                                              (BILN(W)2061)
 FILE 'UFORDAT'

0 BILN
0 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                                                     0 BILN
1 2061
0 BILN 2061
                                                                                                                                                                           0 BILN 2061
(BILN(W)2061)
FILE 'WTEXTILES'
0 BILN
8 2061
0 BILN 2061
(BILN(W)2061)
                             0 BILN
1 2061
0 BILN 2061
   (BILN(W)2061)
FILE 'USPATFULL'
17 RTIN
                                                                                                                                                                            L15 QUE BILN 2061
                       17 BILN
4661 2061
6 BILN 2061
(BILN(W)2061)
                                                                                                                                                                            F1
F2
F3
F4
F5
F6
                                                                                                                                                                                                              EMBASE
SCISEARCH
BIOSIS
INVESTEXT
MEDLINE
PCTFULL
CAPLUS
DDFU
DRUGU
                                                                                                                                                                                                    22
18
15
13
11
10
   ETLE 'USPAT2'
                        72'

0 BILN

210 2061

0 BILN 2061

(BILN(W)2061)
   FILE 'VETB'
                                                                                                                                                                                                              BIOTECHNO
USPATFULL
LIFESCI
PASCAL
TOXCENTER
                             0 BILN
0 2061
0 BILN 2061
                                     (BILN(W)2061)
    FILE 'VETU'
                             0 BILN
3 2061
0 BILN 2061
(BILN(W)2061)
                                                                                                                                                                                                               ESBIOBASE
IMSDRUGNEWS
                                                                                                                                                                                                               IMSDRUGNER
NLDB
ADISCTI
BIOENG
CBNB
COMPENDEX
    FILE 'WATER'
                             0 BILN
2 2061
0 BILN
   0 BILN 2061
(BILN(W)2061)
FILE 'WELDASEARCH'
                                                                                                                                                                             F22
F23
F24
F25
F26
F27
F28
F29
                                                                                                                                                                                                               PHTN
                                                                                                                                                                                                               PHIN
WPIDS
WPINDEX
BABS
CIN
EMBAL
IFIPAT
```

0 BILN 0 2061 0 BILN 2061 (BILN(W)2061)

FILE 'WPIDS'

PROMT

```
FILE COMPENDEX
FILE DRUGU
FILE EMBAL
FILE EMBASE
FILE ESBIOBASE
FILE ITIPAT
FILE IMSDRUGNEWS
FILE INVESTEXT
FILE LIFESCT
FILE MEDLINE
FILE NLDB
FILE PASCAL
FILE PHIN
FILE PHIN
FILE PHIN
FILE PHIN
FILE PROMT
                                                                                                                                                                                                                                                            10
10
42
3
15
4
=> index f1-f29
COST IN U.S. DOLLARS
TOTAL
                                                                                                                                         ENTRY
FULL ESTIMATED COST 94.22
 SESSION
                                                                                                                                           1.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL
                                                                                                                             SINCE FILE
                                                                                                                                          ENTRY
 SESSION
       SUBSCRIBER PRICE
                                                                                                                                                                                                                                                                        FILE PHIN
FILE PROMT
FILE SCISEARCH
FILE TOXCENTER
FILE USPATFULL
FILE WPINDS
FILE WPINDEX
 4.90
 INDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL, CAPLUS, DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER,
ESBIOBASE, IMSDRUGNEWS, NLDB, ADISCTI, BIOENG, CBNB, COMPENDEX, PHIN, WPIDS, WPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON 26 OCT 2004
                                                                                                                                                                                                                         L15
                                                                                                                                                                                                                                                                 QUE BILN 2061
                                                                                                                                                                                                                                     INDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL,
                                                                                                                                                                                                                        CAPLUS,
DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER,
 29 FILES IN THE FILE LIST IN STNINDEX
                                                                                                                                                                                                                         ESBIOBASE,
IMSDRUGNEWS, NLDB, ADISCTI, BIOENG, CBNB, COMPENDEX, PHIN,
 Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^\star with SET DETAIL OFF.
                                                                                                                                                                                                                         WPIDS, WPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON
                                                                                                                                                                                                                        26 OCT 2004
 => d his 114-
              (FILE 'HCAPLUS' ENTERED AT 14\colon\!32\colon\!46 ON 26 OCT 2004) 3 L10 AND PD<20030327
                                                                                                                                                                                                                        > 115 and crystal?

FILE 'EMBASE'

48 "BILN"

124 "2061"

42 BILN 2061

("BILN"(W)"2061")

97097 CRYSTAL?

4 L15 AND CRYSTAL?

FILE 'SCISEARCH'

27 BILN

168 2061

22 BILN 2061

(BILN(W)2061)

689047 CRYSTAL?

FILE 'BIOSIS'

27 BILN

515 AND CRYSTAL?
              FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
               INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
              ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
              BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
  BIBLIODATA, BIOBOSINESS, BLOCOMMERCE, BIOCHO, OFOSIS,
BIOTECHOS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
15:24:55 ON
              26 OCT 2004
                                           SEA BILN 2061
                                                 FILE ADISCTI
FILE BABS
FILE BIOENG
FILE BIOSIS
FILE BIOTECHNO
FILE CAPLUS
FILE CBNB
FILE CIN
                                                                                                                                                                                                                         FILE 'BIOSIS'

27 BILN

129 2061

18 BILN 2061

(BILN(W)2061)

111782 CRYSTAL?

0 L15 AND CRYSTAL?

FILE 'INVESTEXT'
                                      18
                                      10
 20 "BILN"
1 "BILNS"
21 "BILN"
("BILN" OR "BILNS")
1864 "2061"
15 BILN 2061
("BILN" (W) "2061")
34452 CRYSTAL?
FILE 'MEDLINE'
122 2061
13 BILN 2061
(BILN(W) 2061)
122732 CRYSTAL?
FILE 'PCTFULL'
40 BILN
2832 2061
11 BILN 2061
(BILN(W) 2061)
127299 CRYSTAL?
FILE 'CAPLUS'
FILE 'CAPLUS'
FILE 'CAPLUS'
20 BILN
382 2061
                                                                                                                                                                                                                          6 L15 AND CRYSTAL?
                                                                                                                                                                                                                                                FESCI 5 "BILN"
28 "2061"
4 BILN 2061
("BILN"(w)"2061")
27296 CRYSTAL?
                                                                                                                                                                                                                          FILE 'PASCAL'
                                                                                                                                                                                                                         O L15 AND CRYSTAL?

FILE 'PASCAL'

13 BILN
69 2061
4 BILN 2061
(BILN(W)2061)
517682 CRYSTAL?

FILE 'TOXCENTER'
6 BILN
63 2061
4 BILN 2061
(BILN(W)2061)
66181 CRYSTAL?

FILE 'ESBIOBASE'
3 BILN
49 2061
3 BILN 2061
(BILN(W)2061)
41699 CRYSTAL?

FILE 'IMSDRUGNEWS'
3 "BILN"
5 "2061"
3 BILN 2061
(BILN(W)2061)
41699 CRYSTAL?

FILE 'IMSDRUGNEWS'
3 "BILN"
5 "2061"
18 CRYSTAL?
FILE 'IMSDRUGNEWS'
18 BILN 2061
("BILN"(W)"2061")
118 CRYSTAL?

FILE 'NLDB'
4 "BILN"
                    CAPLUS'
20 BILN
382 2061
10 BILN 2061
(BILN(W)2061)
1605797 CRYSTAL?
0 L15 AND CRYSTAL?
   FILE 'DDFU'
                             J'
13 BILN
21 2061
10 BILN 2061
(BILN(W)2061)
7961 CRYSTAL?
0 L15 AND CRYSTAL?
                                                                                                                                                                                                                           FILE 'NLDB'

4 "BILN"

274 "2061"

3 BILN 2061

("BILN"(w)"2061")

32830 CRYSTAL?

0 L15 AND CRYSTAL?

FILE 'ADISCTI'

3 BILN

21 2061

2 BILN 2061

(BILN(W)2061)

463 CRYSTAL?

FILE 'BIOENG'

2 BILN

5 BILN

6 L15 AND CRYSTAL?
                                                                                                                                                                                                                           FILE 'NLDB'
  O L15 AND CRYSTAL?

FILE 'DRUGU'

13 BILN
36 2061
10 BILN 2061
(BILN(W2061)
12117 CRYSTAL?
0 L15 AND CRYSTAL?
FILE 'BIOTECHNO'
12 BILN
43 2061
(BILN(W)2061)
27086 CRYSTAL?
3 L15 AND CRYSTAL?
FILE 'USPATFULL
17 BILN
4661 2061
6 BILN 2061
(BILN(W)2061)
570101 CRYSTAL?
    FILE 'DRUGU'
                                                                                                                                                                                                                                                     ENG'
2 BILN
7 2061
2 BILN 2061
2 BILN 2061
(BILN(W)2061)
7912 CRYSTAL?
0 L15 AND CRYSTAL?
```

SINCE FILE

```
FILE 'CBNB'
                                     2 BILN
5 2061
15 2061

2 BILN 2061

(BILN(W)2061)

5823 CRYSTAL?

0 L15 AND CRYSTAL?

FILE 'COMPENDEX'

4 BILN

22 2061

2 BILN 2061

(BILN(W)2061)

443469 CRYSTAL?

6 L15 AND CRYSTAL?

FILE 'PHIN'
  FILE 'PHIN'
                            N'
3 "BILN"
35 "2061"
2 BILN 2061
("BILN"(W)"2061")
1251 CRYSTAL?
0 L15 AND CRYSTAL?
4 BILN
70 2061
2 BILN 2061
(BILN (2061)
362675 CRYSTAL?
0 L15 AND CRYSTAL?
FILE 'WPINDEX'
                                  4 BILN
70 2061
2 BILN 2061
                       (BILN 2001
(BILN(W)2061)
362675 CRYSTAL?
0 L15 AND CRYSTAL?
  FILE 'BABS'
                          35'

1 BILN
24 2061
1 BILN 2061
(BILN(W)2061)
91052 CRYSTAL?
0 L15 AND CRYSTAL?
  FILE 'CIN'
                                      1 "BILN"
12 "2061"
                             12 "2061"

1 BILN 2061

("BILN"(W)"2061")

6321 CRYSTAL?

0 L15 AND CRYSTAL?
   FILE 'EMBAL'
                                      1 BILN
4 2061
  4 2061
1 BILN 2061
(BILN(W)2061)
1192 CRYSTAL?
O L15 AND CRYSTAL?
```

=> 116 L18

25 L16

=> dup rem
ENTER L# LIST OR (END):118
PROCESSING COMPLETED FOR L18
L19 21 DUP REM L18 (4 DUPLICATES REMOVED)

```
specified Accession Number.

ENTER DISPLAY FORMAT (BIB):iall

L20 ANSWER 1 OF 2 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.

ON STN
```

The same formats (except for HIT, HITIND, KWIC, and OCC) may be used with the DISPLAY ACC command to display the record for a

```
1 BILN
39 2061
1 BILN 2061
(BILN(W)2061)
146324 CRYSTAL?
0 L15 AND CRYSTAL?
FILE 'PROMT'
                 7 "BILN"
538 "2061"
              1 BILN 2061
("BILN"(W)"2061")
95992 CRYSTAL?
0 L15 AND CRYSTAL?
L16 QUE L15 AND CRYSTAL?
    d rank
=>
F1
F2
                            PCTFULL
USPATFULL
F3
F4
F5
                            EMBASE
                             SCISEARCH
=> file f3-5,f1,f2
COST IN U.S. DOLLARS
TOTAL
                                                                                  SINCE FILE
                                                                                           FNTRY
SESSION
FULL ESTIMATED COST
95.93
                                                                                            1.71
                                                                                   SINCE FILE
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                                           ENTRY
 SESSION
CA SUBSCRIBER PRICE 4.90
FILE 'EMBASE' ENTERED AT 15:27:48 ON 26 OCT 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.
 FILE 'SCISEARCH' ENTERED AT 15:27:48 ON 26 OCT 2004
Copyright (c) 2004 The Thomson Corporation.
 FILE 'BIOTECHNO' ENTERED AT 15:27:48 ON 26 OCT 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights
 reserved.
FILE 'PCTFULL' ENTERED AT 15:27:48 ON 26 OCT 2004 COPYRIGHT (C) 2004 Univentio
 FILE 'USPATFULL' ENTERED AT 15:27:48 ON 26 OCT 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
 ⇒> 116, dup rem
L17 0 L16, DUP REM
```

```
ACCESSION NUMBER:
TITLE:
antiviral
                                 2003468113 EMBASE Full-text Current therapy and new molecular approaches to
                                 treatment and prevention of hepatitis C.
                                 Hugle T.; Cerny A.
Dr. A. Cerny, Clinica Medica, Ospedale Civico,
AUTHOR:
CORPORATE SOURCE:
CH-6903
                                 Lugano, Switzerland. andreas.cerny@bluewin.ch
Reviews in Medical Virology, (2003) 13/6
(361-371).
SOURCE:
                                 Refs: 79
ISSN: 1052-9276 CODEN: RMVIEW
                                ISSN: 1052-92/b COUEN. NOTICE.
United Kingdom
Journal; General Review
004 Microbiology
030 Pharmacology
037 Drug Literature Index
Adverse Reactions Titles
COUNTRY:
DOCUMENT TYPE:
FILE SEGMENT:
LANGUAGE:
SUMMARY LANGUAGE:
ABSTRACT:
ABSIMACI:
Current therapeutic options for hepatitis C are limited, especially
for
or genotype 1. For genotypes 2 and 3, pegylated interferon in combination with ribavirin, can lead to a sustained virological response in up to 80%
 patients. Unfortunately, adverse effects of IFN and ribavirin are a
patients. Unfortunatery, aurers of stress major major problem and the list of contraindications for HCV therapy is long, including decompensated cirrhosis of the liver and psychiatric disorders. Therefore, alternative therapeutic approaches are needed. New delivery options
 for IFN and ribavirin are aimed at optimising efficiency and reducing adverse
ribayirin are almed at optimizing effects.

Recent progress in the molecular virology of HCV has identified new
 targets for
antiviral intervention. Inhibition of HCV gene expression and
 replication as
well as immunotherapeutic concepts aimed at enhancing the cellular
 Immune
response against HCV are being explored. Solution of the crystal
structures of HCV key enzymes led to the design of specific
 inhibitors
 including compounds active against the well characterised NS3 serine
 protease
and RNA-dependent RNA polymerase which are currently in the early
 phase
clinical investigation. New strategies for inhibiting HCV gene
 expression include the use of antisense oligodeoxynucleotides and ribozymes. Immunomodulation by agents such as inosine monophosphate
 dehydrogenase inhibitors, thymosin-alpha 1, histamine or amantadine are being
```

```
ribavirin: CT, clinical trial
ribavirin: CM, drug combination
ribavirin: CM, drug comparison
ribavirin: DT, drug therapy
ribavirin: PT, pharmacokinetics
ribavirin: PD, pharmacology
ribavirin: PO, oral drug administration
albumin conjugate: PR, pharmaceutics
polyaminoacid: PR, pharmaceutics
ribavirin derivative: CR, adverse drug reaction
ribavirin derivative: CR, drug combination
ribavirin derivative: CB, drug comparison
ribavirin derivative: DT, drug therapy
ribavirin derivative: DT, drug therapy
ribavirin derivative: PD, pharmacology
viramidine: CT, clinical trial
viramidine: CM, drug comparison
viramidine: CM, drug terapy
viramidine: CM, drug terapy
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: DT, pharmacology
proteinase inhibitor: PN, pharmacology
_{\mbox{\scriptsize 5-U001EO}} in combination with IFN and/or ribavirin. Immunotherapeutic vaccination with
with recombinant HCV E1 protein improved host immunity against HCV and thus seems to be a promising new option. Copyright .COPYRGT. 2003 John Wiley & Sons, Ltd.
                                                                                                       Medical Descriptors:
*hepatitis C: DT, drug therapy
*hepatitis C: ET, etiology
*hepatitis C: PC, prevention
*infection prevention
 CONTROLLED TERM:
                                                                                                     *infection prevention
virus gene
genotype
drug response
drug contraindication
drug delivery system
side effect: SI, side effect
gene expression
drug targeting
immunotherapy
enzyme structure
drug design
drug activity
antiviral activity
protein targeting
immunomodulation
vaccination
Hepatitis C virus
immune response
cellular immunity
hemolytic anemia: SI, side effect
flu like syndrome: SI, side effect
flu like syndrome: SI, side effect
teratogenicity
virus replication
drug hypersensitivity: SI, side effect
tuman
nonhuman
clinical trial
                                                                                                         virus gene
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                biln 2061: AE, adverse drug reaction biln 2061: CT, clinical trial biln 2061: DO, drug dose biln 2061: DO, drug dose biln 2061: DT, drug therapy biln 2061: PK, pharmacology biln 2061: PO, pharmacology biln 2061: PO, oral drug administration vx 950: DT, drug therapy vx 950: PD, pharmacology virus protein NS5B RNA directed DNA polymerase inhibitor: CT,
                                                                                                                                                                                                                                                                                                                                                                                                                                                         administration
                                                                                                        nonhuman colinical trial review
Drug Descriptors:
alpha interferon: AE, adverse drug reaction alpha interferon: CT, clinical trial alpha interferon: CB, drug combination alpha interferon: DT, drug therapy alpha interferon: TO, drug toxicity alpha interferon: PR, pharmaceutics alpha interferon: PR, pharmaceutics alpha interferon: SC, subcutaneous drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                         clinical trial
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  RNA directed DNA polymerase inhibitor: DT, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                           therapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   RNA directed DNA polymerase inhibitor: PD,
                                                                                                                                                                                                                                                                                                                                                                                                                                                         pharmacology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  itk 003: CT, clinical trial
itk 003: DT, drug therapy
jtk 003: PD, pharmacology
ribozyme: AE, adverse drug reaction
  administration
                                                                                                           ribavirin: AE, adverse drug reaction
                                                                                                         ribozyme: CT, clinical trial
ribozyme: DT, drug therapy
ribozyme: DT, drug therapy
ribozyme: PO, drug toxicity
ribozyme: PO, pharmacology
hepatozyme: AE, adverse drug reaction
hepatozyme: CT, clinical trial
hepatozyme: DT, drug therapy
hepatozyme: TO, drug toxicity
hepatozyme: PD, pharmacology
antisense oligodeoxynucleotide: CT, clinical
                                                                                                                                                                                                                                                                                                                                                                                                                                                            L20 ANSWER 2 OF 2 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
                                                                                                                                                                                                                                                                                                                                                                                                                                                            RESERVED.

on STN

ACCESSION NUMBER:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2003195244 EMBASE <u>Full-text</u>
Hepatitis C virus therapies: Current treatments,
                                                                                                                                                                                                                                                                                                                                                                                                                                                             TITLE:
targets
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   and future perspectives.
Walker M.P.; Appleby T.C.; Zhong W.; Lau J.Y.N.;
                                                                                                                                                                                                                                                                                                                                                                                                                                                             AUTHOR:
                                                                                                                                                                                                                                                                                                                                                                                                                                                            Hong Z.
CORPORATE SOURCE:
Mesa, CA,
                                                                                                        antisense oligodeoxynucleotide: CT, clinical antisense oligodeoxynucleotide: DT, drug therapy antisense oligodeoxynucleotide: PD, pharmacology isis 14803: CT, clinical trial isis 14803: DT, drug therapy isis 14803: DT, drug therapy isis 14803: PD, pharmacology RNA derivative: DT, drug therapy RNA derivative: DT, drug therapy RNA derivative: PD, pharmacology small interfering rna: DT, drug development small interfering rna: DT, drug therapy small interfering rna: PD, pharmacology smonoclonal antibody: DT, drug therapy monoclonal antibody: PD, pharmacology xtl 002: PT, drug therapy xtl 002: PT, drug therapy cicavir: DT, drug therapy thymosin alphal: CT, clinical trial thymosin alphal: CB, drug combination thymosin alphal: DT, drug therapy thymosin alphal: PD, pharmacology inosinate dehydrogenase inhibitor: DT, drug inosinate dehydrogenase inhibitor: DT, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Z. Hong, Ribapharm Inc., Hyland Avenue, Costa
    trial
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 United States. zhihong@ribapharm.com
Antiviral Chemistry and Chemotherapy, (2003) 14/1
(1-21).
Refs: 208
ISSN: 0956-3202 CODEN: ACCHEH
United Kingdom
Journal; General Review
004 Microbiology
030 Pharmacology
037 Drug Literature Index
048 Gastroenterology
English
                                                                                                                                                                                                                                                                                                                                                                                                                                                            SOURCE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                            COUNTRY:
DOCUMENT TYPE:
FILE SEGMENT:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  English
English
                                                                                                                                                                                                                                                                                                                                                                                                                                                              LANGUAGE:
SUMMARY LANGUAGE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                              ABSTRACT
                                                                                                                                                                                                                                                                                                                                                                                                                                                            ABSTRACT:
Chronic hepatitis C virus (HCV) infection is the cause of an emerging
global
epidemic of chronic liver disease. Current combination therapies are
at best
80% efficacious and are often poorly tolerated. Strategies to improve
                                                                                                                                                                                                                                                                                                                                                                                                                                                              therapeutic response include the development of novel interferons,
                                                                                                                                                                                                                                                                                                                                                                                                                                                             nucleoside
analogues with reduced haemolysis compared with ribavirin and inosine
5'-monophosphate dehydrogenase inhibitors. Compounds in preclinical
```

or early clinical trials include small molecules that inhibit virus-specific

clinical trials include small molecules that inhibit virus-specific enzymes (such as the serine proteases, RNA polymerase and helicase) or interfere with translation (including antisense molecules, iRNA and ribozymes). Advances in understanding HCV replication, obtaining a sub-genomic replicon and contriving potential small animal models, in addition to solving crystallographic structures for the replication enzymes, have improved prospects for developing novel therapies. This review summarizes current and evolving treatments for

treatments for chronic hepatitis C infection. In addition, progress in HCV targets

and drug and repartits C infection. In addition, progress in new targets and drug tools valuable in the search for novel anti-HCV agents is detailed.

combination inosinate dehydrogenase inhibitor: DT, drug therapy inosinate dehydrogenase inhibitor: PD, pharmacology merimepodib: CT, clinical trial merimepodib: CB, drug combination merimepodib: DT, drug therapy merimepodib: PD, pharmacology unindexed drug unclassified drug (ribavirin) 36791-04-5; (proteinase inhibitor) CAS REGISTRY NO.: 37205-61-1; (thymosin alpha1) 69521-94-4; (merimepodib) 198821-22-6, 198821-38-4 130621-30-4 (1) Vx 950; (2) Jtk 003; Biln 2061; Isis 14803; Xtl 002 (1) Vertex; (2) Akros; Ribozyme Pharmaceuticals; CHEMICAL NAME: COMPANY NAME: NABI; Sciclone: RegeneRx: Maxim

```
Medical Descriptors:
*hepatitis C: DT, drug therapy
*hepatitis C: EP, epidemiology
*hepatitis C: ET, etiology
*chronic liver disease: ET, etiology
drug efficacy
drug tolerance
hemolytic anemia: SI, side effect
side effect: SI, side effect
alanine aminotransferase blood level
virus replication
crystal structure
RNA translation
untranslated region
internal ribosome entry site
monotherapy
virus load
treatment indication
immunomodulation
drug safety
treatment failure
chimpanzee
transgenic mouse
Hepatitis GB virus B
IC 50
structure activity relation
drug structure
virus assembly
human
nonhuman
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       nucleoside derivative: DV, drug development
nucleoside derivative: PR, pharmaceutics
nucleoside derivative: PD, pharmacology
ribavirin: AE, adverse drug reaction
ribavirin: CT, clinical trial
ribavirin: CB, drug combination
ribavirin: CM, drug comparison
ribavirin: DO, drug dose
ribavirin: DT, drug therapy
ribavirin: PD, pharmacology
inosinate dehydrogenase inhibitor: CM, drug
CONTROLLED TERM:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            inosinate dehydrogenase inhibitor: DT, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        therapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            inosinate dehydrogenase inhibitor: PD,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       pharmacology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           serine proteinase: EC, endogenous compound
RNA polymerase: EC, endogenous compound
helicase: EC, endogenous compound
ribozyme: EC, endogenous compound
recombinant alpha2a interferon: CM, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           recombinant alpha2a interferon: DO, drug dose
recombinant alpha2a interferon: DT, drug therapy
recombinant alpha2a interferon: PD, pharmacology
recombinant alpha2a interferon: SC, subcutaneous
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            administration recombinant alpha2b interferon: CM, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           recombinant alpha2b interferon: DO, drug dose
recombinant alpha2b interferon: DT, drug therapy
recombinant alpha2b interferon: PD, pharmacology
recombinant alpha2b interferon: SC, subcutaneous
                                                                                                                  Vilus assembly
human
nonhuman
Clinical trial
review
priority journal
Drug Descriptors:
*antivirus agent: AE, adverse drug reaction
*antivirus agent: CT, clinical trial
*antivirus agent: AN, drug analysis
*antivirus agent: CB, drug combination
*antivirus agent: CM, drug comparison
*antivirus agent: DV, drug development
*antivirus agent: DV, drug development
*antivirus agent: DT, drug therapy
*antivirus agent: PD, pharmacology
*antivirus agent: V, intravenous drug
*antivirus agent: V, intravenous drug
                                                                                                                      human
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         drua
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            administration
consensus interferon: CM, drug comparison
consensus interferon: DO, drug dose
consensus interferon: DT, drug therapy
consensus interferon: PD, pharmacology
consensus interferon: SC, subcutaneous drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           peginterferon alpha2b: CT, clinical trial peginterferon alpha2b: CM, drug combination peginterferon alpha2b: CM, drug combination peginterferon alpha2b: DO, drug dose peginterferon alpha2b: DT, drug therapy peginterferon alpha2b: DT, drug therapy peginterferon alpha2b: DT, pharmacology peginterferon alpha2a: CT, clinical trial peginterferon alpha2a: CM, drug combination peginterferon alpha2a: CM, drug comparison peginterferon alpha2a: DO, drug dose peginterferon alpha2a: TJ, drug therapy peginterferon alpha2a: DT, drug therapy peginterferon alpha2a: DT, drug therapy peginterferon alpha2a: DT, drug therapy levovirin: CT, clinical trial levovirin: CT, clinical trial levovirin: CM, drug comparison
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         administration
     administration
                                                                                                                        *antivirus agent: SC, subcutaneous drug
     administration
                                                                                                                      alpha interferon: AE, adverse drug reaction
alpha interferon: CB, drug combination
alpha interferon: CM, drug comparison
alpha interferon: DO, drug dose
alpha interferon: DT, drug therapy
alpha interferon: PD, pharmacology
nucleoside derivative: AN, drug analysis
nucleoside derivative: CM, drug comparison
                                                                                                                     levovirin: DV, drug development
levovirin: DO, drug dose
levovirin: DT, drug therapy
levovirin: PT, drug therapy
levovirin: PD, pharmacology
viramidine: CT, clinical trial
viramidine: CM, drug analysis
viramidine: DM, drug comparison
viramidine: DM, drug dose
viramidine: DD, drug dose
viramidine: DD, drug dose
viramidine: DT, drug therapy
viramidine: PD, pharmacology
merimepodib: CM, drug comparison
merimepodib: CM, drug comparison
merimepodib: CM, drug comparison
merimepodib: DT, drug therapy
thymosin alphal: CT, clinical trial
thymosin alphal: CB, drug combination
thymosin alphal: DD, drug development
thymosin alphal: DD, drug development
thymosin alphal: DD, drug dose
thymosin alphal: DT, drug therapy
thymosin alphal: DT, drug therapy
thymosin alphal: DT, drug dose
thymosin alphal: DT, drug dose
thymosin alphal: DT, drug therapy
thymosin alphal: DT, drug therapy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             biln 2061: CT, clinical trial
biln 2061: DO, drug dose
biln 2061: PD, pharmacology
biln 2061: PD, pharmacology
biln 2061: PO, oral drug administration
peptide derivative: AN, drug analysis
peptide derivative: DV, drug development
peptide derivative: DV, bharmacology
peptide alpha keto acid: AN, drug analysis
peptide alpha keto acid: DV, drug development
peptide alpha keto acid: PD, pharmacology
pyrrolidine derivative: AN, drug analysis
pyrrolidine derivative: DV, drug development
pyrrolidine derivative: DV, drug development
pyrrolidine 5,5 lactam: DV, drug development
pyrrolidine 5,5 lactam: DV, drug development
DV TOMB3: DV, drug development
TOMB3: DV, drug development
TOMB3: PD, pharmacology
unindexed drug
unclassified drug
isis 14803
gw 3112
gw 2549
gw 0569
n [4 [[[6,7 dihydro 2 (4 methylphenyl) 5h
8 y]]carbonyl]amino]benzyl] n,n dimethyl 2h
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            administration
                                                                                                                      thymosin alphal: PP, pharmacology thymosin alphal: SC, subcutaneous drug amantadine: CT, clinical trial amantadine: CM, drug analysis amantadine: CM, drug comparison amantadine: CM, drug comparison amantadine: DV, drug development amantadine: DV, pharmacology recombinant interleukin 12: CT, clinical trial recombinant interleukin 12: CB, drug comparison recombinant interleukin 12: CB, drug comparison recombinant interleukin 12: DV, drug development recombinant interleukin 12: DT, drug therapy recombinant interleukin 12: PD, pharmacology histamine: CT, clinical trial histamine: CR, drug combination histamine: DV, drug development histamine: DV, drug development histamine: DV, drug development histamine: DV, drug development gamma interferon: CR, drug combination gamma interferon: CR, drug development gamma interferon: DV, drug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                benzocyclohepten
        administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  8 yl]carbonyl]amino]benzyl] n,n dimethyl 2h
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 tetrahydropyran
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4 aminium chloride
1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11
tetraazacyclotetradecane)
(ribavirin) 36791-04-5; (serine proteinase)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                CAS REGISTRY NO.: 37259-58-8;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (RNA polymerase) 9014-24-8; (helicase) 42613-29-
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (recombinant alpha2b interferon) 98530-12-2;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 (peginterferon
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  alpha2b) 215647-85-1; (peginterferon alpha2a)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 198153-51-4:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (merimepodib) 198821-22-6, 198821-38-4; (thymosin
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 alpha1)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   69521-94-4; (amantadine) 665-66-7, 768-94-5;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 (histamine)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   51-45-6, 56-92-8, 93443-21-1; (gamma interferon) 82115-62-6; (proteinase inhibitor) 37205-61-1; (n
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 [4 [[[6,7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  dihydro 2 (4 methylphenyl) 5h benzocyclohepten 8
yl]carbonyl]amino]benzyl] n,n dimethyl 2h
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 tetrahydropyran 4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   aminium chloride) 229005-80-5; (1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane)) 155148-31-5 (1) vx 497; (2) Ceplene; (3) Biln 2061; (4) Isis 14803; Zadaxin; Gw 3112; Gw 2549; Gw 0569; Tak
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CHEMICAL NAME:
```

779; Amd

3100; IDdb3

```
Ingelheim: (4) Isis (United States): Ribapharm:
Merck
                         (United States): Glaxo SmithKline (United
Kingdom): Bristol
                         Myers Squibb (United States); Celera (United
States);
                         Viropharma; Japanese tobacco; IRBM
=> d his
      (FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004)
      INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE,
AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS,
BIOTECHOS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN,
CONFSCI, CROPB, CAPLUS, DESABS, ... ENTERED AT 14:25:23 ON 26 OCT 2004
      FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004
1 S 300832-84-2/RN
SET SMA OFF
DEL SEL Y
SEL RN
SET SMA LOGIN
L1
      INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004
SEA E1 AND OPTICAL?/FA
                    QUE 300832-84-2/BI AND OPTICAL?/FA
L2
      FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004
0 S L1/BMF
L3
      FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004 0 S L1/BPN
L4
            'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004
0 S L1/IMF
L5
      FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004 1 S L1/PEP
L6
            'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT. 2004
0 S L1/PUR
L7
      FILE 'CAPLUS' ENTERED AT 14:29:48 ON 26 OCT 2004 6 S (L1/SPN OR L1/CPN)
L8
L9
                  6 S (L1/SPN 0
6 FOCUS L8 1-
      FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004
```

(1) Vertex (United States); (2) Maxim; (3)

COMPANY NAME:

```
IMSDRUGNEWS, NLDB, ADISCTI, BIOENG, CBNB, COMPENDEX, PHIN,
 WPIDS, WPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON
26 OCT 2004
                                                                                                                     SEA L15 AND CRYSTAL?
                                                                                                                  4 FILE EMBASE
3 FILE SCISEARCH
9 FILE PCTFULL
3 FILE BIOTECHNO
6 FILE USPATFULL
QUE L15 AND CRYSTAL?
L16
                                      FILE 'EMBASE, SCISEARCH, BIOTECHNO, PCTFULL, USPATFULL' ENTERED
                                   15:27:48 ON 26 OCT 2004

0 L16, DUP REM

25 L16

21 DUP REM L18 (4 DUPLICATES REMOVED)

2 L19 AND PD<20030327
L17
L18
L19
 ĹŽŐ
=> stnindex
ENTER FILE OR CLUSTER NAMES (NONE):all
FILE 'ENCOMPLIT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPLIT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
TOTAL
                                                                                                                                                                                                                                                                                                                                                                SINCE FILE
                                                                                                                                                                                                                                                                                                                                                                                                   ENTRY
 SESSION
FULL ESTIMATED COST
112.45
                                                                                                                                                                                                                                                                                                                                                                                                   16.52
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                                                                                                                                                                                                                                                                                                                                SINCE FILE
                                                                                                                                                                                                                                                                                                                                                                                                   ENTRY
 SESSION
CA SUBSCRIBER PRICE 4.90
INDEX 'lmobility, 2mobility, abi-inform, adiscti, aerospace, agricola, % \left( 1\right) =\left( 1\right) \left( 
                                                ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
                                                   BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS
BIOTECHOS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...'
ENTERED AT 15:32:46 ON 26 OCT 2004
143 FILES IN THE FILE LIST IN STNINDEX
Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0^{\star} with SET DETAIL OFF.
```

```
FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
                      INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
   AGRICOLA
                      ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
   BABS,
BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS,
BIOTECHOS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
   15:24:55 ON
26 OCT 2004
                                                              SEA BILN 2061
                                                                       FILE ADISCTI
FILE BABS
FILE BIOENG
                                                                       FILE BIOSIS
FILE BIOSIS
FILE CAPLUS
FILE CAPLUS
FILE COMPENDEX
FILE COMPENDEX
FILE DRUGU
FILE EMBAL
FILE EMBAL
FILE EMBASE
FILE INSDRUGNEWS
FILE INSDRUGNEWS
FILE INSTRUMENT
FILE INSTRUMENT
FILE INSTRUMENT
FILE INFESTEXT
FILE LIFESCI
FILE FILESCI
FILE FILESCI
FILE FILESCI
FILE FILESCI
FILE MEDLINE
                                                       18
8
                                                                        FILE BIOSIS
                                                       1ŏ
                                                       10
10
                                                                       FILE LIFESCI
FILE MEDLINE
FILE NLOB
FILE PASCAL
FILE PCTFULL
FILE PHIN
FILE SCISEARCH
FILE TOXCENTER
FILE USPATFULL
FILE WPIDS
FILE WPIDS
FILE WPINDEX
E BILN 2061
                                                       13
   L15
                                                             OUE BILN 2061
                      INDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL,
  CAPLUS,
DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER,
ESBIOBASE,
-> ciluprevir/cn

FILE 'IMOBILITY'

'CN' IS NOT A VALID FIELD CODE

0 CILUPREVIR/CN

FILE 'ZMOBILITY'

'CN' IS NOT A VALID FIELD CODE

0 CILUPREVIR/CN

FILE 'ABI-INFORM'

'CN' IS NOT A VALID FIELD CODE

0 CILUPREVIR/CN

FILE 'AFROSPACE'

'CN' IS NOT A VALID FIELD CODE

0 CILUPREVIR/CN

FILE 'AGRICOLA'

FILE 'AGRICOLA'

FILE 'ALUMINIUM'

'CN' IS NOT A VALID FIELD CODE

0 CILUPREVIR/CN

FILE 'ALUMINIUM'

'CN' IS NOT A VALID FIELD CODE

0 CILUPREVIR/CN
  FILE 'ALUMINIUM'
'CN' IS NOT A VALID FIELD CODE

O CILUPREVIR/CN

FILE 'ANABSTR'

O CILUPREVIR/CN

O CILUPREVIR/CN
  FILE 'ANTE'
'CN' IS NOT A VALID FIELD CODE
FILE 'ANTE'
'CN' IS NOT A VALID FIELD CODE
FILE 'APOLLIT'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUALINE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUASCI'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'AQUARE'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BABS'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIBLIODATA'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIBLIODATA'
FILE 'BIBLIODATA'
FILE 'BIBLIODATA'
'CN' IS NOT A VALID FIELD CODE
O CILUPREVIR/CN
FILE 'BIOBUSINESS'
FILE 'BIOCOMMERCE'
'CN' IS NOT A VALID FIELD CODE
```

U CILUPKEVIN/CN
FILE 'BIOCOMMERCE'
'CN' IS NOT A VALID FIELD CODE
0 CILUPREVIN/CN
<-----User Break----->

'CN' IS NOT A VALID FIELD CODE O CILUPREVIR/CN FILE 'BIOSIS'

FILE 'BIOSIS'
O CILUPREVIR/CN
SEARCH ENDED BY USER
FILE 'BIOTECHABS'
SEARCH ENDED BY USER

FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004
15 S L1
0 L10 AND CRYSTAL.
0 L10 AND CRYSTAL?
0 L10 AND CRYSTAL?
0 L10 AND ALCOHOL
3 L10 AND PD<20030327

L11 L12 L13 L14

```
0 CILUPREVIR
=> ciluprevir/
FILE 'IMOBILITY'
'CILUPREVIR/' IS NOT A VALID FIELD CODE
For a list of field codes for the current file, enter "HELP SFIELDS"
at an arrow prompt (=>).
                                                                                                                                                                                                                                    0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                     FILE 'BIOSIS'

O CILUPREVIR
O CILUPREVIR
FILE 'BIOTECHABS'
O CILUPREVIR
FILE 'BIOTECHOS'
O CILUPREVIR
FILE 'BIOTECHOO'
O CILUPREVIR
O CILUPREVIR
O CILUPREVIR
O CILUPREVIR
O CILUPREVIR
FILE 'BIODE'
                                                                                                                                                                                                      FILE 'BIOSIS
=> ciluprevir
FILE 'IMOBILITY'

0 CILUPREVIR
FILE '2MOBILITY'
0 CILUPREVIR
FILE 'ABI-INFORM'
0 CILUPREVIR
0 CILUPREVIR
FILE 'ADISCIT'
                                                                                                                                                                                                       FILE 'BLLDB'
                                                                                                                                                                                                                                    0 CILUPREVIR
0 CILUPREVIR
  FILE 'ADISCTI
 FILE 'ADISCTI'

0 CILUPREVIR
0 CILUPREVIR
FILE 'AEROSPACE'
0 CILUPREVIR
FILE 'AGRICOLA'
                                                                                                                                                                                                       FILE 'CABA'
                                                                                                                                                                                                                                     0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                       FILE 'CANCERLIT
                                                                                                                                                                                                                                    0 CILUPREVIR
0 CILUPREVIR
  FILE 'AGRICOLA'

O CILUPREVIR
O CILUPREVIR
FILE 'ALUMINIUM'
                                                                                                                                                                                                       FILE 'CAOLD'
                                                                                                                                                                                                                                     0 CILUPREVIR
0 CILUPREVIR
                               0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                       FILE 'CAPLUS'
                                                                                                                                                                                                       FILE 'CAPLUS'

0 CILUPREVIR

FILE 'CASREACT'

0 CILUPREVIR

0 CILUPREVIR

1 COURT OF CILUPREVIR
  FILE 'ANABSTR
                               0 CILUPREVIR
0 CILUPREVIR
  FILE 'ANTE'
                                0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                       FILE 'CBNB
                                                                                                                                                                                                       FILE 'CBNB'

0 CILUPREVIR
0 CILUPREVIR
0 CILUPREVIR
0 CILUPREVIR
  FILE 'APOLLIT
                                O CILUPREVIR
O CILUPREVIR
  FILE 'AQUALINE'

0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                       FILE 'CEN'
                                                                                                                                                                                                                                     0 CILUPREVIR
0 CILUPREVIR
  FILE 'AOUASCI
                                0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                        FILE 'CERAB'
                                                                                                                                                                                                       FILE 'CERAB'

0 CILUPREVIR
O CILUPREVIR
FILE 'CHEMINFORMRX'
0 CILUPREVIR
FILE 'CHEMSAFE'
0 CILUPREVIR
FILE 'CIN'
   FILE 'AQUIRE'
                                O CILUPREVIR
O CILUPREVIR
  FILE 'BABS'

0 CILUPREVIR
0 CILUPREVIR
FILE 'BIBLIODATA'
0 CILUPREVIR
FILE 'BIOBUSINESS'
0 CILUPREVIR
FILE 'BIOCOMMERCE'
0 CILUPREVIR
FILE 'BIOCOMMERCE'
   FILE 'BABS'
                                                                                                                                                                                                        FILE 'CIN'
                                                                                                                                                                                                                                      0 CILUPREVIR
0 CILUPREVIR
                                                                                                                                                                                                        FILE 'CIVILENG'

0 CILUPREVIR
```

| | 0 CILUPREVIR | 0 CILUPREVIR |
|-------|------------------------------|---------------------------------|
| FILE | 'COMPENDEX' | 0 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'EMBAL' |
| | 0 CILUPREVIR | O CILUPREVIR |
| FILE | 'COMPUAB' | 0 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'EMBASE' 3 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'ENERGY' |
| FILE | 'COMPUSCIENCE' | O CILUPREVIR |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'ENTEC' |
| FILE | | 0 CILUPREVIR |
| | 0 CILUPREVIR
0 CILUPREVIR | O CILUPREVIR |
| ETLE | 'COPPERLIT' | FILE 'ENVIROENG' |
| FILE | 0 CILUPREVIR | 0 CILUPREVIR |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| ETLE | 'CORROSION' | FILE 'ESBIOBASE' |
| | 0 CILUPREVIR | 2 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'EUROPATFULL' |
| FILE | 'CROPB' | 0 CILUPREVIR |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'FOMAD' |
| FILE | 'CROPU' | 0 CILUPREVIA |
| | 0 CILUPREVIR | 0 CILUPREVIR
FILE 'FORIS' |
| | 0 CILUPREVIR | FILE FURIS O CILUPREVIR |
| FILE | 'CSNB' | FILE 'FRANCEPAT' |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| | 0 CILUPREVIR | O CILUPREVIR |
| FILE | 'DDFB' | FILE 'FRFULL' |
| | 0 CILUPREVIR
0 CILUPREVIR | 0 CILUPREVIR |
| CTLC | 'DDFU' | Ó CILUPREVIR |
| FILE | 1 CILUPREVIR | FILE 'FROSTI' |
| ETLE | 'DETHERM' | . 0 CILUPREVIR |
| 1111 | 0 CILUPREVIR | 0 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'FSTA' _ |
| FILE | 'DGENE' | 0 CILUPREVIR |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| | 0 CILUPREVIR | FILE 'GENBANK' |
| FILE | 'DISSABS' | 0 CILUPREVIR
FILE 'GEOREF' |
| | <pre>0 CILUPREVIR</pre> | O CILUPREVIR |
| | . 0 CILUPREVIR | 0 CILUPREVIR |
| FILE | 'DKF' | FILE 'HEALSAFE' |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| CT. C | 0 CILUPREVIR | 0 CILUPREVIR |
| FILE | 0 CILUPREVIR | FILE 'ICONDA' |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| FTLE | 'DRUGB' | 0 CILUPREVIR |
| . 100 | 0 CILUPREVIR | FILE 'IFICLS' |
| | 0 CILUPREVIR | 0 CILUPREVIR |
| FILE | 'DRUGU' | 0 CILUPREVIR |
| | 1 CILUPREVIR | FILE 'IFIPAT' |
| FILE | 'ELCOM' | 0 CILUPREVIR |
| | 0 CILUPREVIR | 0 CILUPREVIR FILE 'IMSDRUGNEWS' |
| | 0 CILUPREVIR | O CILUPREVIR |
| FILE | 'EMA' | U CILOPREVIA |
| | | |

| , | FILE | 'INFODATA | O CILUPREVIR
A' | | FILE | |) CILUPR | | | |
|-----|----------|----------------------|---------------------------------------|-----|----------------|---------------------|----------------------------|--------------|---------------------------------|-------------------|
| | cri e | | O CILUPREVIR
O CILUPREVIR | | FILE | 'NLDB' | CILUPR | | | |
| | LILE | 1 | O CILUPREVIR
O CILUPREVIR | | ETLE | |) CILUPR
) CILUPR | | | |
| , | FILE | 'INPADOC | O CILUPREVIR | | | 0 |) CILUPR
) CILUPR | | | |
| 1 | FILE | 'INSPEC' | O CILUPREVIR | | FILE | | CILUPR | | | • |
| , | ETLE | | O CILUPREVIR
O CILUPREVIR | | FILE | 'OCEAN' |) CILUPR
) CILUPR | | | |
| • | TILL | 1 | O CILUPREVIR
O CILUPREVIR | | FILE | |) CILUPR | | | |
| . 1 | FILE | 'INVESTE | XT'
O CILUPREVIR | | | 0 | CILUPR | | | • |
| ı | FILE | 'IPA' | O CILUPREVIR | | FILE | 'PASCAL'
0 |) CILUPR | EVIR | | |
| | CT1 | | O CILUPREVIR
O CILUPREVIR | | FILE | 'PATDD' | CILUPR | | | |
| , | FILE | | O CILUPREVIR
O CILUPREVIR | | FILE | 'PATDPA' |) CILUPR
) CILUPR | | | |
| 1 | FILE | 'JAPIO' | O CILUPREVIR | | | PATDPAFU : 0 | JLL'
CILUPR | | | |
| , | FILE | 'JICST-E | | | | 'PATOSDE' |) CILUPR | EVIR | | |
| 1 | EYLE | | O CILUPREVIR
O CILUPREVIR | | FILE | |) CILUPR | | | |
| | ILL | | O CILUPREVIR
O CILUPREVIR | | FILE | PATOSWO' | | | | |
| | FILE | 'LIFESCI | O CILUPREVIR | | FILE | O
'PCTFULL' | CILUPR | EVIR | | |
| ı | FILE | 'MATBUS' | O CILUPREVIR | | | 0 |) CILUPR
) CILUPR | | | |
| ı | FTI F | 'MATH' | O CILUPREVIR
O CILUPREVIR | • | FILE | |) CILUPR
) CILUPR | | | |
| | | | O CILUPREVIR
O CILUPREVIR | | FILE | 'PHARMAML | CILUPR | | | |
| 1 | FILE | 'MATHDI' | O CILUPREVIR | | FILE | PHIC' | CILUPR | EVIR | | |
| | FILE | 'MECHENG | | 2 | 571.5 | 0 |) CILUPR
) CILUPR | | | • |
| | FILE | | O CILUPREVIR
O CILUPREVIR | | FIFF | 'PHIN'
0 |) CILUPR
) CILUPR | EVIR | | |
| | | | 2 CILUPREVIR | | FILE | 'PIRA' |) CILUPR | | | |
| | . | | O CILUPREVIR O CILUPREVIR | | FILE | O
POLLUAB: | | | | |
| | FILE | | RT'
O CILUPREVIR
O CILUPREVIR | | CTI C | |) CILUPR
) CILUPR | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | O CILUPREVIR | | | | CILUPR | EVIR | | |
| ı | FILE | 'RAPRA' | O CILUPREVIR O CILUPREVIR | · · | FILE | 'WATER' | CILUPR | EVIR | | |
| ſ | FILE | | O CILUPREVIR | | FILE | 'WELDASEA | RCH'
CILUPR | | | |
| | | 'RUSSCI' | O CILUPREVIR | | FILE | . 'WPIDS' | | | | |
| | cxi e | | O CILUPREVIR O CILUPREVIR | | | 0 |) CILUPR
) CILUPR | | | |
| | | 'SIGLE' | CH
2 CILUPREVIR | | FILE | 'WPIFV'
0
0 | CILUPR | EVIR | | |
| | | 1 | O CILUPREVIR
O CILUPREVIR | | FILE | 'WPINDEX' | CILUPR | | | |
| | FILE | 'SOLIDST | ATE'
O CILUPREVIR | • | FILE | 0
: 'wsca' | CILUPR | EVIR | | |
| ı | FILE | 'SOLIS' | O CILUPREVIR
O CILUPREVIR | | 5T1 5 | |) CILUPR
) CILUPR | | | |
| 1 | FTLE | | O CILUPREVIR | • | FILE | 0 | :5
) CILUPR
) CILUPR | EVIR
EVIR | | |
| | | | O CILUPREVIR
O CILUPREVIR | | L21 | QUE CILUP | | | | |
| • | FILE | | O CILUPREVIR | | => d | rank | | | | |
| J | FILE | TEXTILE. | O CILUPREVIR
TECH'
O CILUPREVIR | • | F1
F2 | 3
2
2 | ESBI | OBASE | | |
| ı | FILE | 'TOXCENT | O CILUPREVIR | | F3
F4
F5 | 2 | SCIS | EARCH | | |
| | | | O CILUPREVIR
O CILUPREVIR | | F6 | î | | | | * |
| ١ | FILE | | O CILUPREVIR | | | il f1-6 | | | | |
| - | FILE | 'TULSA' | O CILUPREVIR
O CILUPREVIR | | TOTA | T IN U.S. D
NL | OLLARS | | | SINCE FILE |
| | FILE | | O CILUPREVIR | | SESS | ION
ESTIMATED | COST | | | ENTRY
5.70 |
| | | | O CILUPREVIR
O CILUPREVIR | , | 118. | .15 | | | | |
| | | 'UFORDAT | ,
O CILUPREVIR | , | DISC
TOTA | | ITS (FOR | QUALIFYING | ACCOUNTS) | SINCE FILE |
| | | 'ULIDAT'
'USPATFU | O CILUPREVIR | | SESS | | DRICE | | | ENTRY
0.00 |
| | | ; | O CILUPREVIR
O CILUPREVIR | | 4.90 | UBSCRIBER
) | rRICE | | | 0.00 |
| i | FILE | 'USPAT2' | O CILUPREVIR | | | | | | 1 ON 26 OCT 20
All rights re | |
| , | FILE | 'VETB' | O CILUPREVIR | | FILE | 'ESBIOBAS | E' ENTE | RED AT 15:3 | 9:01 ON 26 OCT | 2004 |
| ı | FILE | | O CILUPREVIR
O CILUPREVIR | | rese | RIGHT (C)
erved. | 2004 El | sevier Scie | nce B.V., Amst | erdam. All rights |
| ' | | | 0 CILUPREVIR | | FILE | 'MEDLINE' | ENTERE | D AT 15:39: | 01 ON 26 OCT 2 | 004 |
| | | | | | | | | | | |

```
FILE 'SCISEARCH' ENTERED AT 15:39:01 ON 26 OCT 2004 Copyright (c) 2004 The Thomson Corporation.
 FILE 'DDFU' ACCESS NOT AUTHORIZED
 FILE 'DRUGU' ENTERED AT 15:39:01 ON 26 OCT 2004 COPYRIGHT (C) 2004 THE THOMSON CORPORATION
                           10 L21
=> 122 and pd<20030327

1 FILES SEARCHED...

2 FILES SEARCHED...

'20030327' NOT A VALID FIELD CODE

'20030327' NOT A VALID FIELD CODE

L23 1 L22 AND PD<20030327
 => d 123
L23 ANSWER 1 OF 1 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.

ON STN
AN 2004039472 EMBASE Full-text
TI Gateways to Clinical Trials.
AU Bayes M.; Rabasseda X.; Prous J.R.
CS M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona,
 Spain.
           mbayes@prous.com
Methods and Findings in Experimental and Clinical Pharmacology,
            2003) 25/10 (831-855).
            Refs: 145
ISSN: 0379-0355 CODEN: MFEPDX
          ISSN: Us, Spain
Journal; General Review
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
=> FIL STNGUIDE
COST IN U.S. DOLLARS
TOTAL
```

SESSION FULL ESTIMATED COST 126.52

SESSION CA SUBSCRIBER PRICE

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

SINCE FILE

8.37

0.00

```
exenatide, exisulind, ezetimib; Febuxostat; Gallium maltolate, ganirelix acetate, garenoxacin mesilate, gefitinib; H11, HuMax; IL-15, IDD-1, IGLV-C, imatinib mesylate, ISIS-14803, ITF-1697, ivabradine hydrochloride; KRN-5500; L-365260, levetiracetam, levosimendan, licofelone, linezolid, LJP-1082, lopinavir lumiracoxib; MCC-478, melatonin, morphine hydrochloride, morphine-6-glucuronide, moxidectin; N-Acetylcarnosine, natalizumab, NM-702, NNC-05-1869, NSC-703940; Ocinaplon OM-89, omalizumab, omeprazole/sodium bicarbonate, OPC-28326, ospemifene; PEG-filgrastim peginterferon alfa-2a, pegsunercept, pirfenidone, pralmorelin, pregabalin; Recombinant glucagon-like peptide-1 (7-36) amide, repifermin, RSD-1235; S-8184, selodenoson, sodium dichloroacetate, suberanilohydroxamic acid; TAS-102, terfenadine, teriparatide, tipranavir troxacitabine; Ximelagatran; YM-337. .COPYRGT. 2003 Prous Science. All rights reserved.
Medical Descriptors: drug efficacy drug and indication drug efficacy drug safety side effect; SI, side effect patient compliance drug tolerability liver toxicity: SI, side effect bleeding: SI, side effect bleeding: SI, side effect disease exacerbation systemic lupus erythematosus: SI, side effect teratogenicity: SI, side effect
                                                              human
clinical trial
                                                         review
Drug Descriptors:
abetimus: CT, clinical trial
abetimus: CT, clinical trial
abetimus: ST, intravenous drug administration
adalimumab: AE, adverse drug reaction
adalimumab: CT, clinical trial
linezolid: CT, clinical trial
alemtuzumab: CT, clinical trial
ivabradine: CT, clinical trial
ivabradine: CT, clinical trial
ivabradine: CT, clinical trial
ivabradine: IV, intravenous drug administration
recombinant interleukin 1 receptor blocking agent: CT, clinical
trial
recombinant interleukin 1 receptor blocking agent: IA,
intraarterial drug
administration
glucagon like peptide 1: CT, clinical trial
glucagon like peptide 1: SC, subcutaneous drug administration
astemizole: CT, clinical trial
atazanavir: CT, clinical trial
bosentan: CT, clinical trial
botulinum toxin B: CT, clinical trial
caspofungin: CT, clinical trial
ciclesonide: CT, clinical trial
ciclesonide: CT, clinical trial
ciclesonide: CT, clinical trial
ciclesonide: CT, clinical trial
```

```
4.90
FILE 'STNGUIDE' ENTERED AT 15:40:30 ON 26 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE
FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Oct 22, 2004 (20041022/UP).
=> 123 all
MISSING OPERATOR L23 ALL
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
⇒ d 123 a11
YOU HAVE REQUESTED DATA FROM FILE 'EMBASE' - CONTINUE? (Y)/N:y
L23 ANSWER 1 OF 1 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
                RVED.
on STN
2004039472 EMBASE <u>Full-text</u>
Gateways to Clinical Trials.
Bayes M.; Rabasseda X.; Prous J.R.
M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona,
                 1.
mbayes@prous.com
Methods and Findings in Experimental and Clinical Pharmacology,
                  2003) 25/10 (831-855).
Refs: 145
ISSN: 0379-0355 CODEN: MFEPDX
                   Spain
                  Journal; General Review
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
                  English English Gateways to Clinical Trials is a guide to the most recent Clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity*, the drug discovery and development portal, <a href="http://integrity.prous.com">http://integrity.prous.com</a>. This issue focuses on the following selection of drugs: Abetimus sodium, adalimumab, alefacept, alemtuzumab, almotriptan, AMGN-0007, anakinra, anti-CTLA-4 Mab, L-arginine hydrochloride, arzoxifene hydrochloride, astemizole, atazanavir sulfate, atlizumab; Belimumab, BG-9928, binodenoson, bosentan, botulinum toxin type B, bovine lactoferrin, BufferGel; Caspofungin acctate, ciclesonide, cilomilast, ciluprevir, Clofarabine, CVT-3146; Darbepoetin alfa, desloratadine, diflomotecan, doripenem, dronedarone hydrochloride, drotrecogin alfa (accivated), DT388-GM-CSF, duloxetine hydrochloride, E-5564, efalizumab, enfuvirtide, esomeprazole magnesium, estradiol acetate, ETC-642,
```

```
efalizumab: CT, clinical trial
imatinib: CT, clinical trial
terfenadine: CT, clinical trial
tipranavir: CT, clinical trial
tipranavir: O, oral drug administration
ximelagatran: PO, oral drug administration
ym 337: CT, clinical trial
ximelagatran: PO, oral drug administration
ym 337: CT, clinical trial
moxidectin: CT, clinical trial
novel erythropoiesis stimulating protein: CT, clinical trial
novel erythropoiesis stimulating protein: IV, intravenous drug
administration
novel erythropoiesis stimulating protein: SC, subcutaneous drug
administration
desloratadine: CT, clinical trial
desloratadine: CT, clinical trial
desloratadine: CT, clinical trial
desloratadine: PO, oral drug administration
diflomotecan: TV, intravenous drug administration
diflomotecan: TV, intravenous drug administration
diflomotecan: CT, clinical trial
etiracetam: CT, clinical trial
etiracetam: CT, clinical trial
duloxetine: CT, clinical trial
duloxetine: CT, clinical trial
unindexed drug
RN (abetimus) 167362-48-3, 169147-32-4; (adalimumab) 331731-18-1;
(linezolid)
165800-03-3; (alemtuzumab) 216503-57-0; (ivabradine) 148849-67-
148870-80-8, 155974-00-8; (glucagon like peptide 1) 89750-14-1;
 148870-80-8, 155974-00-8; (glucagon like peptide 1) 89750-14-1; (astemizole) 68844-77-9; (atazanavir) 198904-31-3; (bosentan) 147536-97-8,
                   157212-55-0; (caspofungin) 189768-38-5; (ciclesonide) 126544-47-
                   (cilomilast) 153259-65-5; (efalizumab) 214745-43-4; (imatinib) 152459-95-5, 220127-57-1; (terfenadine) 50679-08-8; (tipranavir) 174484-41-4; (ximelagatran) 192939-46-1, 260790-58-7; destin)
  (moxidectin)
113507-06-5; (estradiol) 50-28-2; (desloratadine) 100643-71-8; (diflomotecan) 220997-97-7; (morphine) 52-26-6, 57-27-2;
   (etiracetam) 102767-28-2, 33996-58-6; (doripenem) 148016-81-3; (duloxetine) 116539-59-4, 136434-34-9
   => DIS HIST
                   (FILE 'HOME' ENTERED AT 14:24:22 ON 26 OCT 2004)
                   INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE,
 AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS,
```

BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DGENE, DISSABS, ... ENTERED AT 14:25:23 ON

```
26 OCT 2004
       FILE 'REGISTRY' ENTERED AT 14:26:32 ON 26 OCT 2004
1 S 300832-84-2/RN
SET SMA OFF
DEL SEL Y
SEL RN
SET SMA LOGIN
       INDEX 'BEILSTEIN, GMELIN' ENTERED AT 14:27:43 ON 26 OCT 2004 SEA E1 AND OPTICAL?/FA
                         QUE 300832-84-2/BI AND OPTICAL?/FA
L2
        FILE 'CAPLUS' ENTERED AT 14:28:02 ON 26 OCT 2004
0 S L1/BMF
13
        FILE 'CAPLUS' ENTERED AT 14:28:18 ON 26 OCT 2004 0 S L1/BPN
L4
       FILE 'CAPLUS' ENTERED AT 14:28:28 ON 26 OCT 2004
0 S L1/IMF
L5
        FILE 'CAPLUS' ENTERED AT 14:28:41 ON 26 OCT 2004
1 S L1/PEP
        FILE 'CAPLUS' ENTERED AT 14:29:30 ON 26 OCT 2004 0 S \ensuremath{\text{L1/PUR}}
L7
        FILE 'CAPLUS' ENTERED AT 14.29:48 ON 26 OCT 2004
6 S (L1/SPN OR L1/CPN)
6 FOCUS L8 1-
L8
L9
        FILE 'REGISTRY' ENTERED AT 14:31:45 ON 26 OCT 2004
       FILE 'HCAPLUS' ENTERED AT 14:32:46 ON 26 OCT 2004
                    APLUS' ENTERED AT 14:3
15 S L1
0 L10 AND CRYSTAL
0 L10 AND CRYSTAL?
0 L10 AND ALCOHOL
3 L10 AND PD<20030327
L10
L11
L12
L13
L14
        FILE 'HOME' ENTERED AT 14:39:45 ON 26 OCT 2004
        INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
AGRICOLA
        ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
BABS, BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS,
BIOTECHDS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
15:24:55 ON
        26 OCT 2004
                         SEA BILN 2061
                            FILE ADISCTI
        INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
AGRICOLA
        ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
BABS,
BIBLIODATA, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS,
BIOTECHABS,
BIOTECHOS, BIOTECHNO, BLLDB, CABA, CANCERLIT, ...' ENTERED AT
15:32:46 ON
26 OCT 2004
                         SEA CILUPREVIR/CN
                        O* FILE MOBILITY
O* FILE 2MOBILITY
O* FILE ADISCTI
O* FILE ACROSPACE
O* FILE ALUMINIUM
O* FILE ANTE
O* FILE AQUALINE
O* FILE AQUALINE
O* FILE BABS
O* FILE BIBLIODATA
O* FILE BIBLIODATA
O* FILE BIBLIOMERCE
O* FILE BIBLIOM
                         )* FILE 1MOBILITY
SEA CILUPREVIR
                        0*
                         L FILE DDFU
1 FILE DRUGU
3 FILE EMBASE
2 FILE ESBIOBASE
2 FILE MEDLINE
2 FILE SCISEARCH
QUE CILUPREVIR
        FILE 'EMBASE, ESBIOBASE, MEDLINE, SCISEARCH, DRUGU' ENTERED AT
15:39:01
        9:01
ON 26 OCT 2004
10 S L21
1 L22 AND PD<20030327
        FILE 'STNGUIDE' ENTERED AT 15:40:30 ON 26 OCT 2004
        FILE 'EMBASE' ENTERED AT 15:41:46 ON 26 OCT 2004
        FILE 'STNGUIDE' ENTERED AT 15:41:46 ON 26 OCT 2004
```

---Logging off of STN---

```
FILE BABS
FILE BIOENG
FILE BIOSIS
FILE BIOTECHNO
FILE CAPLUS
                                       10
10
                                                    FILE CAPLUS
FILE CBNB
FILE CIN
FILE COMPENDEX
FILE DDFU
FILE DRUGU
FILE EMBAL
                                       10
10
                                          FILE DRUGU
FILE EMBASE
FILE EMBASE
FILE ESBIOBASE
FILE INFORUCNEWS
FILE INFORUCNEWS
FILE LIFESCI
FILE MEDLINE
FILE MEDLINE
FILE PASCAL
FILE UPASCAL
FILE STATE
FILE OPATFUL
FILE WPINDEX
QUE BILN 2061
                                       1
42
3
1
3
15
                                       4
13
4
11
2
1
22
L15
INDEX 'EMBASE, SCISEARCH, BIOSIS, INVESTEXT, MEDLINE, PCTFULL, CAPLUS, DDFU, DRUGU, BIOTECHNO, USPATFULL, LIFESCI, PASCAL, TOXCENTER, ESBIOBASE,
              IMSDRUGNEWS, NLDB, ADISCTI, BIOENG, CBNB, COMPENDEX, PHIN,
WPIDS,
WPIDS,
WPINDEX, BABS, CIN, EMBAL, IFIPAT, PROMT' ENTERED AT 15:26:20 ON
26 OCT 2004
                                            SEA L15 AND CRYSTAL?
                                            4 FILE EMBASE
3 FILE SCISEARCH
9 FILE PCTFULL
3 FILE BIOTECHNO
6 FILE USPATFULL
QUE L15 AND CRYSTAL?
116
               FILE 'EMBASE, SCISEARCH, BIOTECHNO, PCTFULL, USPATFULL' ENTERED
ΑT
             15:27:48 ON 26 OCT 2004

0 L16, DUP REM

25 L16

21 DUP REM L18 (4 DUPLICATES REMOVED)

2 L19 AND PD<20030327
L17
L18
L19
L20
```

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS
TOTAL

SESSION
FULL ESTIMATED COST
130.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
TOTAL

SESSION
CAS SUBSCRIBER PRICE
4.90

SINCE FILE
ENTRY
CAS SUBSCRIBER PRICE
4.90

STN INTERNATIONAL LOGOFF AT 15:42:43 ON 26 OCT 2004

Google Search: BILN 2061

| | Web | Images | <u>Groups</u> | News | Froogle | more » | |
|--------|--------|--------|---------------|------|---------|--------|--------------------------------|
| Google | BILN 2 | 2061 | | , | | Search | Advanced Search
Preferences |

Web

Results 1 - 10 of about 938 for BILN 2061. (0.21 seconds)

New Data on **BILN 2061**, Experimental HCV Protease Inhibitor from ...

December 14-18, 2003. Kauai, Hawaii. New Data on **BILN 2061**, Experimental HCV Protease Inhibitor from Boehringer Ingelheim By Mark Nelson, MD. By Mark Nelson. ...

www.hivandhepatitis.com/2004icr/ hepdart_2003/docs/011404_a.html - 35k - <u>Cached</u> - <u>Similar pages</u>

BILN 2061 Establishes Proof-of-Concept in Humans for an HCV ...

BILN 2061 Establishes Proof-of-Concept in Humans for an HCV Protease Inhibitor. ... Note:

BILN 2061 is in clinical development by Boehringer Ingelheim. 10/29/03. ...

www.hivandhepatitis.com/2003icr/ 03_assld/docs/1029/102903_a.html - 15k - Cached - Similar pages

[More results from www.hivandhepatitis.com]

Yahoo! News - BILN 2061 Could Offer New Hope to Patients With ...
... Health - Acurian. BILN 2061 Could Offer New Hope to Patients With Hepatitis C. Mon Oct 27, 7:00 PM ET. Source: Acurian Inc. by: Darrin Kiessling. ...
dynamics.org/~altenber/cryo/HCV/BILN2061.Yahoo.html - 43k - Cached - Similar pages

Hepatitis C Vets, Orally available Hepatitis C Virus (HCV) ...
... Orally available Hepatitis C Virus (HCV) Protease Inhibitor (BILN 2061, Boehringer Ingelheim Pharma) Demonstrates Potent Anti-viral Activity in Persons ...
hepcvets.com/drugs/biln2061.html - 11k - Cached - Similar pages

ISMC 2004: Session 2A: The discovery of **BILN 2061**, an NS3 protease ... Session 2A: Keynote lecture. The discovery of **BILN 2061**, an NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. ... www.ismc2004.dk/index.php/ Session_2A__The_discovery_of_B/258/0/ - 11k - Cached - Similar pages

54th Annual Meeting of

... BILN 2061 Establishes Proof-of-Concept in Humans for an HCV Protease Inhibitor ... Note: BILN 2061 is in clinical development by Boehringer Ingelheim. 10/29/03. ... janis7hepc.com/54th_annual_meeting_of10.htm - 101k - Oct 24, 2004 - Cached - Similar pages

Clinical Care Options for Hepatitis - BILN 2061 Inhibits HCV ...

BILN 2061 Inhibits HCV Genotype 2 and 3 Proteases in Vitro, ... This study examined the ability of BILN 2061 to inhibit NS3 protease from genotypes 2 and 3. ...

clinicaloptions.com/hep/conf/aasId2003/cs/300.asp - 20k - Cached - Similar pages

Clinical Care Options for Hepatitis - BILN 2061 shows promise in ...

BILN 2061 shows promise in early clinical trial against HCV genotype 1,

Deanna M. Green, PhD. November 18, 2003 — BILN 2061 induces ...

clinicaloptions.com/hep/news/news_imed_2.asp - 20k - Cached - Similar pages

[More results from clinicaloptions.com]

Serin-Protease-Hemmstoff (BILN-2061) bei Hepatitis-C - [Translate this page] ... Medizinrecht. Neue Medikamente im Pipeline 2002. Serin-Protease-Hemmstoff (BILN-2061) bei Hepatitis-C. ... Die Arbeiten zu BILN 2061 befinden sich am Anfangsphase. ... www.medknowledge.de/neu/2002/ IV-2002-32-biln-2061-pipeline.htm - 38k - Cached - Similar pages

HIV Report Jan 2003: A Promising New Anti-HCV Protease Inhibitor ... Researchers presented 4 papers describing the discovery, safety and early antiviral activity of **BILN 2061**, a serine protease inhibitor [Hepatology 2002;36:167A ... www.hopkins-aids.edu/publications/report/jan03_4.html - 11k - Cached - Similar pages

Google Search: ciluprevir



Images Groups News Froogle more » Web

Search

Advanced Search Preferences

Results 1 - 10 of about 20 for ciluprevir. (0.21 seconds)

[DOC] NO3

File Format: Microsoft Word 2000 - View as HTML

... COUNCIL: USAN CILUPREVIR. PRONUNCIATION (si loo pre' veer). THERAPEUTIC

CLAIM Treatment of Hepatitis C infection. CHEMICAL NAMES. 1 ...

www.ama-assn.org/ama1/pub/upload/mm/365/ciluprevir.doc - Similar pages

AMA (USAN) 2004 Published USAN

... atilmotin avanafil becatecarin bemotrizinol bisoctrizole canfosfamide hydrochloride cariporide mesylate ciclesonide ciluprevir dabuzalgron hydrochloride ... www.ama-assn.org/ama/pub/category/9615.html - 17k - Cached - Similar pages

Antiviral compounds; TerraQSAR-LOGP computed octanol/water ...

... cicloxolone, 52247-86-6, C38H56O7, 624.86, 4.15. ciluprevir, 300832-84-2, C40H50N6O8S. 774.94, -0.53. streptovarycin, 1404-74-6, C40H51NO14, 769.84, 1.87. ...

www.terrabase-inc.com/antivirals.html - 11k - Cached - Similar pages

[Report] Global PharmaVitae Boehringer Ingelheim Market Research ...

... and forecast revenue growth Other products Marketed products R&D compounds Micardis

(telmisartan) BIBH-1 (sibrotuzumab) BILN 2061(ciluprevir) BIBT 986 BIWI-1 ...

www.the-infoshop.com/study/ dc21221 boehringer ingelheim toc.html - 28k - Cached - Similar pages

PharmaVitae 2004: Boehringer Ingelheim Global Analysis: Table of ...

... 94. R&D compounds. 95. Micardis (telmisartan). 96. BIBH-1 (sibrotuzumab). 96. BILN

2061(ciluprevir). 96. BIBT 986. 97. BIWI-1 (bivatuzumab mertansine). 97. ...

www.datamonitor.com/~a36ec16c415a44bbaaf54fea6eee497e~/ products/free/CompanyReport/CSHC1165/020cshc1165.htm -

27k - Cached - Similar pages

Gateways to clinical trials.

... BG-9928, binodenoson, bosentan, botulinum toxin type B, bovine lactoferrin, BufferGel;

Caspofungin acetate, ciclesonide, cilomilast, ciluprevir, clofarabine, CVT ...

www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& db=PubMed&list_uids=14735233&dopt=Abstract - Similar pages

Gateways to clinical trials.

... Bevacizumab, BG-9928, BMS-188667, botulinum toxin type B, BufferGel; Caffeine,

CDP-870, cetuximab, cilomilast, ciluprevir, clofarabine, continuous ...

www.ncbi.nlm.nih.gov/entrez/guery.fcgi?cmd=Retrieve& db=PubMed&dopt=Abstract&list_uids=14988742 -

Similar pages

Datamonitor Research Reports -- PharmaVitae 2004: Boehringer ...

... 96. R&D compounds, 97. Micardis (telmisartan), 98. BIBH-1 (sibrotuzumab), 98. BILN

2061(ciluprevir), 98. BIBT 986, 99. BIWI-1 (bivatuzumab mertansine), 99. ...

www.nhionline.net/products/datamonitorcp58.htm - 101k - Cached - Similar pages

www.ciluprevir.net/


Similar pages

www.ciluprevir.com/

Similar pages

Google ▶

Google Search: 300832-84-2



Web

Results 1 - 2 of 2 for 300832-84-2. (0.23 seconds)



300 832 - 84 - 2 = 300 746

More about calculator.

Antiviral compounds; TerraQSAR-LOGP computed octanol/water cicloxolone, 52247-86-6, C38H56O7, 624.86, 4.15. ciluprevir, 300832-84-2, C40H50N6O8S, 774.94, -0.53. streptovarycin, 1404-74-6, C40H51NO14, 769.84, 1.87. ... www.terrabase-inc.com/antivirals.html - 11k - Cached - Similar pages

[DOC] NO3

File Format: Microsoft Word 2000 - View as HTML

... TRADEMARK Unknown as yet. MANUFACTURER Boehringer Ingelheim Pharma GmbH & Co. KG.

CODE DESIGNATION BILN 2061 ZW. CAS REGISTRY NUMBER 300832-84-2.

www.ama-assn.org/ama1/pub/upload/mm/365/ciluprevir.doc - Similar pages

| | Total conference in a conferent |
|-------------|---------------------------------|
| 200022 04 2 | Coorah |
| 300832-84-2 | Search |
| | 1 1 1 1 1 1 1 1 1 |

Search within results | Language Tools | Search Tips | Dissatisfied? Help us improve

Google Home - Advertising Programs - Business Solutions - About Google

©2004 Google

| | Web | Images | Groups | News | Froogle | more » | |
|--------|--------|--------------|--------|------|---------|--------|-------------------------------|
| Coogle | crysta | llization pr | otocol | | | Search | Advanced Searc
Preferences |
| | | | | | | | |

Web

Results 1 - 10 of about 25,500 for crystallization protocol. (0.14 seconds)

Protocol Online: Biochemistry/Amino Acids & Protein/Protein ...

... Protocols: A Practical Guide to Protein Crystallization (Mark Knapp and Bernhard

Rupp) In order to obtain a crystal, the protein molecules must assemble into a ...

www.protocol-online.org/prot/Biochemistry/ Amino_Acids___Protein/Protein_Crystallization/ - 9k - Cached - Similar pages

Definition of Category exptl crystal grow comp

... However, the number of solutions required to describe the crystallization protocol

is not limited to 2. Details of the crystallization protocol should be ...

msdlocal.ebi.ac.uk/docs/exchange/mmcif_rcsb_nmr.dic/ Categories/exptl_crystal_grow_comp.html - 8k - Cached - Similar pages

High Throughput Protein Crystallization

... with the aim to establish correlations between **crystallization** probability and ... Such an optimized **protocol** maximizes the probability of success while minimizing ...

www-structure.llnl.gov/Xray/ tutorial/High_Throughput_EMBL_full.htm - 79k - Cached - Similar pages

CRYSTOOL Move announcement

CRYSTOOL. Has Moved. There is a new implementation of Brent Segelke's CRYSTOOL program

[1] for creating efficient, customizable, random crystallization screens. ...

www-structure.llnl.gov/crystool/crystool.htm - 3k - Cached - Similar pages

[More results from www-structure.llnl.gov]

(IUCr) Crystallization experiments with 2-enoyl-CoA hydratase ...

... Volume 50 Part 4 Pages 443-447 July 1994 Crystallization experiments with

2-enoyl-CoA hydratase, using an automated `fast-screening' crystallization protocol. ...

scripts.iucr.org/cgi-bin/paper?gr0322 - Similar pages

Protein Crystal Structure Team I | RIKEN

... (2), Development of high-throughput protein crystallization protocol for large scale.

(3), Development of in situ X-ray diffractometer for protein crystal. image ...

www.riken.go.jp/engn/r-world/ research/lab/harima/group-h/crystal1/ - 12k - Cached - Similar pages

Micro-seeding Procedure

... Pre-equilibrated drops contain protein and precipitant that is at a concentration

just below what is required for precipitation or crystallization of the ...

www.hhmi.swmed.edu/Labs/rr/world/seeding.html - 3k - Cached - Similar pages

X-tal protocols: References.

... D50, 443-447 Crystallization Experiments with 2-Enoyl-CoA Hydratase, Using

an Automated 'Fast-Screening' Crystallization Protocol. ...

www.xtal-protocols.de/ref/reference.html - 9k - Cached - Similar pages

Protein Crystallization

... Label your concentrated protein with a batch number. Differences in the purification

protocols may later relate to irreproducibility in crystallization; ...

www-structmed.cimr.cam.ac.uk/ Course/Crystals/Screening/hd_protocol.html - 4k - Cached - Similar pages

The Scientist:: Crystal Illumination, Jan. 19, 2004

... usually 50 nanoliters, is so crucial to its drug-discovery efforts that the company

has patented its proprietary Nano- volume Crystallization™ protocol. ...

www.the-scientist.com/yr2004/jan/tech1_040119.html - Similar pages







PubMed

Nucleotide

Protein

Genome

To combine searches use # before search number, e.g., #2 AND #6.

Search numbers may not be continuous; all searches are represented.

Structure

Preview

Journals Clear Books

Search PubMed

 \mathbf{T}

for BILN 2061

Click on query # to add to strategy

Search History will be lost after eight hours of inactivity.

Clipboard

OMIM

Go

Limits

Preview/Index

History

Details

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby

Related Resources Order Documents NLM Catalog **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Search

#17 Search BILN 2061

#4 Related Articles for PubMed (Select 9477169)

Most Recent Queries

Time Result 15:21:58

13

11:52:24 157

Clear History

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

Oct 13 2004 06:44:09





Click on query # to add to strategy



PMC Books OMIM Journals Genome Structure Nucleotide Protein PubMed Preview Clear Search PubMed Go for crystallization method Details Clipboard History **☑** Limits Preview/Index Search History will be lost after eight hours of inactivity.

• To combine searches use # before search number, e.g., #2 AND #6.

Search numbers may not be continuous; all searches are represented.

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

| Sear | ch Most Recent Queries | Time | Result |
|------|---|----------|--------------|
| | #5 Search crystallization method Limits: Review | 09:47:46 | <u>80</u> |
| | #4 Search crystallization Field: All Fields, Limits: Review | 09:47:07 | 1457 |
| | #3 Search crystallization | 09:46:56 | <u>25455</u> |
| | #2 Search hplc purification column heat | 09:07:15 | <u>123</u> |
| | #1 Search hplc column heat | 09:06:53 | 266 |

Clear History

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Oct 13 2004 06:44:09